CHEBI ONTOLOGY - ANNOTATIONS |
|
The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.
|
Term: | long-chain fatty acid |
|
Accession: | CHEBI:15904
|
browse the term
|
Definition: | A fatty acid with a chain length ranging from C13 to C22. |
Synonyms: | related_synonym: | Formula=CHO2R; Higher fatty acid; LCFA; LCFAs; SMILES=OC([*])=O; long-chain fatty acids |
| alt_id: | CHEBI:13655; CHEBI:14529; CHEBI:25075; CHEBI:6528 |
| xref: | KEGG:C00638 |
| cyclic_relationship: | is_conjugate_acid_of CHEBI:57560 |
|
|
|
G |
Alox15 |
arachidonate 15-lipoxygenase |
multiple interactions |
ISO |
17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [[Dietary Fats co-treated with Cholesterol, Dietary] promotes the reaction [Silver Compounds results in decreased expression of ALOX15 mRNA]] |
CTD |
PMID:34601004 |
|
NCBI chr10:55,060,169...55,068,885
Ensembl chr10:55,060,412...55,068,874
|
|
G |
Alox5 |
arachidonate 5-lipoxygenase |
decreases expression multiple interactions |
ISO |
17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid results in decreased expression of ALOX5 protein 17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [[[Dietary Fats co-treated with Cholesterol, Dietary] results in increased susceptibility to Silver Compounds] which results in decreased expression of ALOX5 mRNA] |
CTD |
PMID:17056761 PMID:34601004 |
|
NCBI chr 4:149,531,329...149,578,696
Ensembl chr 4:149,531,515...149,578,743
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
multiple interactions |
ISO |
17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [[Dietary Fats co-treated with Cholesterol, Dietary] promotes the reaction [Silver Compounds results in increased expression of CCL2 mRNA]]; 17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [[Dietary Fats co-treated with Cholesterol, Dietary] promotes the reaction [Silver Compounds results in increased expression of CCL2 protein]]; 17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [[Silver Compounds results in increased susceptibility to [Dietary Fats co-treated with Cholesterol, Dietary]] which results in increased expression of CCL2 mRNA]; 17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [[Silver Compounds results in increased susceptibility to [Dietary Fats co-treated with Cholesterol, Dietary]] which results in increased expression of CCL2 protein]; 17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [Lipopolysaccharides results in increased secretion of CCL2 protein]; 17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [Silver Compounds results in increased expression of CCL2 mRNA]; 17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [Silver Compounds results in increased expression of CCL2 protein] |
CTD |
PMID:21724996 PMID:34601004 |
|
NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226
|
|
G |
Cxcl2 |
C-X-C motif chemokine ligand 2 |
multiple interactions |
ISO |
17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [[Dietary Fats co-treated with Cholesterol, Dietary] promotes the reaction [Silver Compounds results in increased expression of CXCL2 mRNA]]; 17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [[Dietary Fats co-treated with Cholesterol, Dietary] promotes the reaction [Silver Compounds results in increased expression of CXCL2 protein]]; 17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [[Silver Compounds results in increased susceptibility to [Dietary Fats co-treated with Cholesterol, Dietary]] which results in increased expression of CXCL2 mRNA]; 17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [[Silver Compounds results in increased susceptibility to [Dietary Fats co-treated with Cholesterol, Dietary]] which results in increased expression of CXCL2 protein]; 17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [Dextran Sulfate results in increased expression of CXCL2 protein]; 17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [Silver Compounds results in increased expression of CXCL2 mRNA]; 17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [Silver Compounds results in increased expression of CXCL2 protein]; [Silver Compounds results in increased susceptibility to 17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid] which results in increased expression of CXCL2 mRNA |
CTD |
PMID:21724996 PMID:34601004 |
|
NCBI chr14:17,181,030...17,183,075
Ensembl chr14:17,181,062...17,183,075
|
|
G |
Cxcl3 |
C-X-C motif chemokine ligand 3 |
multiple interactions |
ISO |
17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [Dextran Sulfate results in increased expression of CXCL1 protein] |
CTD |
PMID:21724996 |
|
NCBI chr14:17,270,146...17,289,458
Ensembl chr14:17,270,146...17,289,511
|
|
G |
Icam1 |
intercellular adhesion molecule 1 |
multiple interactions |
ISO |
17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [Dextran Sulfate results in increased expression of ICAM1 mRNA] |
CTD |
PMID:21724996 |
|
NCBI chr 8:19,553,063...19,565,438
Ensembl chr 8:19,553,645...19,565,438
|
|
G |
Ifng |
interferon gamma |
multiple interactions |
ISO |
17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [Lipopolysaccharides results in increased secretion of IFNG protein] |
CTD |
PMID:21724996 |
|
NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
ISO |
17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [Dextran Sulfate results in increased expression of IL1B protein] |
CTD |
PMID:21724996 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
ISO |
17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [[Dietary Fats co-treated with Cholesterol, Dietary] promotes the reaction [Silver Compounds results in increased expression of IL6 mRNA]]; 17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [[Dietary Fats co-treated with Cholesterol, Dietary] promotes the reaction [Silver Compounds results in increased expression of IL6 protein]]; 17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [[Silver Compounds results in increased susceptibility to [Dietary Fats co-treated with Cholesterol, Dietary]] which results in increased expression of IL6 mRNA]; 17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [[Silver Compounds results in increased susceptibility to [Dietary Fats co-treated with Cholesterol, Dietary]] which results in increased expression of IL6 protein]; 17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [Lipopolysaccharides results in increased secretion of IL6 protein]; 17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [Silver Compounds results in increased expression of IL6 mRNA]; 17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [Silver Compounds results in increased expression of IL6 protein] |
CTD |
PMID:21724996 PMID:34601004 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Itgal |
integrin subunit alpha L |
multiple interactions |
ISO |
17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [Dextran Sulfate results in increased expression of ITGAL mRNA] |
CTD |
PMID:21724996 |
|
NCBI chr 1:181,918,183...181,955,735
Ensembl chr 1:181,918,183...181,955,732
|
|
G |
Mpo |
myeloperoxidase |
multiple interactions |
ISO |
17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [Dextran Sulfate results in increased activity of MPO protein]; 17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased activity of MPO protein] |
CTD |
PMID:21724996 |
|
NCBI chr10:72,594,458...72,608,862
Ensembl chr10:72,594,661...72,604,819
|
|
G |
Nfkbia |
NFKB inhibitor alpha |
multiple interactions |
ISO |
17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [Dextran Sulfate results in increased expression of NFKBIA mRNA] |
CTD |
PMID:21724996 |
|
NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
multiple interactions |
ISO |
17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid binds to and affects the activity of PPARG protein |
CTD |
PMID:17056761 |
|
NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions |
ISO |
17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 mRNA] |
CTD |
PMID:21724996 |
|
NCBI chr13:62,164,080...62,169,770
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
ISO |
17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [Dextran Sulfate results in increased activity of RELA protein] |
CTD |
PMID:21724996 |
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions decreases secretion |
ISO |
17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [Dextran Sulfate results in increased expression of TNF protein]; 17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [Lipopolysaccharides results in increased secretion of TNF protein] 17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid results in decreased secretion of TNF protein |
CTD |
PMID:17056761 PMID:21724996 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Vcam1 |
vascular cell adhesion molecule 1 |
multiple interactions |
ISO |
17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [Dextran Sulfate results in increased expression of VCAM1 mRNA] |
CTD |
PMID:21724996 |
|
NCBI chr 2:204,038,120...204,057,852
Ensembl chr 2:204,038,114...204,057,958
|
|
|
G |
Crp |
C-reactive protein |
affects expression |
ISO |
docosapentaenoic acid affects the expression of CRP protein |
CTD |
PMID:22113248 |
|
NCBI chr13:85,131,635...85,175,179
Ensembl chr13:85,124,977...85,175,178
|
|
G |
Pla2g6 |
phospholipase A2 group VI |
multiple interactions |
EXP |
docosapentaenoic acid inhibits the reaction [Ethanol results in decreased expression of PLA2G6 protein] |
CTD |
PMID:25029343 |
|
NCBI chr 7:110,851,378...110,891,557
Ensembl chr 7:110,851,378...110,891,114
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
decreases expression multiple interactions |
EXP |
docosapentaenoic acid results in decreased expression of PTGS2 protein docosapentaenoic acid inhibits the reaction [Dimethoate results in increased expression of PTGS2 protein] |
CTD |
PMID:22476691 |
|
NCBI chr13:62,164,080...62,169,770
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Rxra |
retinoid X receptor alpha |
affects binding |
ISO |
docosapentaenoic acid binds to RXRA protein |
CTD |
PMID:16258897 |
|
NCBI chr 3:10,989,832...11,076,366
Ensembl chr 3:10,989,832...11,073,712
|
|
|
G |
Alox15 |
arachidonate 15-lipoxygenase |
multiple interactions increases abundance increases chemical synthesis |
EXP ISO |
[[Oxygen deficiency results in increased activity of ALOX15 protein] which results in increased chemical synthesis of 15-hydroxy-5,8,11,13-eicosatetraenoic acid] which results in decreased expression of KCNA5 mRNA; [[Oxygen deficiency results in increased activity of ALOX15 protein] which results in increased chemical synthesis of 15-hydroxy-5,8,11,13-eicosatetraenoic acid] which results in decreased expression of KCNA5 protein; [Oxygen deficiency results in increased activity of ALOX15 protein] which results in increased chemical synthesis of 15-hydroxy-5,8,11,13-eicosatetraenoic acid; cinnamyl-3,4-dihydroxycyanocinnamate inhibits the reaction [[[Oxygen deficiency results in increased activity of ALOX15 protein] which results in increased chemical synthesis of 15-hydroxy-5,8,11,13-eicosatetraenoic acid] which results in decreased expression of KCNA5 mRNA]; Masoprocol inhibits the reaction [[[Oxygen deficiency results in increased activity of ALOX15 protein] which results in increased chemical synthesis of 15-hydroxy-5,8,11,13-eicosatetraenoic acid] which results in decreased expression of KCNA5 mRNA] ALOX15 protein results in increased abundance of 15-hydroxy-5,8,11,13-eicosatetraenoic acid [ALOX15 protein affects the metabolism of Arachidonic Acid] which results in increased abundance of 15-hydroxy-5,8,11,13-eicosatetraenoic acid ALOX15 protein results in increased chemical synthesis of 15-hydroxy-5,8,11,13-eicosatetraenoic acid |
CTD |
PMID:18984061 PMID:21193584 PMID:23872364 |
|
NCBI chr10:55,060,169...55,068,885
Ensembl chr10:55,060,412...55,068,874
|
|
G |
Alox5 |
arachidonate 5-lipoxygenase |
multiple interactions |
ISO |
[benoxaprofen results in decreased activity of ALOX5 protein] which results in increased abundance of 15-hydroxy-5,8,11,13-eicosatetraenoic acid; [Masoprocol results in decreased activity of ALOX5 protein] which results in increased abundance of 15-hydroxy-5,8,11,13-eicosatetraenoic acid; [RS 43179 results in decreased activity of ALOX5 protein] which results in increased abundance of 15-hydroxy-5,8,11,13-eicosatetraenoic acid; [tenidap results in decreased activity of ALOX5 protein] which results in increased abundance of 15-hydroxy-5,8,11,13-eicosatetraenoic acid |
CTD |
PMID:2849922 |
|
NCBI chr 4:149,531,329...149,578,696
Ensembl chr 4:149,531,515...149,578,743
|
|
G |
App |
amyloid beta precursor protein |
increases secretion multiple interactions |
ISO |
APP protein modified form results in increased secretion of 15-hydroxy-5,8,11,13-eicosatetraenoic acid CNB 001 inhibits the reaction [APP protein modified form results in increased secretion of 15-hydroxy-5,8,11,13-eicosatetraenoic acid]; Dronabinol inhibits the reaction [APP protein modified form results in increased secretion of 15-hydroxy-5,8,11,13-eicosatetraenoic acid]; L 685458 inhibits the reaction [APP protein modified form results in increased secretion of 15-hydroxy-5,8,11,13-eicosatetraenoic acid] |
CTD |
PMID:28721267 |
|
NCBI chr11:24,019,774...24,236,584
Ensembl chr11:24,019,778...24,236,561
|
|
G |
Egf |
epidermal growth factor |
multiple interactions increases chemical synthesis |
ISO |
15-hydroxy-5,8,11,13-eicosatetraenoic acid promotes the reaction [EGF protein affects the localization of PRKCA protein] EGF protein results in increased chemical synthesis of 15-hydroxy-5,8,11,13-eicosatetraenoic acid |
CTD |
PMID:15613483 |
|
NCBI chr 2:218,219,408...218,302,370
Ensembl chr 2:218,219,415...218,302,064
|
|
G |
Ephx2 |
epoxide hydrolase 2 |
increases activity |
ISO |
15-hydroxy-5,8,11,13-eicosatetraenoic acid results in increased activity of EPHX2 protein |
CTD |
PMID:25600587 |
|
NCBI chr15:40,289,901...40,327,632
Ensembl chr15:40,289,902...40,327,615
|
|
G |
Hgf |
hepatocyte growth factor |
multiple interactions |
ISO |
15-hydroxy-5,8,11,13-eicosatetraenoic acid promotes the reaction [HGF protein affects the localization of PRKCA protein] |
CTD |
PMID:15613483 |
|
NCBI chr 4:18,673,736...18,745,582
Ensembl chr 4:18,677,101...18,745,409
|
|
G |
Il1b |
interleukin 1 beta |
increases secretion multiple interactions |
ISO |
15-hydroxy-5,8,11,13-eicosatetraenoic acid results in increased secretion of IL1B protein IL1B protein affects the reaction [15-hydroxy-5,8,11,13-eicosatetraenoic acid results in increased secretion of LYZ protein]; IL1B protein affects the reaction [TNF protein affects the reaction [15-hydroxy-5,8,11,13-eicosatetraenoic acid results in increased secretion of LYZ protein]]; TNF protein affects the reaction [IL1B protein affects the reaction [15-hydroxy-5,8,11,13-eicosatetraenoic acid results in increased secretion of LYZ protein]] |
CTD |
PMID:23355332 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Kcna5 |
potassium voltage-gated channel subfamily A member 5 |
multiple interactions affects activity |
EXP |
[[Oxygen deficiency results in increased activity of ALOX15 protein] which results in increased chemical synthesis of 15-hydroxy-5,8,11,13-eicosatetraenoic acid] which results in decreased expression of KCNA5 mRNA; [[Oxygen deficiency results in increased activity of ALOX15 protein] which results in increased chemical synthesis of 15-hydroxy-5,8,11,13-eicosatetraenoic acid] which results in decreased expression of KCNA5 protein; cinnamyl-3,4-dihydroxycyanocinnamate inhibits the reaction [[[Oxygen deficiency results in increased activity of ALOX15 protein] which results in increased chemical synthesis of 15-hydroxy-5,8,11,13-eicosatetraenoic acid] which results in decreased expression of KCNA5 mRNA]; Masoprocol inhibits the reaction [[[Oxygen deficiency results in increased activity of ALOX15 protein] which results in increased chemical synthesis of 15-hydroxy-5,8,11,13-eicosatetraenoic acid] which results in decreased expression of KCNA5 mRNA] 15-hydroxy-5,8,11,13-eicosatetraenoic acid affects the activity of KCNA5 protein |
CTD |
PMID:18984061 |
|
NCBI chr 4:159,354,689...159,358,173
Ensembl chr 4:159,350,097...159,357,697
|
|
G |
Kcnb1 |
potassium voltage-gated channel subfamily B member 1 |
affects activity |
EXP |
15-hydroxy-5,8,11,13-eicosatetraenoic acid affects the activity of KCNB1 protein |
CTD |
PMID:18984061 |
|
NCBI chr 3:155,820,255...155,913,383
Ensembl chr 3:155,822,963...155,916,194
|
|
G |
Kcnc4 |
potassium voltage-gated channel subfamily C member 4 |
affects activity |
EXP |
15-hydroxy-5,8,11,13-eicosatetraenoic acid affects the activity of KCNC4 protein |
CTD |
PMID:18984061 |
|
NCBI chr 2:195,063,967...195,099,233
Ensembl chr 2:195,071,769...195,099,233
|
|
G |
Krt1 |
keratin 1 |
multiple interactions |
ISO |
15-hydroxy-5,8,11,13-eicosatetraenoic acid inhibits the reaction [Calcium results in increased expression of KRT1 mRNA] |
CTD |
PMID:12069687 |
|
NCBI chr 7:132,976,618...132,981,844
Ensembl chr 7:132,976,620...132,981,844
|
|
G |
Lyz2 |
lysozyme 2 |
increases secretion multiple interactions |
ISO |
15-hydroxy-5,8,11,13-eicosatetraenoic acid results in increased secretion of LYZ protein [parthenolide co-treated with artemisinin co-treated with Quercetin] inhibits the reaction [15-hydroxy-5,8,11,13-eicosatetraenoic acid results in increased secretion of LYZ protein]; artemisinin inhibits the reaction [15-hydroxy-5,8,11,13-eicosatetraenoic acid results in increased secretion of LYZ protein]; IL1B protein affects the reaction [15-hydroxy-5,8,11,13-eicosatetraenoic acid results in increased secretion of LYZ protein]; IL1B protein affects the reaction [TNF protein affects the reaction [15-hydroxy-5,8,11,13-eicosatetraenoic acid results in increased secretion of LYZ protein]]; parthenolide inhibits the reaction [15-hydroxy-5,8,11,13-eicosatetraenoic acid results in increased secretion of LYZ protein]; Quercetin inhibits the reaction [15-hydroxy-5,8,11,13-eicosatetraenoic acid results in increased secretion of LYZ protein]; SB 203580 inhibits the reaction [15-hydroxy-5,8,11,13-eicosatetraenoic acid results in increased secretion of LYZ protein]; TNF protein affects the reaction [15-hydroxy-5,8,11,13-eicosatetraenoic acid results in increased secretion of LYZ protein]; TNF protein affects the reaction [IL1B protein affects the reaction [15-hydroxy-5,8,11,13-eicosatetraenoic acid results in increased secretion of LYZ protein]] |
CTD |
PMID:23355332 |
|
NCBI chr 7:52,906,810...52,912,154
Ensembl chr 7:52,906,811...52,912,106
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
increases phosphorylation |
ISO |
15-hydroxy-5,8,11,13-eicosatetraenoic acid results in increased phosphorylation of MAPK1 protein |
CTD |
PMID:25600587 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
increases phosphorylation |
ISO |
15-hydroxy-5,8,11,13-eicosatetraenoic acid results in increased phosphorylation of MAPK3 protein |
CTD |
PMID:25600587 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Nfkb1 |
nuclear factor kappa B subunit 1 |
increases activity affects localization multiple interactions |
ISO |
15-hydroxy-5,8,11,13-eicosatetraenoic acid results in increased activity of NFKB1 protein 15-hydroxy-5,8,11,13-eicosatetraenoic acid affects the localization of NFKB1 protein artemisinin inhibits the reaction [15-hydroxy-5,8,11,13-eicosatetraenoic acid affects the localization of NFKB1 protein] |
CTD |
PMID:23355332 PMID:25600587 |
|
NCBI chr 2:224,016,214...224,132,135
Ensembl chr 2:224,016,214...224,110,404
|
|
G |
Nfkbia |
NFKB inhibitor alpha |
multiple interactions |
ISO |
15-hydroxy-5,8,11,13-eicosatetraenoic acid results in increased phosphorylation of and results in increased degradation of NFKBIA protein; calphostin C inhibits the reaction [15-hydroxy-5,8,11,13-eicosatetraenoic acid results in increased phosphorylation of and results in increased degradation of NFKBIA protein] 15-hydroxy-5,8,11,13-eicosatetraenoic acid results in increased phosphorylation of and results in increased degradation of NFKBIA protein; Quercetin inhibits the reaction [15-hydroxy-5,8,11,13-eicosatetraenoic acid results in increased phosphorylation of and results in increased degradation of NFKBIA protein] |
CTD |
PMID:15451026 PMID:23355332 |
|
NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941
|
|
G |
Nppa |
natriuretic peptide A |
increases expression |
ISO |
15-hydroxy-5,8,11,13-eicosatetraenoic acid results in increased expression of NPPA mRNA |
CTD |
PMID:25600587 |
|
NCBI chr 5:158,429,042...158,430,351
Ensembl chr 5:158,429,042...158,430,351
|
|
G |
Nppb |
natriuretic peptide B |
increases expression |
ISO |
15-hydroxy-5,8,11,13-eicosatetraenoic acid results in increased expression of NPPB mRNA |
CTD |
PMID:25600587 |
|
NCBI chr 5:158,416,813...158,418,175
Ensembl chr 5:158,416,866...158,418,168
|
|
G |
Ppard |
peroxisome proliferator-activated receptor delta |
multiple interactions |
ISO |
15-hydroxy-5,8,11,13-eicosatetraenoic acid binds to and results in increased activity of PPARD protein |
CTD |
PMID:12069687 |
|
NCBI chr20:6,298,785...6,363,970
Ensembl chr20:6,298,785...6,363,968
|
|
G |
Prkca |
protein kinase C, alpha |
multiple interactions increases activity affects localization |
ISO |
15-hydroxy-5,8,11,13-eicosatetraenoic acid promotes the reaction [EGF protein affects the localization of PRKCA protein]; 15-hydroxy-5,8,11,13-eicosatetraenoic acid promotes the reaction [HGF protein affects the localization of PRKCA protein] calphostin C inhibits the reaction [15-hydroxy-5,8,11,13-eicosatetraenoic acid results in increased activity of PRKCA protein] 15-hydroxy-5,8,11,13-eicosatetraenoic acid affects the localization of PRKCA protein |
CTD |
PMID:15451026 PMID:15613483 |
|
NCBI chr10:92,889,390...93,288,013
Ensembl chr10:92,894,012...93,288,012
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
increases activity multiple interactions affects localization |
ISO |
15-hydroxy-5,8,11,13-eicosatetraenoic acid results in increased activity of RELA protein artemisinin inhibits the reaction [15-hydroxy-5,8,11,13-eicosatetraenoic acid affects the localization of RELA protein] |
CTD |
PMID:23355332 PMID:25600587 |
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions increases secretion |
ISO |
IL1B protein affects the reaction [TNF protein affects the reaction [15-hydroxy-5,8,11,13-eicosatetraenoic acid results in increased secretion of LYZ protein]]; TNF protein affects the reaction [15-hydroxy-5,8,11,13-eicosatetraenoic acid results in increased secretion of LYZ protein]; TNF protein affects the reaction [IL1B protein affects the reaction [15-hydroxy-5,8,11,13-eicosatetraenoic acid results in increased secretion of LYZ protein]] 15-hydroxy-5,8,11,13-eicosatetraenoic acid results in increased secretion of TNF protein |
CTD |
PMID:23355332 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Ugt1a1 |
UDP glucuronosyltransferase family 1 member A1 |
increases glucuronidation |
ISO |
UGT1A1 protein results in increased glucuronidation of 15-hydroxy-5,8,11,13-eicosatetraenoic acid |
CTD |
PMID:15231852 |
|
NCBI chr 9:88,801,344...88,808,465
Ensembl chr 9:88,713,184...88,808,465
|
|
G |
Ugt1a2 |
UDP glucuronosyltransferase 1 family, polypeptide A2 |
increases glucuronidation |
ISO |
UGT1A3 protein results in increased glucuronidation of 15-hydroxy-5,8,11,13-eicosatetraenoic acid |
CTD |
PMID:15231852 |
|
NCBI chr 9:88,791,216...88,808,465
Ensembl chr 9:88,713,184...88,808,465
|
|
G |
Ugt1a5 |
UDP glucuronosyltransferase family 1 member A5 |
increases glucuronidation |
ISO |
UGT1A4 protein results in increased glucuronidation of 15-hydroxy-5,8,11,13-eicosatetraenoic acid |
CTD |
PMID:15231852 |
|
NCBI chr 9:88,762,250...88,808,465
Ensembl chr 9:88,713,184...88,808,465
|
|
G |
Ugt1a9 |
UDP glucuronosyltransferase family 1 member A9 |
increases glucuronidation |
ISO |
UGT1A9 protein results in increased glucuronidation of 15-hydroxy-5,8,11,13-eicosatetraenoic acid |
CTD |
PMID:15231852 |
|
NCBI chr 9:88,696,981...88,808,465
Ensembl chr 9:88,713,184...88,808,465
|
|
G |
Ugt2b7 |
UDP glucuronosyltransferase family 2 member B7 |
increases glucuronidation |
ISO |
UGT2B7 protein results in increased glucuronidation of 15-hydroxy-5,8,11,13-eicosatetraenoic acid |
CTD |
PMID:15231852 |
|
NCBI chr14:20,896,682...20,919,604
Ensembl chr14:20,896,682...20,919,604
|
|
|
G |
Abca1 |
ATP binding cassette subfamily A member 1 |
decreases expression |
ISO |
trilinolenin results in decreased expression of ABCA1 mRNA |
CTD |
PMID:18356535 |
|
NCBI chr 5:67,678,267...67,801,162
Ensembl chr 5:67,681,297...67,801,170
|
|
G |
Abcg5 |
ATP binding cassette subfamily G member 5 |
decreases expression |
ISO |
trilinolenin results in decreased expression of ABCG5 mRNA |
CTD |
PMID:18356535 |
|
NCBI chr 6:9,965,118...9,990,563
Ensembl chr 6:9,965,118...9,990,563
|
|
G |
Abcg8 |
ATP binding cassette subfamily G member 8 |
decreases expression |
ISO |
trilinolenin results in decreased expression of ABCG8 mRNA |
CTD |
PMID:18356535 |
|
NCBI chr 6:9,945,629...9,964,912
Ensembl chr 6:9,945,629...9,964,912
|
|
G |
Cyp27a1 |
cytochrome P450, family 27, subfamily a, polypeptide 1 |
decreases expression |
ISO |
trilinolenin results in decreased expression of CYP27A1 mRNA |
CTD |
PMID:18356535 |
|
NCBI chr 9:76,264,655...76,294,551
Ensembl chr 9:76,264,860...76,294,551
|
|
G |
Hmgcr |
3-hydroxy-3-methylglutaryl-CoA reductase |
increases expression |
ISO |
trilinolenin results in increased expression of HMGCR mRNA |
CTD |
PMID:18356535 |
|
NCBI chr 2:27,997,523...28,018,983
Ensembl chr 2:27,997,525...28,019,703
|
|
G |
Mttp |
microsomal triglyceride transfer protein |
increases expression |
ISO |
trilinolenin results in increased expression of MTTP mRNA |
CTD |
PMID:18356535 |
|
NCBI chr 2:226,613,090...226,654,239
Ensembl chr 2:226,613,090...226,654,239
|
|
G |
Npc1l1 |
NPC1 like intracellular cholesterol transporter 1 |
decreases expression |
ISO |
trilinolenin results in decreased expression of NPC1L1 mRNA |
CTD |
PMID:18356535 |
|
NCBI chr14:81,071,448...81,091,113
Ensembl chr14:81,071,451...81,091,113
|
|
G |
Scd |
stearoyl-CoA desaturase |
decreases expression |
ISO |
trilinolenin results in decreased expression of SCD1 mRNA |
CTD |
PMID:8729090 |
|
NCBI chr 1:243,269,745...243,282,878
Ensembl chr 1:243,269,747...243,282,562
|
|
|
G |
Abca1 |
ATP binding cassette subfamily A member 1 |
decreases expression |
ISO |
trilinolein results in decreased expression of ABCA1 mRNA |
CTD |
PMID:18356535 |
|
NCBI chr 5:67,678,267...67,801,162
Ensembl chr 5:67,681,297...67,801,170
|
|
G |
Abcg5 |
ATP binding cassette subfamily G member 5 |
decreases expression |
ISO |
trilinolein results in decreased expression of ABCG5 mRNA |
CTD |
PMID:18356535 |
|
NCBI chr 6:9,965,118...9,990,563
Ensembl chr 6:9,965,118...9,990,563
|
|
G |
Abcg8 |
ATP binding cassette subfamily G member 8 |
decreases expression |
ISO |
trilinolein results in decreased expression of ABCG8 mRNA |
CTD |
PMID:18356535 |
|
NCBI chr 6:9,945,629...9,964,912
Ensembl chr 6:9,945,629...9,964,912
|
|
G |
Cyp27a1 |
cytochrome P450, family 27, subfamily a, polypeptide 1 |
decreases expression |
ISO |
trilinolein results in decreased expression of CYP27A1 mRNA |
CTD |
PMID:18356535 |
|
NCBI chr 9:76,264,655...76,294,551
Ensembl chr 9:76,264,860...76,294,551
|
|
G |
Hmgcr |
3-hydroxy-3-methylglutaryl-CoA reductase |
increases expression |
ISO |
trilinolein results in increased expression of HMGCR mRNA |
CTD |
PMID:18356535 |
|
NCBI chr 2:27,997,523...28,018,983
Ensembl chr 2:27,997,525...28,019,703
|
|
G |
Mttp |
microsomal triglyceride transfer protein |
increases expression |
ISO |
trilinolein results in increased expression of MTTP mRNA |
CTD |
PMID:18356535 |
|
NCBI chr 2:226,613,090...226,654,239
Ensembl chr 2:226,613,090...226,654,239
|
|
G |
Npc1l1 |
NPC1 like intracellular cholesterol transporter 1 |
decreases expression |
ISO |
trilinolein results in decreased expression of NPC1L1 mRNA |
CTD |
PMID:18356535 |
|
NCBI chr14:81,071,448...81,091,113
Ensembl chr14:81,071,451...81,091,113
|
|
G |
Scd |
stearoyl-CoA desaturase |
multiple interactions decreases expression |
ISO |
Clofibrate inhibits the reaction [trilinolein results in decreased expression of SCD1 mRNA] |
CTD |
PMID:8790349 |
|
NCBI chr 1:243,269,745...243,282,878
Ensembl chr 1:243,269,747...243,282,562
|
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
ISO |
1,2-Dipalmitoylphosphatidylcholine inhibits the reaction [Asbestos, Crocidolite results in increased secretion of IL6 protein] |
CTD |
PMID:19041333 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Prnp |
prion protein |
multiple interactions affects folding |
ISO |
Copper affects the reaction [1,2-Dipalmitoylphosphatidylcholine affects the folding of PRNP protein modified form] |
CTD |
PMID:20936829 |
|
NCBI chr 3:119,186,073...119,201,513
Ensembl chr 3:119,177,485...119,203,937
|
|
|
G |
Fech |
ferrochelatase |
affects abundance |
ISO |
FECH protein affects the abundance of 1-palmitoyl-2-docosahexaenoyl-sn-glycero-3-phosphocholine |
CTD |
PMID:29906468 |
|
NCBI chr18:57,945,123...57,978,327
Ensembl chr18:57,945,122...57,979,348
|
|
|
G |
Fech |
ferrochelatase |
affects abundance |
ISO |
FECH protein affects the abundance of 1-palmitoyl-2-linoleoylphosphatidylcholine |
CTD |
PMID:29906468 |
|
NCBI chr18:57,945,123...57,978,327
Ensembl chr18:57,945,122...57,979,348
|
|
|
G |
Acta2 |
actin alpha 2, smooth muscle |
increases expression multiple interactions |
ISO |
lysophosphatidic acid results in increased expression of ACTA2 mRNA N-(4-chlorophenyl)-1-((3-(furan-2-yl)phenyl)carbonyl)piperidine-3-carboxamide inhibits the reaction [lysophosphatidic acid results in increased expression of ACTA2 mRNA] |
CTD |
PMID:24706986 |
|
NCBI chr 1:231,746,527...231,759,307
Ensembl chr 1:231,746,548...231,759,554
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
multiple interactions increases phosphorylation |
ISO EXP |
2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of AKT1 protein]; Resveratrol inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of AKT1 protein] 1-Butanol inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of AKT1 protein]; exoenzyme C3, Clostridium botulinum inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of AKT1 protein] |
CTD |
PMID:14769825 PMID:17550345 PMID:20103642 |
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Alox5 |
arachidonate 5-lipoxygenase |
multiple interactions |
ISO |
ALOX5 protein promotes the reaction [lysophosphatidic acid results in increased abundance of Hydrogen Peroxide]; Masoprocol inhibits the reaction [ALOX5 protein promotes the reaction [lysophosphatidic acid results in increased abundance of Hydrogen Peroxide]]; zileuton inhibits the reaction [ALOX5 protein promotes the reaction [lysophosphatidic acid results in increased abundance of Hydrogen Peroxide]] |
CTD |
PMID:10698703 |
|
NCBI chr 4:149,531,329...149,578,696
Ensembl chr 4:149,531,515...149,578,743
|
|
G |
Alpl |
alkaline phosphatase, biomineralization associated |
multiple interactions |
ISO |
[Lithocholic Acid co-treated with lysophosphatidic acid] results in increased activity of ALPL protein |
CTD |
PMID:19646460 |
|
NCBI chr 5:149,951,397...150,006,424
Ensembl chr 5:149,951,409...150,006,446
|
|
G |
Bcar1 |
BCAR1 scaffold protein, Cas family member |
increases phosphorylation |
ISO |
lysophosphatidic acid results in increased phosphorylation of BCAR1 protein |
CTD |
PMID:11792571 |
|
NCBI chr19:39,679,218...39,713,952
Ensembl chr19:39,679,204...39,713,907
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
increases expression |
ISO |
lysophosphatidic acid analog results in increased expression of BCL2 protein; lysophosphatidic acid results in increased expression of BCL2 protein |
CTD |
PMID:23251428 |
|
NCBI chr13:22,689,783...22,853,920
|
|
G |
C5 |
complement C5 |
increases expression |
ISO |
lysophosphatidic acid results in increased expression of HC protein |
CTD |
PMID:25822713 |
|
NCBI chr 3:18,270,696...18,361,994
Ensembl chr 3:18,270,696...18,361,994
|
|
G |
Casp3 |
caspase 3 |
multiple interactions |
ISO |
lysophosphatidic acid analog inhibits the reaction [cobaltous chloride results in increased activity of CASP3 protein]; lysophosphatidic acid inhibits the reaction [cobaltous chloride results in increased activity of CASP3 protein] |
CTD |
PMID:23251428 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Ccl12 |
C-C motif chemokine ligand 12 |
increases expression multiple interactions |
ISO |
lysophosphatidic acid results in increased expression of CCL12 protein 3-(4-(4-((1-(2-chlorophenyl)ethoxy)carbonyl amino)-3-methyl-5-isoxazolyl) benzylsulfanyl) propanoic acid inhibits the reaction [lysophosphatidic acid results in increased expression of CCL12 protein] |
CTD |
PMID:25822713 |
|
NCBI chr10:67,070,230...67,071,780
Ensembl chr10:67,070,230...67,071,780
|
|
G |
Ccl28 |
C-C motif chemokine ligand 28 |
multiple interactions increases expression |
ISO |
3-(4-(4-((1-(2-chlorophenyl)ethoxy)carbonyl amino)-3-methyl-5-isoxazolyl) benzylsulfanyl) propanoic acid inhibits the reaction [lysophosphatidic acid results in increased expression of CCL28 protein] |
CTD |
PMID:25822713 |
|
NCBI chr 2:51,601,354...51,625,999
Ensembl chr 2:51,601,331...51,625,997
|
|
G |
Ccn1 |
cellular communication network factor 1 |
multiple interactions increases expression |
ISO |
3-(4-(4-((1-(2-chlorophenyl)ethoxy)carbonyl amino)-3-methyl-5-isoxazolyl) benzylsulfanyl) propanoic acid inhibits the reaction [lysophosphatidic acid results in increased expression of CCN1 protein] |
CTD |
PMID:25822713 |
|
NCBI chr 2:234,562,410...234,565,370
Ensembl chr 2:234,562,408...234,565,484
|
|
G |
Ccn2 |
cellular communication network factor 2 |
increases expression multiple interactions |
EXP ISO |
lysophosphatidic acid results in increased expression of CCN2 protein N-(4-chlorophenyl)-1-((3-(furan-2-yl)phenyl)carbonyl)piperidine-3-carboxamide inhibits the reaction [lysophosphatidic acid results in increased expression of CCN2 mRNA] Simvastatin inhibits the reaction [lysophosphatidic acid results in increased expression of CCN2 protein]; Y 27632 inhibits the reaction [lysophosphatidic acid results in increased expression of CCN2 protein] |
CTD |
PMID:15200425 PMID:24706986 |
|
NCBI chr 1:20,802,199...20,805,315
Ensembl chr 1:20,802,199...20,805,734
|
|
G |
Col1a2 |
collagen type I alpha 2 chain |
increases expression multiple interactions |
ISO |
lysophosphatidic acid results in increased expression of COL1A2 mRNA N-(4-chlorophenyl)-1-((3-(furan-2-yl)phenyl)carbonyl)piperidine-3-carboxamide inhibits the reaction [lysophosphatidic acid results in increased expression of COL1A2 mRNA] |
CTD |
PMID:24706986 |
|
NCBI chr 4:32,563,938...32,598,868
Ensembl chr 4:32,563,381...32,598,867
|
|
G |
Csf1 |
colony stimulating factor 1 |
increases expression |
ISO |
lysophosphatidic acid results in increased expression of CSF1 protein |
CTD |
PMID:25822713 |
|
NCBI chr 2:195,377,215...195,396,608
Ensembl chr 2:195,377,215...195,411,704
|
|
G |
Cxcl12 |
C-X-C motif chemokine ligand 12 |
increases expression multiple interactions |
ISO |
lysophosphatidic acid results in increased expression of CXCL12 protein 3-(4-(4-((1-(2-chlorophenyl)ethoxy)carbonyl amino)-3-methyl-5-isoxazolyl) benzylsulfanyl) propanoic acid inhibits the reaction [lysophosphatidic acid results in increased expression of CXCL12 protein] |
CTD |
PMID:25822713 |
|
NCBI chr 4:150,388,326...150,401,173
Ensembl chr 4:150,388,325...150,401,168
|
|
G |
Cxcl16 |
C-X-C motif chemokine ligand 16 |
increases expression multiple interactions |
ISO |
lysophosphatidic acid results in increased expression of CXCL16 protein 3-(4-(4-((1-(2-chlorophenyl)ethoxy)carbonyl amino)-3-methyl-5-isoxazolyl) benzylsulfanyl) propanoic acid inhibits the reaction [lysophosphatidic acid results in increased expression of CXCL16 protein] |
CTD |
PMID:25822713 |
|
NCBI chr10:55,166,721...55,171,316
Ensembl chr10:55,166,723...55,171,592
|
|
G |
Cxcr1 |
C-X-C motif chemokine receptor 1 |
multiple interactions decreases expression |
ISO |
lysophosphatidic acid inhibits the reaction [CXCR1 protein binds to LPAR1 protein]; lysophosphatidic acid results in decreased expression of [CXCR1 protein binds to LPAR1 protein] lysophosphatidic acid results in decreased expression of CXCR1 mRNA |
CTD |
PMID:16224106 |
|
NCBI chr 9:75,768,124...75,771,122
Ensembl chr 9:75,766,770...75,771,084
|
|
G |
Dgka |
diacylglycerol kinase, alpha |
multiple interactions |
ISO |
DGKA protein promotes the reaction [lysophosphatidic acid results in increased activity of PIP5K1A protein] |
CTD |
PMID:10913605 |
|
NCBI chr 7:1,148,734...1,175,324
Ensembl chr 7:1,148,735...1,175,110
|
|
G |
Egfr |
epidermal growth factor receptor |
multiple interactions increases phosphorylation |
ISO |
GNA13 mutant form inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of EGFR protein]; Pertussis Toxin inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of EGFR protein]; resveratrol inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of EGFR protein] |
CTD |
PMID:23127547 |
|
NCBI chr14:91,176,931...91,349,722
Ensembl chr14:91,177,067...91,344,382
|
|
G |
Eif4ebp1 |
eukaryotic translation initiation factor 4E binding protein 1 |
multiple interactions increases phosphorylation |
EXP |
1-Butanol inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of EIF4EBP1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of EIF4EBP1 protein]; 2-butanol inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of EIF4EBP1 protein]; exoenzyme C3, Clostridium botulinum inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of EIF4EBP1 protein] |
CTD |
PMID:14769825 |
|
NCBI chr16:64,792,595...64,805,984
Ensembl chr16:64,790,226...64,805,984
|
|
G |
Enpp2 |
ectonucleotide pyrophosphatase/phosphodiesterase 2 |
multiple interactions decreases expression |
ISO EXP |
1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid acetoxymethyl ester inhibits the reaction [[ENPP2 protein co-treated with Capsaicin] results in increased abundance of lysophosphatidic acid]; 3-(2-methoxybenzylamino)-2-phenylpiperidine inhibits the reaction [[ENPP2 protein co-treated with Capsaicin] results in increased abundance of lysophosphatidic acid]; [[Capsaicin results in increased chemical synthesis of Lysophosphatidylcholines] which results in increased secretion of Lysophosphatidylcholines] promotes the reaction [ENPP2 results in increased chemical synthesis of lysophosphatidic acid]; [[ONO-8430506 results in decreased activity of ENPP2 protein] which results in decreased abundance of lysophosphatidic acid] which results in decreased expression of NFE2L2; [[ONO-8430506 results in decreased activity of ENPP2 protein] which results in decreased chemical synthesis of and results in decreased abundance of lysophosphatidic acid] which results in increased expression of ENPP2 mRNA; [ENPP2 protein co-treated with Capsaicin] results in increased abundance of lysophosphatidic acid; [ENPP2 protein co-treated with Lysophosphatidylcholines] results in increased chemical synthesis of lysophosphatidic acid; [ONO-8430506 results in decreased activity of ENPP2 protein] which results in decreased abundance of lysophosphatidic acid; [ONO-8430506 results in decreased activity of ENPP2 protein] which results in decreased chemical synthesis of and results in decreased abundance of lysophosphatidic acid; arachidonyltrifluoromethane inhibits the reaction [[ENPP2 protein co-treated with Capsaicin] results in increased abundance of lysophosphatidic acid]; bisindolylmaleimide I inhibits the reaction [[ENPP2 protein co-treated with Capsaicin] results in increased abundance of lysophosphatidic acid]; Dizocilpine Maleate inhibits the reaction [[ENPP2 protein co-treated with Capsaicin] results in increased abundance of lysophosphatidic acid]; IL1B protein inhibits the reaction [lysophosphatidic acid results in decreased expression of ENPP2 protein]; TNF protein inhibits the reaction [lysophosphatidic acid results in decreased expression of ENPP2 protein]; U 0126 inhibits the reaction [[ENPP2 protein co-treated with Capsaicin] results in increased abundance of lysophosphatidic acid]; xestospongin C inhibits the reaction [[ENPP2 protein co-treated with Capsaicin] results in increased abundance of lysophosphatidic acid] lysophosphatidic acid inhibits the reaction [ENPP2 mutant form results in decreased expression of MBP mRNA] |
CTD |
PMID:18594965 PMID:19014389 PMID:24599971 PMID:24747415 PMID:25398768 PMID:25896349 More...
|
|
NCBI chr 7:86,202,345...86,325,050
Ensembl chr 7:86,202,350...86,324,827
|
|
G |
Epo |
erythropoietin |
multiple interactions |
ISO |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [[lysophosphatidic acid co-treated with KITLG protein co-treated with EPO protein] results in increased expression of TFRC protein]; [lysophosphatidic acid co-treated with KITLG protein co-treated with EPO protein] results in increased expression of GATA1 mRNA; [lysophosphatidic acid co-treated with KITLG protein co-treated with EPO protein] results in increased expression of TFRC mRNA; [lysophosphatidic acid co-treated with KITLG protein co-treated with EPO protein] results in increased expression of TFRC protein; lysophosphatidic acid promotes the reaction [[KITLG protein co-treated with EPO protein] results in increased expression of GATA1 mRNA]; lysophosphatidic acid promotes the reaction [[KITLG protein co-treated with EPO protein] results in increased expression of GYPA mRNA]; lysophosphatidic acid promotes the reaction [[KITLG protein co-treated with EPO protein] results in increased expression of TFRC mRNA]; lysophosphatidic acid promotes the reaction [[KITLG protein co-treated with EPO protein] results in increased expression of TFRC protein]; Quercetin inhibits the reaction [[lysophosphatidic acid co-treated with KITLG protein co-treated with EPO protein] results in increased expression of GATA1 mRNA]; Quercetin inhibits the reaction [[lysophosphatidic acid co-treated with KITLG protein co-treated with EPO protein] results in increased expression of TFRC mRNA]; Quercetin inhibits the reaction [[lysophosphatidic acid co-treated with KITLG protein co-treated with EPO protein] results in increased expression of TFRC protein]; WP1066 inhibits the reaction [[lysophosphatidic acid co-treated with KITLG protein co-treated with EPO protein] results in increased expression of TFRC protein] |
CTD |
PMID:21915944 |
|
NCBI chr12:19,204,258...19,207,948
Ensembl chr12:19,204,508...19,207,946
|
|
G |
Gata1 |
GATA binding protein 1 |
multiple interactions |
ISO |
[lysophosphatidic acid co-treated with KITLG protein co-treated with EPO protein] results in increased expression of GATA1 mRNA; lysophosphatidic acid promotes the reaction [[KITLG protein co-treated with EPO protein] results in increased expression of GATA1 mRNA]; Quercetin inhibits the reaction [[lysophosphatidic acid co-treated with KITLG protein co-treated with EPO protein] results in increased expression of GATA1 mRNA] |
CTD |
PMID:21915944 |
|
NCBI chr X:14,529,706...14,537,530
Ensembl chr X:14,529,702...14,537,530
|
|
G |
Gna13 |
G protein subunit alpha 13 |
multiple interactions |
ISO |
GNA13 mutant form inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of EGFR protein] |
CTD |
PMID:23127547 |
|
NCBI chr10:94,337,939...94,370,774
Ensembl chr10:94,337,725...94,370,774
|
|
G |
Gypa |
glycophorin A |
multiple interactions |
ISO |
lysophosphatidic acid promotes the reaction [[KITLG protein co-treated with EPO protein] results in increased expression of GYPA mRNA] |
CTD |
PMID:21915944 |
|
NCBI chr19:27,450,311...27,465,940
Ensembl chr19:27,450,308...27,465,822
|
|
G |
Hif1a |
hypoxia inducible factor 1 subunit alpha |
multiple interactions increases expression |
ISO |
L-4F peptide inhibits the reaction [lysophosphatidic acid results in increased expression of HIF1A protein]; resveratrol inhibits the reaction [lysophosphatidic acid results in increased expression of HIF1A protein] [lysophosphatidic acid results in increased expression of HIF1A protein] which results in increased expression of VEGFA mRNA; [lysophosphatidic acid results in increased expression of HIF1A protein] which results in increased expression of VEGFA protein; lysophosphatidic acid results in increased expression of HIF1A protein |
CTD |
PMID:17919812 PMID:22537771 |
|
NCBI chr 6:92,624,059...92,669,262
Ensembl chr 6:92,624,390...92,669,261
|
|
G |
Hspb1 |
heat shock protein family B (small) member 1 |
multiple interactions increases phosphorylation |
EXP |
MK2i peptide inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of HSPB1 protein]; SB 203580 inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of HSPB1 protein] |
CTD |
PMID:20864298 |
|
NCBI chr12:20,794,014...20,795,675
Ensembl chr12:20,794,028...20,795,743
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
ISO |
IL1B protein inhibits the reaction [lysophosphatidic acid results in decreased expression of ENPP2 protein] |
CTD |
PMID:25896349 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il6 |
interleukin 6 |
increases secretion |
ISO |
lysophosphatidic acid results in increased secretion of IL6 protein |
CTD |
PMID:21821728 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Il6st |
interleukin 6 cytokine family signal transducer |
multiple interactions increases expression |
ISO |
3-(4-(4-((1-(2-chlorophenyl)ethoxy)carbonyl amino)-3-methyl-5-isoxazolyl) benzylsulfanyl) propanoic acid inhibits the reaction [lysophosphatidic acid results in increased expression of IL6ST protein] |
CTD |
PMID:25822713 |
|
NCBI chr 2:44,065,979...44,106,255
Ensembl chr 2:44,066,130...44,109,936
|
|
G |
Kitlg |
KIT ligand |
multiple interactions |
ISO |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [[lysophosphatidic acid co-treated with KITLG protein co-treated with EPO protein] results in increased expression of TFRC protein]; [lysophosphatidic acid co-treated with KITLG protein co-treated with EPO protein] results in increased expression of GATA1 mRNA; [lysophosphatidic acid co-treated with KITLG protein co-treated with EPO protein] results in increased expression of TFRC mRNA; [lysophosphatidic acid co-treated with KITLG protein co-treated with EPO protein] results in increased expression of TFRC protein; lysophosphatidic acid promotes the reaction [[KITLG protein co-treated with EPO protein] results in increased expression of GATA1 mRNA]; lysophosphatidic acid promotes the reaction [[KITLG protein co-treated with EPO protein] results in increased expression of GYPA mRNA]; lysophosphatidic acid promotes the reaction [[KITLG protein co-treated with EPO protein] results in increased expression of TFRC mRNA]; lysophosphatidic acid promotes the reaction [[KITLG protein co-treated with EPO protein] results in increased expression of TFRC protein]; Quercetin inhibits the reaction [[lysophosphatidic acid co-treated with KITLG protein co-treated with EPO protein] results in increased expression of GATA1 mRNA]; Quercetin inhibits the reaction [[lysophosphatidic acid co-treated with KITLG protein co-treated with EPO protein] results in increased expression of TFRC mRNA]; Quercetin inhibits the reaction [[lysophosphatidic acid co-treated with KITLG protein co-treated with EPO protein] results in increased expression of TFRC protein]; WP1066 inhibits the reaction [[lysophosphatidic acid co-treated with KITLG protein co-treated with EPO protein] results in increased expression of TFRC protein] |
CTD |
PMID:21915944 |
|
NCBI chr 7:34,896,075...34,977,215
Ensembl chr 7:34,896,053...34,977,214
|
|
G |
Kng2 |
kininogen 2 |
multiple interactions |
EXP |
KNG1 protein inhibits the reaction [[wortmannin co-treated with lysophosphatidic acid] results in increased phosphorylation of PTK2 protein] |
CTD |
PMID:10537051 |
|
NCBI chr11:77,913,876...77,936,247
Ensembl chr11:77,909,612...78,002,971
|
|
G |
Lama3 |
laminin subunit alpha 3 |
increases expression |
ISO |
lysophosphatidic acid results in increased expression of LAMA3 mRNA |
CTD |
PMID:15541073 |
|
NCBI chr18:3,523,168...3,751,722
Ensembl chr18:3,523,133...3,751,353
|
|
G |
Lamb3 |
laminin subunit beta 3 |
increases expression |
ISO |
lysophosphatidic acid results in increased expression of LAMB3 mRNA |
CTD |
PMID:15541073 |
|
NCBI chr13:104,833,810...104,875,405
Ensembl chr13:104,833,873...104,875,405
|
|
G |
Lamc2 |
laminin subunit gamma 2 |
increases expression |
ISO |
lysophosphatidic acid results in increased expression of LAMC2 mRNA |
CTD |
PMID:15541073 |
|
NCBI chr13:65,284,664...65,344,200
Ensembl chr13:65,284,664...65,344,200
|
|
G |
Lpar1 |
lysophosphatidic acid receptor 1 |
increases response to substance multiple interactions |
ISO |
LPAR1 protein results in increased susceptibility to lysophosphatidic acid LPAR1 protein affects the reaction [lysophosphatidic acid results in increased stability of and affects the localization of NFE2L2 protein]; lysophosphatidic acid inhibits the reaction [CXCR1 protein binds to LPAR1 protein]; lysophosphatidic acid results in decreased expression of [CXCR1 protein binds to LPAR1 protein] |
CTD |
PMID:16224106 PMID:16809448 PMID:25398768 |
|
NCBI chr 5:73,229,047...73,347,874
Ensembl chr 5:73,229,625...73,369,895
|
|
G |
Lpar3 |
lysophosphatidic acid receptor 3 |
multiple interactions |
ISO |
Endocannabinoids inhibits the reaction [lysophosphatidic acid binds to and results in increased activity of LPAR3 protein]; lysophosphatidic acid binds to and results in increased activity of LPAR3 protein |
CTD |
PMID:30102254 |
|
NCBI chr 2:235,125,234...235,193,916
Ensembl chr 2:235,149,065...235,193,357
|
|
G |
Lpar5 |
lysophosphatidic acid receptor 5 |
multiple interactions |
ISO |
Endocannabinoids inhibits the reaction [lysophosphatidic acid binds to and results in increased activity of LPAR5 protein]; lysophosphatidic acid binds to and results in increased activity of LPAR5 protein |
CTD |
PMID:30102254 |
|
NCBI chr 4:157,870,493...157,883,970
Ensembl chr 4:157,881,796...157,882,950
|
|
G |
Lpar6 |
lysophosphatidic acid receptor 6 |
multiple interactions |
ISO |
lysophosphatidic acid binds to and results in increased activity of LPAR6 protein |
CTD |
PMID:18297070 |
|
NCBI chr15:48,416,548...48,418,357
Ensembl chr15:48,416,544...48,422,331
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions increases phosphorylation |
ISO EXP |
Hydrogen Peroxide promotes the reaction [lysophosphatidic acid results in increased phosphorylation of MAPK1 protein]; resveratrol inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of MAPK1 protein] 1-Butanol inhibits the reaction [PLD1 protein affects the reaction [lysophosphatidic acid results in increased phosphorylation of MAPK1 protein]]; 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of MAPK1 protein]; Pertussis Toxin inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of MAPK1 protein]; PLD1 protein affects the reaction [lysophosphatidic acid results in increased phosphorylation of MAPK1 protein]; U 0126 inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of MAPK1 protein] |
CTD |
PMID:11243883 PMID:12657697 PMID:15081308 PMID:17919812 PMID:21179406 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions increases phosphorylation |
ISO EXP |
Hydrogen Peroxide promotes the reaction [lysophosphatidic acid results in increased phosphorylation of MAPK3 protein]; resveratrol inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of MAPK3 protein] 1-Butanol inhibits the reaction [PLD1 protein affects the reaction [lysophosphatidic acid results in increased phosphorylation of MAPK3 protein]]; 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of MAPK3 protein]; Pertussis Toxin inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of MAPK3 protein]; PLD1 protein affects the reaction [lysophosphatidic acid results in increased phosphorylation of MAPK3 protein]; U 0126 inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:11243883 PMID:12657697 PMID:15081308 PMID:17919812 PMID:21179406 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Mbp |
myelin basic protein |
multiple interactions |
EXP |
lysophosphatidic acid inhibits the reaction [ENPP2 mutant form results in decreased expression of MBP mRNA] |
CTD |
PMID:18594965 |
|
NCBI chr18:75,855,878...75,966,404
Ensembl chr18:75,855,878...75,966,404
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
multiple interactions increases expression |
ISO |
gefitinib inhibits the reaction [lysophosphatidic acid results in increased expression of MMP9 mRNA]; gefitinib promotes the reaction [resveratrol inhibits the reaction [lysophosphatidic acid results in increased expression of MMP9 mRNA]]; resveratrol inhibits the reaction [lysophosphatidic acid results in increased expression of MMP9 mRNA]; resveratrol promotes the reaction [gefitinib inhibits the reaction [lysophosphatidic acid results in increased expression of MMP9 mRNA]] |
CTD |
PMID:23127547 |
|
NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120
|
|
G |
Mtor |
mechanistic target of rapamycin kinase |
increases phosphorylation |
EXP |
lysophosphatidic acid results in increased phosphorylation of MTOR protein |
CTD |
PMID:14769825 |
|
NCBI chr 5:158,884,856...158,994,311
Ensembl chr 5:158,884,804...158,994,311
|
|
G |
Myl9 |
myosin light chain 9 |
increases phosphorylation multiple interactions |
ISO |
lysophosphatidic acid results in increased phosphorylation of MYL9 protein Farnesol analog inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of MYL9 protein]; geranylgeraniol analog inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of MYL9 protein] |
CTD |
PMID:24587105 |
|
NCBI chr 3:145,281,943...145,288,333
Ensembl chr 3:145,281,937...145,288,333
|
|
G |
Mylk |
myosin light chain kinase |
affects response to substance |
ISO |
MYLK protein affects the susceptibility to lysophosphatidic acid |
CTD |
PMID:10640419 |
|
NCBI chr11:65,783,008...66,030,239
Ensembl chr11:65,783,008...66,030,261
|
|
G |
Nfe2l2 |
NFE2 like bZIP transcription factor 2 |
multiple interactions |
ISO |
LPAR1 protein affects the reaction [lysophosphatidic acid results in increased stability of and affects the localization of NFE2L2 protein]; lysophosphatidic acid results in increased stability of and affects the localization of NFE2L2 protein [[ONO-8430506 results in decreased activity of ENPP2 protein] which results in decreased abundance of lysophosphatidic acid] which results in decreased expression of NFE2L2 |
CTD |
PMID:25398768 |
|
NCBI chr 3:60,594,239...60,621,785
Ensembl chr 3:60,594,242...60,621,737
|
|
G |
Nppa |
natriuretic peptide A |
multiple interactions increases expression |
EXP |
Pertussis Toxin inhibits the reaction [lysophosphatidic acid results in increased expression of NPPA protein]; Y 27632 inhibits the reaction [lysophosphatidic acid results in increased expression of NPPA protein] |
CTD |
PMID:15081308 PMID:25449040 |
|
NCBI chr 5:158,429,042...158,430,351
Ensembl chr 5:158,429,042...158,430,351
|
|
G |
Pip5k1a |
phosphatidylinositol-4-phosphate 5-kinase, type 1, alpha |
multiple interactions increases activity |
ISO |
1-Butanol inhibits the reaction [lysophosphatidic acid results in increased activity of PIP5K1A protein]; DGKA protein promotes the reaction [lysophosphatidic acid results in increased activity of PIP5K1A protein] |
CTD |
PMID:10913605 |
|
NCBI chr 2:182,628,299...182,671,584
Ensembl chr 2:182,628,300...182,671,598
|
|
G |
Plau |
plasminogen activator, urokinase |
multiple interactions increases expression |
ISO |
gefitinib inhibits the reaction [lysophosphatidic acid results in increased expression of PLAU mRNA]; gefitinib promotes the reaction [resveratrol inhibits the reaction [lysophosphatidic acid results in increased expression of PLAU mRNA]]; resveratrol inhibits the reaction [lysophosphatidic acid results in increased expression of PLAU mRNA]; resveratrol promotes the reaction [gefitinib inhibits the reaction [lysophosphatidic acid results in increased expression of PLAU mRNA]] |
CTD |
PMID:23127547 |
|
NCBI chr15:3,456,230...3,462,732
Ensembl chr15:3,456,232...3,462,775
|
|
G |
Pld1 |
phospholipase D1 |
multiple interactions increases activity |
EXP |
1-Butanol inhibits the reaction [PLD1 protein affects the reaction [lysophosphatidic acid results in increased phosphorylation of MAPK1 protein]]; 1-Butanol inhibits the reaction [PLD1 protein affects the reaction [lysophosphatidic acid results in increased phosphorylation of MAPK3 protein]]; bisindolylmaleimide I inhibits the reaction [lysophosphatidic acid results in increased activity of PLD1 protein]; Pertussis Toxin inhibits the reaction [lysophosphatidic acid results in increased activity of PLD1 protein]; PLD1 protein affects the reaction [lysophosphatidic acid results in increased phosphorylation of MAPK1 protein]; PLD1 protein affects the reaction [lysophosphatidic acid results in increased phosphorylation of MAPK3 protein]; toxB protein, Clostridium difficile inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of PLD1 protein] |
CTD |
PMID:11243883 PMID:14769825 |
|
NCBI chr 2:110,849,205...111,047,692
Ensembl chr 2:110,893,608...111,047,692
|
|
G |
Ppp1r12a |
protein phosphatase 1, regulatory subunit 12A |
increases phosphorylation multiple interactions |
EXP |
lysophosphatidic acid results in increased phosphorylation of PPP1R12A protein Y 27632 inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of PPP1R12A protein] |
CTD |
PMID:25449040 |
|
NCBI chr 7:43,482,808...43,593,689
Ensembl chr 7:43,482,803...43,593,425
|
|
G |
Ptk2 |
protein tyrosine kinase 2 |
increases phosphorylation multiple interactions |
ISO EXP |
lysophosphatidic acid results in increased phosphorylation of PTK2 protein [wortmannin co-treated with lysophosphatidic acid] results in increased phosphorylation of PTK2 protein; KNG1 protein inhibits the reaction [[wortmannin co-treated with lysophosphatidic acid] results in increased phosphorylation of PTK2 protein] [wortmannin co-treated with lysophosphatidic acid] results in increased phosphorylation of PTK2 protein; Atropine inhibits the reaction [oxotremorine M inhibits the reaction [[wortmannin co-treated with lysophosphatidic acid] results in increased phosphorylation of PTK2 protein]]; oxotremorine M inhibits the reaction [[wortmannin co-treated with lysophosphatidic acid] results in increased phosphorylation of PTK2 protein] |
CTD |
PMID:10537051 PMID:11792571 |
|
NCBI chr 7:105,126,725...105,331,848
Ensembl chr 7:105,126,728...105,331,783
|
|
G |
Ptk2b |
protein tyrosine kinase 2 beta |
increases phosphorylation |
ISO |
lysophosphatidic acid results in increased phosphorylation of PTK2B protein |
CTD |
PMID:11792571 |
|
NCBI chr15:40,360,722...40,481,235
Ensembl chr15:40,360,723...40,481,282
|
|
G |
Rhoa |
ras homolog family member A |
increases activity multiple interactions |
EXP ISO |
lysophosphatidic acid results in increased activity of RHOA protein Farnesol analog inhibits the reaction [lysophosphatidic acid results in increased activity of RHOA protein]; geranylgeraniol analog inhibits the reaction [lysophosphatidic acid results in increased activity of RHOA protein] |
CTD |
PMID:15081308 PMID:24587105 |
|
NCBI chr 8:108,991,926...109,025,746
Ensembl chr 8:108,991,954...109,025,746
|
|
G |
Rhoc |
ras homolog family member C |
multiple interactions increases activity |
ISO |
Farnesol analog inhibits the reaction [lysophosphatidic acid results in increased activity of RHOC protein]; geranylgeraniol analog inhibits the reaction [lysophosphatidic acid results in increased activity of RHOC protein] |
CTD |
PMID:24587105 |
|
NCBI chr 2:192,287,065...192,293,292
Ensembl chr 2:192,287,130...192,295,306
|
|
G |
Rps6kb1 |
ribosomal protein S6 kinase B1 |
increases phosphorylation multiple interactions |
ISO EXP |
lysophosphatidic acid results in increased phosphorylation of RPS6KB1 protein resveratrol inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of RPS6KB1 protein] 1-Butanol inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of RPS6KB1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of RPS6KB1 protein]; exoenzyme C3, Clostridium botulinum inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of RPS6KB1 protein] |
CTD |
PMID:14769825 PMID:17919812 |
|
NCBI chr10:71,323,777...71,367,908
Ensembl chr10:71,323,777...71,367,908
|
|
G |
Tfrc |
transferrin receptor |
multiple interactions |
ISO |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [[lysophosphatidic acid co-treated with KITLG protein co-treated with EPO protein] results in increased expression of TFRC protein]; [lysophosphatidic acid co-treated with KITLG protein co-treated with EPO protein] results in increased expression of TFRC mRNA; [lysophosphatidic acid co-treated with KITLG protein co-treated with EPO protein] results in increased expression of TFRC protein; lysophosphatidic acid promotes the reaction [[KITLG protein co-treated with EPO protein] results in increased expression of TFRC mRNA]; lysophosphatidic acid promotes the reaction [[KITLG protein co-treated with EPO protein] results in increased expression of TFRC protein]; Quercetin inhibits the reaction [[lysophosphatidic acid co-treated with KITLG protein co-treated with EPO protein] results in increased expression of TFRC mRNA]; Quercetin inhibits the reaction [[lysophosphatidic acid co-treated with KITLG protein co-treated with EPO protein] results in increased expression of TFRC protein]; WP1066 inhibits the reaction [[lysophosphatidic acid co-treated with KITLG protein co-treated with EPO protein] results in increased expression of TFRC protein] |
CTD |
PMID:21915944 |
|
NCBI chr11:68,163,413...68,185,257
Ensembl chr11:68,163,413...68,185,257
|
|
G |
Timp1 |
TIMP metallopeptidase inhibitor 1 |
multiple interactions increases expression |
ISO |
3-(4-(4-((1-(2-chlorophenyl)ethoxy)carbonyl amino)-3-methyl-5-isoxazolyl) benzylsulfanyl) propanoic acid inhibits the reaction [lysophosphatidic acid results in increased expression of TIMP1 protein] |
CTD |
PMID:25822713 |
|
NCBI chr X:1,212,969...1,217,714
Ensembl chr X:1,212,972...1,217,664
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
ISO |
TNF protein inhibits the reaction [lysophosphatidic acid results in decreased expression of ENPP2 protein] |
CTD |
PMID:25896349 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Vegfa |
vascular endothelial growth factor A |
increases expression multiple interactions |
ISO |
[lysophosphatidic acid results in increased expression of HIF1A protein] which results in increased expression of VEGFA mRNA; [lysophosphatidic acid results in increased expression of HIF1A protein] which results in increased expression of VEGFA protein resveratrol inhibits the reaction [lysophosphatidic acid results in increased expression of VEGFA protein] |
CTD |
PMID:17919812 |
|
NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641
|
|
|
G |
Lipc |
lipase C, hepatic type |
multiple interactions decreases abundance |
ISO |
[LIPC gene mutant form co-treated with LIPG gene mutant form] results in decreased abundance of 1-stearoyl-2-oleoyl-sn-glycerol LIPC gene mutant form results in decreased abundance of 1-stearoyl-2-oleoyl-sn-glycerol |
CTD |
PMID:24777581 |
|
NCBI chr 8:71,509,633...71,635,663
Ensembl chr 8:71,509,635...71,635,464
|
|
G |
Lipg |
lipase G, endothelial type |
decreases abundance multiple interactions |
ISO |
LIPG gene mutant form results in decreased abundance of 1-stearoyl-2-oleoyl-sn-glycerol [LIPC gene mutant form co-treated with LIPG gene mutant form] results in decreased abundance of 1-stearoyl-2-oleoyl-sn-glycerol |
CTD |
PMID:24777581 |
|
NCBI chr18:68,514,923...68,536,105
Ensembl chr18:68,514,923...68,536,260
|
|
|
G |
Lipg |
lipase G, endothelial type |
increases hydrolysis |
ISO |
LIPG protein results in increased hydrolysis of 1-O-hexadecyl-2-arachidonyl-sn-glycero-3-phosphocholine |
CTD |
PMID:15953354 |
|
NCBI chr18:68,514,923...68,536,105
Ensembl chr18:68,514,923...68,536,260
|
|
|
G |
Lipc |
lipase C, hepatic type |
decreases abundance |
ISO |
LIPC gene mutant form results in decreased abundance of 1-palmitoyl-2-oleoyl-sn-glycerol |
CTD |
PMID:24777581 |
|
NCBI chr 8:71,509,633...71,635,663
Ensembl chr 8:71,509,635...71,635,464
|
|
G |
Lipg |
lipase G, endothelial type |
decreases abundance |
ISO |
LIPG gene mutant form results in decreased abundance of 1-palmitoyl-2-oleoyl-sn-glycerol |
CTD |
PMID:24777581 |
|
NCBI chr18:68,514,923...68,536,105
Ensembl chr18:68,514,923...68,536,260
|
|
|
G |
Col1a1 |
collagen type I alpha 1 chain |
multiple interactions |
ISO |
1-stearoyl-2-arachidonoylglycerol inhibits the reaction [TGFB1 protein results in increased expression of COL1A1 mRNA] |
CTD |
PMID:27936102 |
|
NCBI chr10:79,883,622...79,900,625
Ensembl chr10:79,883,622...79,900,624
|
|
G |
Dagla |
diacylglycerol lipase, alpha |
increases metabolic processing |
ISO |
DAGLA protein results in increased metabolism of 1-stearoyl-2-arachidonoylglycerol |
CTD |
PMID:18657971 |
|
NCBI chr 1:206,890,635...206,947,332
Ensembl chr 1:206,890,638...206,947,232
|
|
G |
Daglb |
diacylglycerol lipase, beta |
increases metabolic processing |
ISO |
DAGLB protein results in increased metabolism of 1-stearoyl-2-arachidonoylglycerol |
CTD |
PMID:18657971 |
|
NCBI chr12:11,059,732...11,102,170
Ensembl chr12:11,059,732...11,102,154
|
|
G |
Dgke |
diacylglycerol kinase epsilon |
increases phosphorylation |
ISO |
DGKE protein results in increased phosphorylation of 1-stearoyl-2-arachidonoylglycerol |
CTD |
PMID:17455907 |
|
NCBI chr10:73,852,679...73,877,334
Ensembl chr10:73,855,583...73,877,100
|
|
G |
Ppargc1a |
PPARG coactivator 1 alpha |
increases expression |
ISO |
1-stearoyl-2-arachidonoylglycerol results in increased expression of PPARGC1A mRNA |
CTD |
PMID:23056435 |
|
NCBI chr14:58,860,752...59,516,525
Ensembl chr14:58,861,144...59,512,656
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
multiple interactions |
ISO |
1-stearoyl-2-arachidonoylglycerol inhibits the reaction [TGFB1 protein results in increased expression of COL1A1 mRNA] |
CTD |
PMID:27936102 |
|
NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847
|
|
G |
Trpm6 |
transient receptor potential cation channel, subfamily M, member 6 |
multiple interactions |
ISO |
TRPM6 protein affects the reaction [1-stearoyl-2-arachidonoylglycerol results in increased transport of Barium]; TRPM6 protein affects the reaction [1-stearoyl-2-arachidonoylglycerol results in increased transport of Calcium] |
CTD |
PMID:11988098 |
|
NCBI chr 1:216,136,407...216,320,523
Ensembl chr 1:216,170,038...216,320,520
|
|
|
G |
Lipc |
lipase C, hepatic type |
decreases abundance |
ISO |
LIPC gene mutant form results in decreased abundance of 1-stearoyl-2-linoleoyl-sn-glycerol |
CTD |
PMID:24777581 |
|
NCBI chr 8:71,509,633...71,635,663
Ensembl chr 8:71,509,635...71,635,464
|
|
G |
Lipg |
lipase G, endothelial type |
decreases abundance |
ISO |
LIPG gene mutant form results in decreased abundance of 1-stearoyl-2-linoleoyl-sn-glycerol |
CTD |
PMID:24777581 |
|
NCBI chr18:68,514,923...68,536,105
Ensembl chr18:68,514,923...68,536,260
|
|
|
G |
Lipc |
lipase C, hepatic type |
multiple interactions |
ISO |
[LIPC gene mutant form co-treated with LIPG gene mutant form] results in increased abundance of stearoyl alpha-lysolecithin |
CTD |
PMID:24777581 |
|
NCBI chr 8:71,509,633...71,635,663
Ensembl chr 8:71,509,635...71,635,464
|
|
G |
Lipg |
lipase G, endothelial type |
multiple interactions |
ISO |
[LIPC gene mutant form co-treated with LIPG gene mutant form] results in increased abundance of stearoyl alpha-lysolecithin |
CTD |
PMID:24777581 |
|
NCBI chr18:68,514,923...68,536,105
Ensembl chr18:68,514,923...68,536,260
|
|
|
G |
Gpx1 |
glutathione peroxidase 1 |
increases response to substance |
ISO |
GPX1 protein results in increased susceptibility to 12-HPETE |
CTD |
PMID:11115402 |
|
NCBI chr 8:109,026,905...109,028,031
Ensembl chr 8:109,026,905...109,028,024
|
|
G |
Gpx4 |
glutathione peroxidase 4 |
increases chemical synthesis |
ISO |
GPX4 protein results in increased chemical synthesis of 12-HPETE |
CTD |
PMID:11115402 |
|
NCBI chr 7:9,650,186...9,652,982
Ensembl chr 7:9,650,185...9,652,982
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions |
ISO |
12-HPETE inhibits the reaction [Sodium Salicylate inhibits the reaction [PTGS2 protein results in increased metabolism of Arachidonic Acid]]; 12-HPETE inhibits the reaction [Sodium Salicylate results in decreased activity of PTGS2 protein] |
CTD |
PMID:12538810 |
|
NCBI chr13:62,164,080...62,169,770
Ensembl chr13:62,163,932...62,172,188
|
|
|
G |
Ptgs1 |
prostaglandin-endoperoxide synthase 1 |
multiple interactions |
ISO |
[PTGS1 protein results in increased metabolism of Arachidonic Acid] which results in increased chemical synthesis of 12-hydroxy-5,8,10-heptadecatrienoic acid; arzanol inhibits the reaction [[PTGS1 protein results in increased metabolism of Arachidonic Acid] which results in increased chemical synthesis of 12-hydroxy-5,8,10-heptadecatrienoic acid] |
CTD |
PMID:20933508 |
|
NCBI chr 3:19,584,015...19,605,589
Ensembl chr 3:19,584,015...19,605,586
|
|
G |
Tbxas1 |
thromboxane A synthase 1 |
multiple interactions |
ISO |
[Sulfasalazine results in decreased activity of TBXAS1 protein] which results in decreased chemical synthesis of 12-hydroxy-5,8,10-heptadecatrienoic acid |
CTD |
PMID:2572437 |
|
NCBI chr 4:67,664,963...67,837,096
Ensembl chr 4:67,665,007...67,837,096
|
|
|
G |
Ptgr1 |
prostaglandin reductase 1 |
increases abundance multiple interactions |
ISO |
PTGR1 protein results in increased abundance of 15-keto-13,14-dihydroprostaglandin F2alpha [PTGR1 protein results in increased metabolism of 15-ketoprostaglandin F2alpha] which results in increased abundance of 15-keto-13,14-dihydroprostaglandin F2alpha |
CTD |
PMID:25619643 |
|
NCBI chr 5:73,784,000...73,802,624
Ensembl chr 5:73,784,009...73,802,666
|
|
|
G |
Cxcl2 |
C-X-C motif chemokine ligand 2 |
increases expression multiple interactions |
ISO |
13,14-dihydro-15-ketoprostaglandin D2 results in increased expression of CXCL2 protein 13,14-dihydro-15-ketoprostaglandin D2 promotes the reaction [Flutamide results in increased expression of CXCL2 mRNA] |
CTD |
PMID:21094227 PMID:21735453 |
|
NCBI chr14:17,181,030...17,183,075
Ensembl chr14:17,181,062...17,183,075
|
|
G |
Gata3 |
GATA binding protein 3 |
multiple interactions |
ISO |
13,14-dihydro-15-ketoprostaglandin D2 promotes the reaction [Flutamide results in increased expression of GATA3 mRNA] |
CTD |
PMID:21735453 |
|
NCBI chr17:68,643,760...68,666,000
Ensembl chr17:68,643,873...68,665,391
|
|
G |
Il4 |
interleukin 4 |
multiple interactions |
ISO |
13,14-dihydro-15-ketoprostaglandin D2 promotes the reaction [Flutamide results in increased expression of IL4 protein] |
CTD |
PMID:21735453 |
|
NCBI chr10:37,771,203...37,776,750
Ensembl chr10:37,771,203...37,776,750
|
|
G |
Ptgdr |
prostaglandin D2 receptor |
multiple interactions |
ISO |
13,14-dihydro-15-ketoprostaglandin D2 binds to and results in increased activity of PTGDR protein; 13,14-dihydro-15-ketoprostaglandin D2 inhibits the reaction [Prostaglandin D2 binds to PTGDR protein] |
CTD |
PMID:9579725 |
|
NCBI chr15:17,360,304...17,367,679
Ensembl chr15:17,360,304...17,367,679
|
|
G |
Ptgdr2 |
prostaglandin D2 receptor 2 |
multiple interactions |
ISO EXP |
13,14-dihydro-15-ketoprostaglandin D2 inhibits the reaction [Prostaglandin D2 binds to PTGDR2 protein] 13,14-dihydro-15-ketoprostaglandin D2 binds to and results in increased activity of PTGDR2 protein 13,14-dihydro-15-ketoprostaglandin D2 binds to and results in increased activity of PTGDR2 protein; ramatroban inhibits the reaction [13,14-dihydro-15-ketoprostaglandin D2 binds to and results in increased activity of PTGDR2 protein] |
CTD |
PMID:12721327 PMID:15528449 PMID:16256979 |
|
NCBI chr 1:207,585,088...207,590,275
Ensembl chr 1:207,587,917...207,589,213
|
|
|
G |
Ptgr1 |
prostaglandin reductase 1 |
increases abundance multiple interactions |
ISO |
PTGR1 protein results in increased abundance of 15-keto-13,14-dihydroprostaglandin E2 [PTGR1 protein results in increased metabolism of 15-ketoprostaglandin E2] which results in increased abundance of 15-keto-13,14-dihydroprostaglandin E2 |
CTD |
PMID:25619643 |
|
NCBI chr 5:73,784,000...73,802,624
Ensembl chr 5:73,784,009...73,802,666
|
|
|
G |
Ptgr1 |
prostaglandin reductase 1 |
increases abundance multiple interactions |
ISO |
PTGR1 protein results in increased abundance of 13,14-dihydro-15-ketoprostaglandin E1 [PTGR1 protein results in increased metabolism of 15-ketoprostaglandin E] which results in increased abundance of 13,14-dihydro-15-ketoprostaglandin E1 |
CTD |
PMID:25619643 |
|
NCBI chr 5:73,784,000...73,802,624
Ensembl chr 5:73,784,009...73,802,666
|
|
|
G |
Bdnf |
brain-derived neurotrophic factor |
increases expression multiple interactions |
EXP |
9-deoxy-9,10-didehydro-12,13-didehydro-13,14-dihydroprostaglandin D2 analog results in increased expression of BDNF mRNA Dactinomycin inhibits the reaction [9-deoxy-9,10-didehydro-12,13-didehydro-13,14-dihydroprostaglandin D2 analog results in increased expression of BDNF mRNA] |
CTD |
PMID:22982731 |
|
NCBI chr 3:96,165,042...96,215,621
Ensembl chr 3:96,165,042...96,215,615
|
|
G |
Gdnf |
glial cell derived neurotrophic factor |
multiple interactions increases expression |
EXP |
Dactinomycin inhibits the reaction [9-deoxy-9,10-didehydro-12,13-didehydro-13,14-dihydroprostaglandin D2 analog results in increased expression of GDNF mRNA]; NFE2L2 protein affects the reaction [9-deoxy-9,10-didehydro-12,13-didehydro-13,14-dihydroprostaglandin D2 analog results in increased expression of GDNF mRNA] |
CTD |
PMID:22982731 |
|
NCBI chr 2:56,893,992...56,919,935
Ensembl chr 2:56,895,010...56,917,209
|
|
G |
Nfe2l2 |
NFE2 like bZIP transcription factor 2 |
multiple interactions |
EXP |
NFE2L2 protein affects the reaction [9-deoxy-9,10-didehydro-12,13-didehydro-13,14-dihydroprostaglandin D2 analog results in increased expression of GDNF mRNA] |
CTD |
PMID:22982731 |
|
NCBI chr 3:60,594,239...60,621,785
Ensembl chr 3:60,594,242...60,621,737
|
|
G |
Ngf |
nerve growth factor |
multiple interactions increases expression |
EXP |
Dactinomycin inhibits the reaction [9-deoxy-9,10-didehydro-12,13-didehydro-13,14-dihydroprostaglandin D2 analog results in increased expression of NGF mRNA] |
CTD |
PMID:22982731 |
|
NCBI chr 2:189,901,058...189,954,452
Ensembl chr 2:189,901,058...189,954,452
|
|
|
G |
Cat |
catalase |
increases expression |
ISO |
13-hydroperoxy-9,11-octadecadienoic acid results in increased expression of CAT protein |
CTD |
PMID:10946007 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Cav1 |
caveolin 1 |
increases expression |
ISO |
13-hydroperoxy-9,11-octadecadienoic acid results in increased expression of CAV1 mRNA |
CTD |
PMID:27257344 |
|
NCBI chr 4:45,640,624...45,673,708
Ensembl chr 4:45,634,918...45,673,705
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
multiple interactions |
EXP |
[13-hydroperoxy-9,11-octadecadienoic acid co-treated with 2-chloro-5-nitrobenzanilide] results in increased expression of CCL2 mRNA; [13-hydroperoxy-9,11-octadecadienoic acid co-treated with 2-chloro-5-nitrobenzanilide] results in increased expression of CCL2 protein; [13-hydroperoxy-9,11-octadecadienoic acid co-treated with MK-886] results in increased expression of CCL2 mRNA; [13-hydroperoxy-9,11-octadecadienoic acid co-treated with MK-886] results in increased expression of CCL2 protein |
CTD |
PMID:22135674 |
|
NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226
|
|
G |
Egr1 |
early growth response 1 |
multiple interactions |
EXP |
[13-hydroperoxy-9,11-octadecadienoic acid co-treated with 2-chloro-5-nitrobenzanilide] results in increased expression of EGR1 mRNA; [13-hydroperoxy-9,11-octadecadienoic acid co-treated with 2-chloro-5-nitrobenzanilide] results in increased expression of EGR1 protein; [13-hydroperoxy-9,11-octadecadienoic acid co-treated with MK-886] results in increased expression of EGR1 mRNA; [13-hydroperoxy-9,11-octadecadienoic acid co-treated with MK-886] results in increased expression of EGR1 protein |
CTD |
PMID:22135674 |
|
NCBI chr18:26,463,333...26,465,531
Ensembl chr18:26,462,981...26,466,766
|
|
G |
Ppara |
peroxisome proliferator activated receptor alpha |
increases expression |
EXP |
13-hydroperoxy-9,11-octadecadienoic acid results in increased expression of PPARA protein |
CTD |
PMID:22135674 |
|
NCBI chr 7:116,832,405...116,900,878
Ensembl chr 7:116,832,756...116,895,346
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
increases expression |
EXP |
13-hydroperoxy-9,11-octadecadienoic acid results in increased expression of PPARG protein |
CTD |
PMID:22135674 |
|
NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468
|
|
|
G |
Gsta1 |
glutathione S-transferase alpha 1 |
affects metabolic processing |
ISO |
GSTA1 protein affects the metabolism of 13-oxo-9,11-octadecadienoic acid |
CTD |
PMID:12031293 |
|
NCBI chr 9:23,703,476...23,720,121
Ensembl chr 9:23,703,477...23,720,121
|
|
G |
Gsta4 |
glutathione S-transferase alpha 4 |
affects metabolic processing |
ISO |
GSTA4 protein affects the metabolism of 13-oxo-9,11-octadecadienoic acid |
CTD |
PMID:12031293 |
|
NCBI chr 8:79,066,967...79,084,193
Ensembl chr 8:79,066,934...79,084,182
|
|
|
G |
Ace |
angiotensin I converting enzyme |
decreases activity |
EXP |
14,15-epoxy-5,8,11-eicosatrienoic acid analog results in decreased activity of ACE protein |
CTD |
PMID:27428043 |
|
NCBI chr10:90,910,316...90,930,437
Ensembl chr10:90,910,316...90,931,131
|
|
G |
Ace2 |
angiotensin I converting enzyme 2 |
multiple interactions |
ISO |
14,15-epoxy-5,8,11-eicosatrienoic acid analog promotes the reaction [REN2 protein results in increased expression of ACE2 protein] |
CTD |
PMID:27428043 |
|
NCBI chr X:30,293,597...30,340,961
Ensembl chr X:30,293,589...30,340,977
|
|
G |
Agt |
angiotensinogen |
decreases expression multiple interactions increases cleavage |
EXP ISO |
14,15-epoxy-5,8,11-eicosatrienoic acid analog results in decreased expression of AGT protein modified form [14,15-epoxy-5,8,11-eicosatrienoic acid analog results in increased cleavage of AGT protein modified form] which results in increased abundance of angiotensin I (1-7) 14,15-epoxy-5,8,11-eicosatrienoic acid analog inhibits the reaction [REN2 protein results in increased expression of AGT protein modified form] |
CTD |
PMID:27428043 |
|
NCBI chr19:52,529,139...52,549,618
Ensembl chr19:52,529,185...52,540,977
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
increases phosphorylation |
ISO |
14,15-epoxy-5,8,11-eicosatrienoic acid results in increased phosphorylation of AKT1 protein |
CTD |
PMID:16286479 |
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Cyp2c79 |
cytochrome P450, family 2, subfamily c, polypeptide 79 |
increases chemical synthesis |
ISO |
CYP2C8 protein results in increased chemical synthesis of 14,15-epoxy-5,8,11-eicosatrienoic acid |
CTD |
PMID:12675279 |
|
|
|
G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
multiple interactions increases chemical synthesis |
ISO |
Ketoconazole inhibits the reaction [CYP3A4 protein results in increased chemical synthesis of 14,15-epoxy-5,8,11-eicosatrienoic acid] |
CTD |
PMID:12675279 |
|
NCBI chr12:9,207,986...9,230,038
Ensembl chr12:9,015,383...9,285,008
|
|
G |
Ephx2 |
epoxide hydrolase 2 |
multiple interactions increases abundance |
ISO |
[Arsenites results in increased expression of and results in increased activity of EPHX2 protein] which results in decreased abundance of 14,15-epoxy-5,8,11-eicosatrienoic acid; [Mercuric Chloride results in increased expression of and results in increased activity of EPHX2 protein] which results in decreased abundance of 14,15-epoxy-5,8,11-eicosatrienoic acid EPHX2 gene mutant form results in increased abundance of 14,15-epoxy-5,8,11-eicosatrienoic acid |
CTD |
PMID:19896470 PMID:22680237 PMID:24472606 |
|
NCBI chr15:40,289,901...40,327,632
Ensembl chr15:40,289,902...40,327,615
|
|
G |
Fgf2 |
fibroblast growth factor 2 |
increases expression |
ISO |
14,15-epoxy-5,8,11-eicosatrienoic acid results in increased expression of FGF2 protein |
CTD |
PMID:16286479 |
|
NCBI chr 2:120,236,328...120,290,673
Ensembl chr 2:120,236,328...120,291,221
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
increases phosphorylation |
ISO |
14,15-epoxy-5,8,11-eicosatrienoic acid results in increased phosphorylation of MAPK1 protein |
CTD |
PMID:19464254 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
increases phosphorylation |
ISO |
14,15-epoxy-5,8,11-eicosatrienoic acid results in increased phosphorylation of MAPK3 protein |
CTD |
PMID:19464254 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Rps6kb1 |
ribosomal protein S6 kinase B1 |
increases phosphorylation |
ISO |
14,15-epoxy-5,8,11-eicosatrienoic acid results in increased phosphorylation of RPS6KB1 protein |
CTD |
PMID:16286479 |
|
NCBI chr10:71,323,777...71,367,908
Ensembl chr10:71,323,777...71,367,908
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
decreases secretion multiple interactions |
ISO |
TGFB1 protein results in decreased secretion of 14,15-epoxy-5,8,11-eicosatrienoic acid 12-(3-adamantan-1-ylureido)dodecanoic acid inhibits the reaction [TGFB1 protein results in decreased secretion of 14,15-epoxy-5,8,11-eicosatrienoic acid] |
CTD |
PMID:28694203 |
|
NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847
|
|
|
G |
Hpgd |
15-hydroxyprostaglandin dehydrogenase |
increases chemical synthesis |
ISO |
HPGD protein results in increased chemical synthesis of 15-ketoprostaglandin E2 |
CTD |
PMID:20448048 |
|
NCBI chr16:33,986,265...34,024,228
Ensembl chr16:33,986,266...34,024,228
|
|
G |
Ptgr1 |
prostaglandin reductase 1 |
multiple interactions increases metabolic processing increases reduction |
EXP ISO |
15-ketoprostaglandin E2 inhibits the reaction [PTGR1 protein results in increased reduction of 10-nitro-oleic acid analog]; Dithionitrobenzoic Acid inhibits the reaction [PTGR1 protein results in increased reduction of 15-ketoprostaglandin E2]; Indomethacin inhibits the reaction [PTGR1 protein results in increased reduction of 15-ketoprostaglandin E2] [PTGR1 protein results in increased metabolism of 15-ketoprostaglandin E2] which results in increased abundance of 15-keto-13,14-dihydroprostaglandin E2 |
CTD |
PMID:23878198 PMID:25619643 |
|
NCBI chr 5:73,784,000...73,802,624
Ensembl chr 5:73,784,009...73,802,666
|
|
|
G |
Abcc1 |
ATP binding cassette subfamily C member 1 |
multiple interactions affects export affects glutathionylation increases transport |
ISO |
[ABCC1 protein results in increased transport of 15-deoxy-delta(12,14)-prostaglandin J2 metabolite] affects the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of GCLC protein]; [verlukast binds to and results in decreased activity of ABCC1 protein] inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of GCLC protein]; ABCC1 protein affects the reaction [15-deoxy-delta(12,14)-prostaglandin J2 promotes the reaction [NFE2L2 protein results in increased expression of GCLC protein]]; ABCC1 protein affects the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of GCLC protein] ABCC1 protein affects the export of 15-deoxy-delta(12,14)-prostaglandin J2 analog ABCC1 protein affects the glutathionylation of 15-deoxy-delta(12,14)-prostaglandin J2 |
CTD |
PMID:14979731 PMID:21728338 |
|
NCBI chr10:528,961...655,179
Ensembl chr10:531,812...655,114
|
|
G |
Abcc3 |
ATP binding cassette subfamily C member 3 |
affects export |
ISO |
ABCC3 protein affects the export of 15-deoxy-delta(12,14)-prostaglandin J2 analog |
CTD |
PMID:14979731 |
|
NCBI chr10:79,296,681...79,342,749
Ensembl chr10:79,296,693...79,342,595
|
|
G |
Acaa2 |
acetyl-CoA acyltransferase 2 |
multiple interactions |
ISO |
[15-deoxy-delta(12,14)-prostaglandin J2 co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of ACAA2 mRNA |
CTD |
PMID:34323617 |
|
NCBI chr18:68,345,136...68,373,246
Ensembl chr18:68,345,012...68,373,249
|
|
G |
Adipoq |
adiponectin, C1Q and collagen domain containing |
multiple interactions |
ISO |
[15-deoxy-delta(12,14)-prostaglandin J2 co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of ADIPOQ mRNA |
CTD |
PMID:34323617 |
|
NCBI chr11:77,721,912...77,735,644
Ensembl chr11:77,721,912...77,735,564
|
|
G |
Agt |
angiotensinogen |
multiple interactions |
EXP |
15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [AGT protein results in decreased expression of PPARG protein]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [AGT protein results in increased expression of and results in increased secretion of SERPINE1 protein]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [AGT protein results in increased expression of SERPINE1 mRNA]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [AGT protein results in increased expression of TGFB1 protein]; 2,2-bis(4-glycidyloxyphenyl)propane inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [AGT protein results in increased expression of and results in increased secretion of SERPINE1 protein]]; 2,2-bis(4-glycidyloxyphenyl)propane inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [AGT protein results in increased expression of SERPINE1 mRNA]]; 2-chloro-5-nitrobenzanilide inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [AGT protein results in increased expression of and results in increased secretion of SERPINE1 protein]]; 2-chloro-5-nitrobenzanilide inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [AGT protein results in increased expression of SERPINE1 mRNA]] |
CTD |
PMID:18278065 |
|
NCBI chr19:52,529,139...52,549,618
Ensembl chr19:52,529,185...52,540,977
|
|
G |
Akr1c3 |
aldo-keto reductase family 1, member C3 |
multiple interactions |
ISO |
[Medroxyprogesterone Acetate inhibits the reaction [[AKR1C3 protein results in increased metabolism of Prostaglandin D2] which results in increased abundance of Dinoprost]] which results in increased abundance of 15-deoxy-delta(12,14)-prostaglandin J2 |
CTD |
PMID:19997560 |
|
NCBI chr17:66,110,970...66,127,867
Ensembl chr17:66,110,963...66,127,873
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
multiple interactions |
ISO |
[15-deoxy-delta(12,14)-prostaglandin J2 co-treated with alitretinoin] results in decreased phosphorylation of AKT1 protein |
CTD |
PMID:16611854 |
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Bglap |
bone gamma-carboxyglutamate protein |
decreases expression |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 results in decreased expression of BGLAP mRNA |
CTD |
PMID:12021203 |
|
NCBI chr 2:173,838,518...173,839,495
Ensembl chr 2:173,838,518...173,839,495
|
|
G |
Birc2 |
baculoviral IAP repeat-containing 2 |
decreases expression |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 results in decreased expression of BIRC2 protein |
CTD |
PMID:15498850 |
|
NCBI chr 8:4,968,856...4,989,325
Ensembl chr 8:4,968,842...4,988,732
|
|
G |
Birc3 |
baculoviral IAP repeat-containing 3 |
decreases expression |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 results in decreased expression of BIRC3 protein |
CTD |
PMID:15498850 |
|
NCBI chr 8:5,000,844...5,028,470
Ensembl chr 8:5,000,845...5,015,802
|
|
G |
Casp3 |
caspase 3 |
increases activity multiple interactions increases cleavage |
ISO EXP |
15-deoxy-delta(12,14)-prostaglandin J2 results in increased activity of CASP3 protein [delta(12)-prostaglandin J(2) co-treated with 9-deoxy-delta-9-prostaglandin D2 co-treated with 15-deoxy-delta(12,14)-prostaglandin J2] results in increased cleavage of CASP3 protein 15-deoxy-delta(12,14)-prostaglandin J2 results in increased cleavage of CASP3 protein 15-deoxy-delta(12,14)-prostaglandin J2 results in increased cleavage of and results in increased activity of CASP3 protein |
CTD |
PMID:11785780 PMID:15498850 PMID:16299251 PMID:23973622 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp8 |
caspase 8 |
multiple interactions |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 results in increased cleavage of and results in increased activity of CASP8 protein |
CTD |
PMID:15498850 |
|
NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542
|
|
G |
Casp9 |
caspase 9 |
multiple interactions |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 results in increased cleavage of and results in increased activity of CASP9 protein |
CTD |
PMID:15498850 |
|
NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
|
|
G |
Cat |
catalase |
multiple interactions |
ISO |
CAT protein inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IFNG protein results in increased phosphorylation of STAT1 protein]] |
CTD |
PMID:12847270 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
multiple interactions |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [[Dexamethasone binds to NR3C1 protein] which results in decreased expression of CCL2 protein] |
CTD |
PMID:15187150 |
|
NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226
|
|
G |
Ccl5 |
C-C motif chemokine ligand 5 |
multiple interactions |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of CCL5 mRNA] |
CTD |
PMID:23688403 |
|
NCBI chr10:68,322,826...68,327,365
Ensembl chr10:68,322,829...68,327,377
|
|
G |
Ccn2 |
cellular communication network factor 2 |
multiple interactions |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [TGFB1 protein results in increased expression of and results in increased secretion of CCN2 protein]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [TGFB1 protein results in increased expression of CCN2 mRNA]; SMAD2 protein modified form affects the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [TGFB1 protein results in increased expression of CCN2]] |
CTD |
PMID:19429239 |
|
NCBI chr 1:20,802,199...20,805,315
Ensembl chr 1:20,802,199...20,805,734
|
|
G |
Ccna2 |
cyclin A2 |
decreases expression |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 results in decreased expression of CCNA2 protein |
CTD |
PMID:15729575 |
|
NCBI chr 2:119,427,239...119,433,645
Ensembl chr 2:119,426,089...119,433,577
|
|
G |
Ccnb1 |
cyclin B1 |
decreases expression |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 results in decreased expression of CCNB1 protein |
CTD |
PMID:15729575 |
|
NCBI chr 2:31,912,190...31,921,163
Ensembl chr 2:31,912,193...31,921,172
|
|
G |
Ccnd3 |
cyclin D3 |
decreases expression |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 results in decreased expression of CCND3 protein |
CTD |
PMID:15729575 |
|
NCBI chr 9:13,394,161...13,400,341
Ensembl chr 9:13,394,169...13,489,371
|
|
G |
Ccne1 |
cyclin E1 |
decreases expression |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 results in decreased expression of CCNE1 protein |
CTD |
PMID:15729575 |
|
NCBI chr 1:90,781,947...90,791,188
Ensembl chr 1:90,781,949...90,791,101
|
|
G |
Cdk2 |
cyclin dependent kinase 2 |
decreases expression |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 results in decreased expression of CDK2 protein |
CTD |
PMID:15729575 |
|
NCBI chr 7:1,129,878...1,137,431
Ensembl chr 7:1,129,811...1,137,403
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
increases expression decreases expression |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of CDKN1A 15-deoxy-delta(12,14)-prostaglandin J2 results in decreased expression of CDKN1A protein |
CTD |
PMID:15254749 PMID:15729575 |
|
NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585
|
|
G |
Cdkn1b |
cyclin-dependent kinase inhibitor 1B |
decreases expression |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 results in decreased expression of CDKN1B protein |
CTD |
PMID:15729575 |
|
NCBI chr 4:167,760,067...167,765,177
Ensembl chr 4:167,760,181...167,764,982
|
|
G |
Cebpa |
CCAAT/enhancer binding protein alpha |
increases expression |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of CEBPA mRNA |
CTD |
PMID:12021203 |
|
NCBI chr 1:87,759,631...87,762,303
Ensembl chr 1:87,759,433...87,762,412
|
|
G |
Cflar |
CASP8 and FADD-like apoptosis regulator |
decreases expression |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 results in decreased expression of CFLAR protein |
CTD |
PMID:15498850 |
|
NCBI chr 9:60,185,338...60,236,173
Ensembl chr 9:60,185,452...60,237,034
|
|
G |
Chuk |
component of inhibitor of nuclear factor kappa B kinase complex |
multiple interactions |
ISO EXP |
15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [Tetradecanoylphorbol Acetate results in increased activity of CHUK protein] 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [manganese chloride results in increased phosphorylation of CHUK protein] |
CTD |
PMID:15498850 PMID:22245093 |
|
NCBI chr 1:242,959,539...242,995,066
Ensembl chr 1:242,959,760...242,995,065
|
|
G |
Cidec |
cell death-inducing DFFA-like effector c |
multiple interactions |
ISO |
[15-deoxy-delta(12,14)-prostaglandin J2 co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of CIDEC mRNA |
CTD |
PMID:34323617 |
|
NCBI chr 4:146,569,288...146,582,173
Ensembl chr 4:146,569,289...146,582,173
|
|
G |
Col1a1 |
collagen type I alpha 1 chain |
decreases expression |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 results in decreased expression of COL1A1 mRNA |
CTD |
PMID:12021203 |
|
NCBI chr10:79,883,622...79,900,625
Ensembl chr10:79,883,622...79,900,624
|
|
G |
Csf2 |
colony stimulating factor 2 |
multiple interactions |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IL1B protein results in increased expression of CSF2 mRNA]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IL1B protein results in increased expression of CSF2 protein]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [Lipopolysaccharides results in increased expression of CSF2 mRNA]; Dexamethasone promotes the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IL1B protein results in increased expression of CSF2 mRNA]] |
CTD |
PMID:12604364 PMID:14998300 |
|
NCBI chr10:38,386,945...38,388,926
Ensembl chr10:38,386,945...38,389,199
|
|
G |
Ddx58 |
DEXD/H-box helicase 58 |
multiple interactions |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [Lipopolysaccharides results in increased expression of DDX58 mRNA] |
CTD |
PMID:16303604 |
|
NCBI chr 5:55,321,229...55,369,947
Ensembl chr 5:55,321,235...55,370,819
|
|
G |
Egr1 |
early growth response 1 |
multiple interactions |
EXP |
15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [Oxygen deficiency results in increased expression of and results in increased activity of EGR1 protein]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [Oxygen deficiency results in increased expression of EGR1 mRNA] |
CTD |
PMID:12468449 |
|
NCBI chr18:26,463,333...26,465,531
Ensembl chr18:26,462,981...26,466,766
|
|
G |
Fabp4 |
fatty acid binding protein 4 |
multiple interactions increases expression |
ISO |
[15-deoxy-delta(12,14)-prostaglandin J2 co-treated with Tretinoin] results in increased expression of FABP4 mRNA [15-deoxy-delta(12,14)-prostaglandin J2 co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of FABP4 mRNA 15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of FABP4 mRNA |
CTD |
PMID:9543393 PMID:12021203 PMID:16573735 PMID:34323617 |
|
NCBI chr 2:91,580,858...91,585,578
Ensembl chr 2:91,580,885...91,585,578
|
|
G |
Fas |
Fas cell surface death receptor |
decreases expression |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 results in decreased expression of FAS mRNA |
CTD |
PMID:16712844 |
|
NCBI chr 1:231,798,963...231,832,591
Ensembl chr 1:231,798,960...231,832,591
|
|
G |
Fos |
Fos proto-oncogene, AP-1 transcription factor subunit |
multiple interactions increases expression |
ISO EXP |
15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IL1B protein results in increased activity of [FOS protein binds to JUN protein]] 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of FOS mRNA]; U 0126 inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of FOS mRNA]; wortmannin inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of FOS mRNA] |
CTD |
PMID:11457450 PMID:11687581 |
|
NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036
|
|
G |
Gclc |
glutamate-cysteine ligase, catalytic subunit |
multiple interactions increases expression |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 promotes the reaction [NFE2L2 protein results in increased expression of GCLC protein]; [ABCC1 protein results in increased transport of 15-deoxy-delta(12,14)-prostaglandin J2 metabolite] affects the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of GCLC protein]; [verlukast binds to and results in decreased activity of ABCC1 protein] inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of GCLC protein]; ABCC1 protein affects the reaction [15-deoxy-delta(12,14)-prostaglandin J2 promotes the reaction [NFE2L2 protein results in increased expression of GCLC protein]]; ABCC1 protein affects the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of GCLC protein]; Acetylcysteine inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of GCLC protein]; NFE2L2 protein affects the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of GCLC protein] 15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of GCLC mRNA; 15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of GCLC protein |
CTD |
PMID:21728338 |
|
NCBI chr 8:78,629,899...78,668,547
Ensembl chr 8:78,630,127...78,668,544
|
|
G |
Gfap |
glial fibrillary acidic protein |
increases expression decreases expression multiple interactions |
ISO EXP |
15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of GFAP 15-deoxy-delta(12,14)-prostaglandin J2 results in decreased expression of GFAP mRNA 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [ochratoxin A results in decreased expression of GFAP mRNA] |
CTD |
PMID:15254749 PMID:15994020 |
|
NCBI chr10:87,852,891...87,861,631
Ensembl chr10:87,852,890...87,861,589
|
|
G |
Gsta3 |
glutathione S-transferase alpha 3 |
increases expression |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of GSTA3 mRNA |
CTD |
PMID:14652005 |
|
NCBI chr 9:23,658,574...23,684,240
Ensembl chr 9:23,658,574...23,684,240
|
|
G |
Gstm1 |
glutathione S-transferase mu 1 |
multiple interactions |
ISO |
GSTM1 protein affects the metabolism of [15-deoxy-delta(12,14)-prostaglandin J2 co-treated with Glutathione] |
CTD |
PMID:14979731 |
|
NCBI chr 2:195,649,845...195,655,402
Ensembl chr 2:195,649,845...195,655,411
|
|
G |
Gstp1 |
glutathione S-transferase pi 1 |
increases expression multiple interactions |
EXP |
15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of GSTP1 mRNA; 15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of GSTP1 protein Soybean Oil promotes the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of GSTP1 mRNA]; Soybean Oil promotes the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of GSTP1 protein] |
CTD |
PMID:11600134 |
|
NCBI chr 1:201,337,762...201,340,230
Ensembl chr 1:201,321,672...201,340,226
|
|
G |
Hdac1 |
histone deacetylase 1 |
decreases expression |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 results in decreased expression of HDAC1 mRNA |
CTD |
PMID:21957481 |
|
NCBI chr 5:141,853,992...141,881,057
Ensembl chr 5:141,853,989...141,881,111
|
|
G |
Hdac2 |
histone deacetylase 2 |
decreases expression |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 results in decreased expression of HDAC2 mRNA |
CTD |
PMID:21957481 |
|
NCBI chr20:40,548,250...40,571,609
Ensembl chr20:40,548,250...40,571,609
|
|
G |
Hdac3 |
histone deacetylase 3 |
decreases expression |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 results in decreased expression of HDAC3 mRNA |
CTD |
PMID:21957481 |
|
NCBI chr18:29,770,637...29,789,850
Ensembl chr18:29,770,636...29,793,856
|
|
G |
Hif1a |
hypoxia inducible factor 1 subunit alpha |
affects stability multiple interactions increases expression |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 affects the stability of HIF1A protein Acetylcysteine inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of HIF1A protein]; Buthionine Sulfoximine promotes the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of HIF1A protein]; Dithiothreitol inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of HIF1A protein]; Glutathione inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of HIF1A protein] |
CTD |
PMID:17658243 |
|
NCBI chr 6:92,624,059...92,669,262
Ensembl chr 6:92,624,390...92,669,261
|
|
G |
Hmox1 |
heme oxygenase 1 |
multiple interactions increases expression |
ISO EXP |
15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of and results in increased activity of HMOX1 protein; [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of and results in increased activity of HMOX1 protein] which results in increased abundance of Iron; [[15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of and results in increased activity of HMOX1 protein] which results in increased abundance of Iron] which results in increased abundance of Reactive Oxygen Species; [[15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of and results in increased activity of HMOX1 protein] which results in increased abundance of Iron] which results in increased expression of MMP1 mRNA; [[[15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of and results in increased activity of HMOX1 protein] which results in increased abundance of Iron] which results in increased abundance of Reactive Oxygen Species] which results in increased expression of MMP1 protein; Acetylcysteine inhibits the reaction [[[[15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of and results in increased activity of HMOX1 protein] which results in increased abundance of Iron] which results in increased abundance of Reactive Oxygen Species] which results in increased expression of MMP1 protein]; HMOX1 protein promotes the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of and results in increased activity of MMP1 protein]; HSF1 protein inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of HMOX1 mRNA]; NFE2L2 protein promotes the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of HMOX1 mRNA]; zinc protoporphyrin inhibits the reaction [[15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of and results in increased activity of HMOX1 protein] which results in increased abundance of Iron] ochratoxin A inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of HMOX1 mRNA] 15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of HMOX1 mRNA; 15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of HMOX1 protein |
CTD |
PMID:11078701 PMID:15618017 PMID:15994020 PMID:19136476 |
|
NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079
|
|
G |
Hsf1 |
heat shock transcription factor 1 |
multiple interactions increases activity |
ISO |
HSF1 protein inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of HMOX1 mRNA] 15-deoxy-delta(12,14)-prostaglandin J2 results in increased activity of HSF1 protein |
CTD |
PMID:15618017 PMID:34170685 |
|
NCBI chr 7:108,196,040...108,223,011
Ensembl chr 7:108,196,056...108,223,011
|
|
G |
Hspb1 |
heat shock protein family B (small) member 1 |
decreases expression |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 results in decreased expression of HSPB1 protein |
CTD |
PMID:16299251 |
|
NCBI chr12:20,794,014...20,795,675
Ensembl chr12:20,794,028...20,795,743
|
|
G |
Ifng |
interferon gamma |
multiple interactions decreases expression decreases secretion |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [[IFNG protein results in increased expression of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IFNG protein results in increased activity of and results in increased localization of [STAT1 protein binds to STAT1 protein]]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IFNG protein results in increased expression of IRF1 mRNA]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IFNG protein results in increased expression of NOS2 mRNA]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IFNG protein results in increased phosphorylation of and results in increased activity of JAK2 protein]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IFNG protein results in increased phosphorylation of STAT1 protein]; 2,2-bis(4-glycidyloxyphenyl)propane inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in decreased secretion of IFNG protein]; Acetylcysteine inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IFNG protein results in increased phosphorylation of and results in increased activity of JAK2 protein]]; Acetylcysteine inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IFNG protein results in increased phosphorylation of STAT1 protein]]; CAT protein inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IFNG protein results in increased phosphorylation of STAT1 protein]]; Glutathione inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IFNG protein results in increased phosphorylation of and results in increased activity of JAK2 protein]]; Glutathione inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IFNG protein results in increased phosphorylation of STAT1 protein]]; Hydrogen Peroxide promotes the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IFNG protein results in increased phosphorylation of STAT1 protein]]; peroxyvanadate inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IFNG protein results in increased abundance of Nitric Oxide]]; peroxyvanadate inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IFNG protein results in increased phosphorylation of STAT1 protein]]; T 0070907 inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in decreased secretion of IFNG protein] 15-deoxy-delta(12,14)-prostaglandin J2 results in decreased expression of IFNG protein |
CTD |
PMID:12847270 PMID:16844232 PMID:19888466 |
|
NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375
|
|
G |
Il1a |
interleukin 1 alpha |
multiple interactions |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IL1B protein results in increased expression of IL1A mRNA] |
CTD |
PMID:14998300 |
|
NCBI chr 3:116,526,601...116,537,055
Ensembl chr 3:116,526,604...116,536,822
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions decreases expression decreases activity |
ISO EXP |
15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IL1B protein affects the localization of RELA protein]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IL1B protein results in decreased abundance of Prostaglandins]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IL1B protein results in increased abundance of Nitric Oxide]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IL1B protein results in increased activity of [FOS protein binds to JUN protein]]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IL1B protein results in increased activity of [RELA protein binds to NFKB1 protein]]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IL1B protein results in increased expression of CSF2 mRNA]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IL1B protein results in increased expression of CSF2 protein]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IL1B protein results in increased expression of CXCL8 mRNA]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IL1B protein results in increased expression of IL1A mRNA]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IL1B protein results in increased expression of NOS2 mRNA]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IL1B protein results in increased expression of PTGS2 mRNA]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B mRNA]; 15-deoxy-delta(12,14)-prostaglandin J2 promotes the reaction [IL1B protein affects the localization of JUN protein]; Dexamethasone promotes the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IL1B protein results in increased expression of CSF2 mRNA]] 15-deoxy-delta(12,14)-prostaglandin J2 results in decreased expression of IL1B protein [15-deoxy-delta(12,14)-prostaglandin J2 co-treated with IL1B protein] results in decreased secretion of IL1B protein 15-deoxy-delta(12,14)-prostaglandin J2 results in decreased activity of IL1B protein |
CTD |
PMID:11457450 PMID:12604364 PMID:14998300 PMID:15751073 PMID:16461118 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il1rn |
interleukin 1 receptor antagonist |
decreases expression |
EXP |
15-deoxy-delta(12,14)-prostaglandin J2 results in decreased expression of IL1RN mRNA |
CTD |
PMID:15751073 |
|
NCBI chr 3:7,111,567...7,127,451
Ensembl chr 3:7,111,550...7,127,445
|
|
G |
Il4 |
interleukin 4 |
multiple interactions |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased degradation of NFKBIA protein]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of CCL5 mRNA]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of CXCL8 mRNA]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP mRNA]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP protein]; 4-(5H-dibenzo(a,d)cyclohepten-5-ylidene)-1-(4-(2H-tetrazol-5-yl)butyl)piperidine inhibits the reaction [amorolfine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in decreased secretion of 15-deoxy-delta(12,14)-prostaglandin J2]]; 4-(5H-dibenzo(a,d)cyclohepten-5-ylidene)-1-(4-(2H-tetrazol-5-yl)butyl)piperidine inhibits the reaction [butenafine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in decreased secretion of 15-deoxy-delta(12,14)-prostaglandin J2]]; 4-(5H-dibenzo(a,d)cyclohepten-5-ylidene)-1-(4-(2H-tetrazol-5-yl)butyl)piperidine inhibits the reaction [Itraconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in decreased secretion of 15-deoxy-delta(12,14)-prostaglandin J2]]; 4-(5H-dibenzo(a,d)cyclohepten-5-ylidene)-1-(4-(2H-tetrazol-5-yl)butyl)piperidine inhibits the reaction [Ketoconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in decreased secretion of 15-deoxy-delta(12,14)-prostaglandin J2]]; 4-(5H-dibenzo(a,d)cyclohepten-5-ylidene)-1-(4-(2H-tetrazol-5-yl)butyl)piperidine inhibits the reaction [luliconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in decreased secretion of 15-deoxy-delta(12,14)-prostaglandin J2]]; 4-(5H-dibenzo(a,d)cyclohepten-5-ylidene)-1-(4-(2H-tetrazol-5-yl)butyl)piperidine inhibits the reaction [Terbinafine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in decreased secretion of 15-deoxy-delta(12,14)-prostaglandin J2]]; [Poly I-C co-treated with IL4 protein] results in decreased secretion of 15-deoxy-delta(12,14)-prostaglandin J2; amorolfine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in decreased secretion of 15-deoxy-delta(12,14)-prostaglandin J2]; butenafine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in decreased secretion of 15-deoxy-delta(12,14)-prostaglandin J2]; Itraconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in decreased secretion of 15-deoxy-delta(12,14)-prostaglandin J2]; Ketoconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in decreased secretion of 15-deoxy-delta(12,14)-prostaglandin J2]; luliconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in decreased secretion of 15-deoxy-delta(12,14)-prostaglandin J2]; Terbinafine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in decreased secretion of 15-deoxy-delta(12,14)-prostaglandin J2] |
CTD |
PMID:23688403 |
|
NCBI chr10:37,771,203...37,776,750
Ensembl chr10:37,771,203...37,776,750
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IL6 protein results in increased phosphorylation of STAT1 protein]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IL6 protein results in increased phosphorylation of STAT3 protein]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 mRNA] |
CTD |
PMID:12604364 PMID:12847270 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Ins2 |
insulin 2 |
multiple interactions |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [Fatty Acids, Nonesterified inhibits the reaction [INS protein results in increased secretion of Glucose]]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [Fatty Acids, Nonesterified results in decreased expression of INS mRNA] |
CTD |
PMID:14625208 |
|
NCBI chr 1:197,843,277...197,992,522
Ensembl chr 1:197,843,281...197,864,775
|
|
G |
Irf1 |
interferon regulatory factor 1 |
multiple interactions |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IFNG protein results in increased expression of IRF1 mRNA] |
CTD |
PMID:12847270 |
|
NCBI chr10:37,917,155...37,924,166
Ensembl chr10:37,916,670...37,924,166
|
|
G |
Jak2 |
Janus kinase 2 |
multiple interactions |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IFNG protein results in increased phosphorylation of and results in increased activity of JAK2 protein]; Acetylcysteine inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IFNG protein results in increased phosphorylation of and results in increased activity of JAK2 protein]]; Glutathione inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IFNG protein results in increased phosphorylation of and results in increased activity of JAK2 protein]] |
CTD |
PMID:12847270 |
|
NCBI chr 1:226,995,334...227,054,381
Ensembl chr 1:226,995,334...227,054,189
|
|
G |
Jun |
Jun proto-oncogene, AP-1 transcription factor subunit |
multiple interactions |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IL1B protein results in increased activity of [FOS protein binds to JUN protein]]; 15-deoxy-delta(12,14)-prostaglandin J2 promotes the reaction [IL1B protein affects the localization of JUN protein] |
CTD |
PMID:11457450 |
|
NCBI chr 5:109,894,175...109,897,268
Ensembl chr 5:109,893,145...109,897,656
|
|
G |
Klf6 |
Kruppel-like factor 6 |
multiple interactions |
ISO |
[15-deoxy-delta(12,14)-prostaglandin J2 co-treated with alitretinoin] results in decreased phosphorylation of KLF6 protein; RPS6KB1 protein inhibits the reaction [[15-deoxy-delta(12,14)-prostaglandin J2 co-treated with alitretinoin] results in decreased phosphorylation of KLF6 protein] |
CTD |
PMID:16611854 |
|
NCBI chr17:64,539,456...64,548,451
Ensembl chr17:64,531,463...64,588,570
|
|
G |
Lep |
leptin |
multiple interactions increases secretion |
ISO |
[Dexamethasone co-treated with 15-deoxy-delta(12,14)-prostaglandin J2] results in decreased secretion of LEP protein 15-deoxy-delta(12,14)-prostaglandin J2 results in increased secretion of LEP protein |
CTD |
PMID:11092516 |
|
NCBI chr 4:57,661,127...57,675,262
Ensembl chr 4:57,661,131...57,675,262
|
|
G |
Lif |
LIF, interleukin 6 family cytokine |
multiple interactions |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [LIF protein results in increased expression of STAT3 protein]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [LIF protein results in increased phosphorylation of STAT3 protein]; 2,2-bis(4-glycidyloxyphenyl)propane inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [LIF protein results in increased expression of STAT3 protein]]; 2,2-bis(4-glycidyloxyphenyl)propane inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [LIF protein results in increased phosphorylation of STAT3 protein]]; T 0070907 inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [LIF protein results in increased expression of STAT3 protein]]; T 0070907 inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [LIF protein results in increased phosphorylation of STAT3 protein]] |
CTD |
PMID:19922793 |
|
NCBI chr14:79,131,049...79,140,486
Ensembl chr14:79,134,574...79,140,482
|
|
G |
Lpl |
lipoprotein lipase |
increases expression |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of LPL mRNA |
CTD |
PMID:12021203 |
|
NCBI chr16:20,830,055...20,853,855
Ensembl chr16:20,829,465...20,855,249
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
decreases phosphorylation multiple interactions increases phosphorylation |
ISO EXP |
15-deoxy-delta(12,14)-prostaglandin J2 results in decreased phosphorylation of MAPK1 protein 15-deoxy-delta(12,14)-prostaglandin J2 results in increased phosphorylation of and results in increased activity of MAPK1 protein; 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased phosphorylation of and results in increased activity of MAPK1 protein]; U 0126 inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased phosphorylation of and results in increased activity of MAPK1 protein] 15-deoxy-delta(12,14)-prostaglandin J2 results in increased phosphorylation of MAPK1 protein 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased phosphorylation of MAPK1 protein]; [15-deoxy-delta(12,14)-prostaglandin J2 co-treated with alitretinoin] results in decreased phosphorylation of MAPK1 protein; Glutathione inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased phosphorylation of MAPK1 protein]; manganese(III)-tetrakis(4-benzoic acid)porphyrin inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased phosphorylation of MAPK1 protein] |
CTD |
PMID:11687581 PMID:12083801 PMID:16611854 PMID:19888466 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
decreases phosphorylation multiple interactions increases phosphorylation |
ISO EXP |
15-deoxy-delta(12,14)-prostaglandin J2 results in decreased phosphorylation of MAPK3 protein 15-deoxy-delta(12,14)-prostaglandin J2 results in increased phosphorylation of and results in increased activity of MAPK3 protein; 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased phosphorylation of and results in increased activity of MAPK3 protein]; U 0126 inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased phosphorylation of and results in increased activity of MAPK3 protein] 15-deoxy-delta(12,14)-prostaglandin J2 results in increased phosphorylation of MAPK3 protein 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased phosphorylation of MAPK3 protein]; [15-deoxy-delta(12,14)-prostaglandin J2 co-treated with alitretinoin] results in decreased phosphorylation of MAPK3 protein; Glutathione inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased phosphorylation of MAPK3 protein]; manganese(III)-tetrakis(4-benzoic acid)porphyrin inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:11687581 PMID:12083801 PMID:16611854 PMID:19888466 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Med1 |
mediator complex subunit 1 |
multiple interactions |
ISO |
MED1 protein promotes the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased activity of PPARG protein] |
CTD |
PMID:16324150 |
|
NCBI chr10:83,145,538...83,189,260
Ensembl chr10:83,145,568...83,189,299
|
|
G |
Mmp1 |
matrix metallopeptidase 1 |
multiple interactions increases expression |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of and results in increased activity of MMP1 protein; [[15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of and results in increased activity of HMOX1 protein] which results in increased abundance of Iron] which results in increased expression of MMP1 mRNA; [[[15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of and results in increased activity of HMOX1 protein] which results in increased abundance of Iron] which results in increased abundance of Reactive Oxygen Species] which results in increased expression of MMP1 protein; Acetylcysteine inhibits the reaction [[[[15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of and results in increased activity of HMOX1 protein] which results in increased abundance of Iron] which results in increased abundance of Reactive Oxygen Species] which results in increased expression of MMP1 protein]; Cycloheximide inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of MMP1 protein]; Dactinomycin inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of MMP1 protein]; Deferoxamine inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of MMP1 mRNA]; Deferoxamine inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of MMP1 protein]; HMOX1 protein promotes the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of and results in increased activity of MMP1 protein]; NFE2L2 protein promotes the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of MMP1 mRNA] |
CTD |
PMID:19136476 |
|
NCBI chr 8:4,658,588...4,679,099
Ensembl chr 8:4,658,588...4,679,097
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
multiple interactions decreases expression |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 results in decreased activity of and results in decreased expression of MMP9 protein; 2-chloro-5-nitrobenzanilide inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in decreased activity of and results in decreased expression of MMP9 protein]; 2-chloro-5-nitrobenzanilide inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in decreased expression of MMP9 mRNA] |
CTD |
PMID:19997048 |
|
NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120
|
|
G |
Mtor |
mechanistic target of rapamycin kinase |
multiple interactions |
ISO |
[15-deoxy-delta(12,14)-prostaglandin J2 co-treated with alitretinoin] results in decreased phosphorylation of MTOR protein |
CTD |
PMID:16611854 |
|
NCBI chr 5:158,884,856...158,994,311
Ensembl chr 5:158,884,804...158,994,311
|
|
G |
Nes |
nestin |
increases expression |
EXP |
15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of NES protein |
CTD |
PMID:15212945 |
|
NCBI chr 2:173,437,867...173,447,777
Ensembl chr 2:173,438,734...173,447,777
|
|
G |
Nfe2l2 |
NFE2 like bZIP transcription factor 2 |
multiple interactions |
ISO EXP |
15-deoxy-delta(12,14)-prostaglandin J2 affects the localization of and results in increased activity of NFE2L2 protein; 15-deoxy-delta(12,14)-prostaglandin J2 promotes the reaction [NFE2L2 protein results in increased expression of GCLC protein]; ABCC1 protein affects the reaction [15-deoxy-delta(12,14)-prostaglandin J2 promotes the reaction [NFE2L2 protein results in increased expression of GCLC protein]]; Acetylcysteine inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased activity of NFE2L2 protein]; NFE2L2 protein affects the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of GCLC protein]; NFE2L2 protein promotes the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of HMOX1 mRNA]; NFE2L2 protein promotes the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of MMP1 mRNA] 15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of and affects the localization of NFE2L2 protein; manganese chloride inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of NFE2L2 protein] |
CTD |
PMID:19136476 PMID:21728338 PMID:22245093 |
|
NCBI chr 3:60,594,239...60,621,785
Ensembl chr 3:60,594,242...60,621,737
|
|
G |
Nfkb1 |
nuclear factor kappa B subunit 1 |
multiple interactions decreases localization |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IL1B protein results in increased activity of [RELA protein binds to NFKB1 protein]] 15-deoxy-delta(12,14)-prostaglandin J2 results in decreased localization of NFKB1 protein |
CTD |
PMID:11457450 PMID:16299251 |
|
NCBI chr 2:224,016,214...224,132,135
Ensembl chr 2:224,016,214...224,110,404
|
|
G |
Nfkbia |
NFKB inhibitor alpha |
multiple interactions decreases phosphorylation |
ISO EXP |
15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased degradation of NFKBIA protein] 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [manganese chloride results in increased degradation of NFKBIA protein] 15-deoxy-delta(12,14)-prostaglandin J2 results in decreased phosphorylation of NFKBIA protein |
CTD |
PMID:15498850 PMID:22245093 PMID:23688403 |
|
NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions decreases activity decreases expression |
ISO EXP |
15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IL1B protein results in increased expression of NOS2 mRNA] 15-deoxy-delta(12,14)-prostaglandin J2 results in decreased activity of NOS2 protein 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [ochratoxin A results in increased expression of NOS2 mRNA]; 15-deoxy-delta(12,14)-prostaglandin J2 results in decreased activity of and results in decreased expression of NOS2 protein 15-deoxy-delta(12,14)-prostaglandin J2 results in decreased expression of NOS2 mRNA 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [[IFNG protein results in increased expression of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [Bleomycin results in increased expression of NOS2 protein]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IFNG protein results in increased expression of NOS2 mRNA]; 15-deoxy-delta(12,14)-prostaglandin J2 results in decreased activity of and results in decreased expression of NOS2 protein; 2-chloro-5-nitrobenzanilide inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in decreased activity of and results in decreased expression of NOS2 protein]; 2-chloro-5-nitrobenzanilide inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in decreased expression of NOS2 mRNA] |
CTD |
PMID:11457450 PMID:11890746 PMID:12847270 PMID:15684285 PMID:15994020 PMID:16461118 PMID:19997048 More...
|
|
NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
|
|
G |
Nos3 |
nitric oxide synthase 3 |
decreases activity |
EXP |
15-deoxy-delta(12,14)-prostaglandin J2 results in decreased activity of NOS3 protein |
CTD |
PMID:11890746 |
|
NCBI chr 4:10,793,834...10,814,170
Ensembl chr 4:10,793,834...10,814,166
|
|
G |
Nr3c1 |
nuclear receptor subfamily 3, group C, member 1 |
affects activity multiple interactions |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 affects the activity of NR3C1 protein 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [[Dexamethasone binds to NR3C1 protein] which results in decreased expression of CCL2 protein]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [Dexamethasone binds to NR3C1 protein] |
CTD |
PMID:15187150 |
|
NCBI chr18:31,271,681...31,393,320
Ensembl chr18:31,271,681...31,393,375
|
|
G |
Park7 |
Parkinsonism associated deglycase |
multiple interactions |
EXP |
15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [manganese chloride results in decreased expression of PARK7 mRNA]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [manganese chloride results in decreased expression of PARK7 protein] |
CTD |
PMID:22245093 |
|
NCBI chr 5:161,353,718...161,376,993
Ensembl chr 5:161,353,719...161,376,970
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
increases cleavage multiple interactions |
ISO EXP |
15-deoxy-delta(12,14)-prostaglandin J2 results in increased cleavage of PARP1 protein [delta(12)-prostaglandin J(2) co-treated with 9-deoxy-delta-9-prostaglandin D2 co-treated with 15-deoxy-delta(12,14)-prostaglandin J2] results in increased cleavage of PARP1 protein |
CTD |
PMID:15498850 PMID:23973622 |
|
NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
|
|
G |
Pck1 |
phosphoenolpyruvate carboxykinase 1 |
increases expression |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of PCK1 mRNA |
CTD |
PMID:9518257 |
|
NCBI chr 3:161,930,256...161,936,205
Ensembl chr 3:161,930,256...161,936,191
|
|
G |
Plin1 |
perilipin 1 |
multiple interactions |
ISO |
[15-deoxy-delta(12,14)-prostaglandin J2 co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of PLIN1 mRNA |
CTD |
PMID:34323617 |
|
NCBI chr 1:133,664,294...133,676,854
Ensembl chr 1:133,664,892...133,676,828
|
|
G |
Ppara |
peroxisome proliferator activated receptor alpha |
multiple interactions |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 binds to and results in increased activity of PPARA protein [15-deoxy-delta(12,14)-prostaglandin J2 co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of PPARA mRNA |
CTD |
PMID:9013583 PMID:34323617 |
|
NCBI chr 7:116,832,405...116,900,878
Ensembl chr 7:116,832,756...116,895,346
|
|
G |
Ppard |
peroxisome proliferator-activated receptor delta |
increases expression |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of PPARD protein |
CTD |
PMID:17341418 |
|
NCBI chr20:6,298,785...6,363,970
Ensembl chr20:6,298,785...6,363,968
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
affects expression decreases response to substance increases expression increases activity multiple interactions decreases expression |
ISO EXP |
15-deoxy-delta(12,14)-prostaglandin J2 affects the expression of PPARG PPARG protein mutant form results in decreased susceptibility to 15-deoxy-delta(12,14)-prostaglandin J2 15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of PPARG mRNA; 15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of PPARG protein 15-deoxy-delta(12,14)-prostaglandin J2 results in increased activity of PPARG protein 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [AGT protein results in decreased expression of PPARG protein]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [ochratoxin A results in increased expression of PPARG mRNA] 15-deoxy-delta(12,14)-prostaglandin J2 binds to and results in increased activity of PPARG protein; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [PPARG protein affects the reaction [Lipopolysaccharides results in increased abundance of Nitric Oxide]]; MED1 protein promotes the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased activity of PPARG protein] 15-deoxy-delta(12,14)-prostaglandin J2 affects the localization of and results in increased expression of PPARG protein; 15-deoxy-delta(12,14)-prostaglandin J2 binds to and results in decreased activity of PPARG protein; 15-deoxy-delta(12,14)-prostaglandin J2 binds to and results in increased activity of PPARG protein; 15-deoxy-delta(12,14)-prostaglandin J2 binds to and results in increased localization of and results in increased activity of PPARG protein; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [deoxynivalenol results in increased expression of PPARG protein]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [Fatty Acids, Nonesterified results in decreased expression of PPARG mRNA]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [Lipopolysaccharides results in decreased expression of PPARG mRNA]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased activity of PPARG protein]; MG 262 promotes the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased activity of PPARG protein]; PPARG protein affects the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in decreased expression of TBXA2R mRNA alternative form] 15-deoxy-delta(12,14)-prostaglandin J2 results in decreased expression of PPARG protein |
CTD |
PMID:9013583 PMID:10662598 PMID:11030710 PMID:12065695 PMID:12604364 PMID:12839938 PMID:12847270 PMID:14625208 PMID:14979731 PMID:14998300 PMID:15212945 PMID:15254749 PMID:15322177 PMID:15491415 PMID:15707588 PMID:15729575 PMID:15866424 PMID:15994020 PMID:16324150 PMID:16499875 PMID:17341418 PMID:18278065 PMID:18485432 PMID:19922793 PMID:23943857 PMID:26172262 PMID:30138673 More...
|
|
NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468
|
|
G |
Pten |
phosphatase and tensin homolog |
multiple interactions |
ISO |
[15-deoxy-delta(12,14)-prostaglandin J2 co-treated with alitretinoin] results in increased expression of PTEN protein |
CTD |
PMID:16611854 |
|
NCBI chr 1:230,631,303...230,696,754
Ensembl chr 1:230,630,338...230,696,838
|
|
G |
Ptgdr |
prostaglandin D2 receptor |
multiple interactions |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 binds to and results in increased activity of PTGDR protein; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [Prostaglandin D2 binds to PTGDR protein] |
CTD |
PMID:9579725 |
|
NCBI chr15:17,360,304...17,367,679
Ensembl chr15:17,360,304...17,367,679
|
|
G |
Ptgdr2 |
prostaglandin D2 receptor 2 |
multiple interactions |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 binds to and results in increased activity of PTGDR2 protein; ramatroban inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 binds to and results in increased activity of PTGDR2 protein] 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [Prostaglandin D2 binds to PTGDR2 protein] |
CTD |
PMID:12721327 PMID:16256979 |
|
NCBI chr 1:207,585,088...207,590,275
Ensembl chr 1:207,587,917...207,589,213
|
|
G |
Ptgs1 |
prostaglandin-endoperoxide synthase 1 |
multiple interactions |
ISO |
PTGS1 protein promotes the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased abundance of 15-deoxy-delta(12,14)-prostaglandin J2] |
CTD |
PMID:17439952 |
|
NCBI chr 3:19,584,015...19,605,589
Ensembl chr 3:19,584,015...19,605,586
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions decreases expression increases expression |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IL1B protein results in increased expression of PTGS2 mRNA]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 mRNA] 15-deoxy-delta(12,14)-prostaglandin J2 results in decreased activity of and results in decreased expression of PTGS2 protein; 2-chloro-5-nitrobenzanilide inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in decreased activity of and results in decreased expression of PTGS2 protein]; 2-chloro-5-nitrobenzanilide inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in decreased expression of PTGS2 mRNA] 15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of PTGS2 |
CTD |
PMID:11457450 PMID:12604364 PMID:15254749 PMID:19997048 |
|
NCBI chr13:62,164,080...62,169,770
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Ptpn11 |
protein tyrosine phosphatase, non-receptor type 11 |
increases phosphorylation |
EXP |
15-deoxy-delta(12,14)-prostaglandin J2 results in increased phosphorylation of PTPN11 protein |
CTD |
PMID:12584205 |
|
NCBI chr12:35,365,436...35,424,925
Ensembl chr12:35,383,144...35,424,925
|
|
G |
Raf1 |
Raf-1 proto-oncogene, serine/threonine kinase |
multiple interactions |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 results in increased activity of and results in decreased phosphorylation of RAF1 protein |
CTD |
PMID:12083801 |
|
NCBI chr 4:148,679,534...148,740,265
Ensembl chr 4:148,679,530...148,740,317
|
|
G |
Rarb |
retinoic acid receptor, beta |
multiple interactions increases expression |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [ciglitazone promotes the reaction [SR 11237 results in increased expression of RARB protein]] 15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of RARB |
CTD |
PMID:12839938 PMID:15254749 |
|
NCBI chr15:8,700,533...9,051,288
Ensembl chr15:8,406,492...9,051,288
|
|
G |
Rb1 |
RB transcriptional corepressor 1 |
multiple interactions |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 results in decreased phosphorylation of and results in decreased expression of RB1 protein |
CTD |
PMID:15729575 |
|
NCBI chr15:48,371,295...48,502,473
Ensembl chr15:48,371,296...48,502,302
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions decreases activity |
ISO EXP |
15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IL1B protein affects the localization of RELA protein]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IL1B protein results in increased activity of [RELA protein binds to NFKB1 protein]]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [Lipopolysaccharides results in increased activity of RELA protein] 15-deoxy-delta(12,14)-prostaglandin J2 results in decreased activity of RELA protein 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [manganese chloride affects the localization of RELA protein] |
CTD |
PMID:11457450 PMID:15498850 PMID:20174873 PMID:22245093 |
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Rps6ka1 |
ribosomal protein S6 kinase A1 |
multiple interactions |
ISO |
[15-deoxy-delta(12,14)-prostaglandin J2 co-treated with alitretinoin] results in decreased phosphorylation of RPS6KA1 protein |
CTD |
PMID:16611854 |
|
NCBI chr 5:146,079,018...146,118,272
Ensembl chr 5:146,079,021...146,118,272
|
|
G |
Rps6kb1 |
ribosomal protein S6 kinase B1 |
multiple interactions |
ISO |
[15-deoxy-delta(12,14)-prostaglandin J2 co-treated with alitretinoin] results in decreased phosphorylation of and results in decreased activity of RPS6KB1 protein; RPS6KB1 protein inhibits the reaction [[15-deoxy-delta(12,14)-prostaglandin J2 co-treated with alitretinoin] results in decreased expression of TGFB1 mRNA]; RPS6KB1 protein inhibits the reaction [[15-deoxy-delta(12,14)-prostaglandin J2 co-treated with alitretinoin] results in decreased phosphorylation of KLF6 protein] |
CTD |
PMID:16611854 |
|
NCBI chr10:71,323,777...71,367,908
Ensembl chr10:71,323,777...71,367,908
|
|
G |
Runx2 |
RUNX family transcription factor 2 |
decreases expression |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 results in decreased expression of RUNX2 mRNA |
CTD |
PMID:12021203 |
|
NCBI chr 9:16,167,504...16,492,826
Ensembl chr 9:16,167,482...16,492,167
|
|
G |
Rxra |
retinoid X receptor alpha |
increases expression |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of RXRA |
CTD |
PMID:15254749 |
|
NCBI chr 3:10,989,832...11,076,366
Ensembl chr 3:10,989,832...11,073,712
|
|
G |
Serpine1 |
serpin family E member 1 |
multiple interactions |
EXP |
15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [AGT protein results in increased expression of and results in increased secretion of SERPINE1 protein]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [AGT protein results in increased expression of SERPINE1 mRNA]; 2,2-bis(4-glycidyloxyphenyl)propane inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [AGT protein results in increased expression of and results in increased secretion of SERPINE1 protein]]; 2,2-bis(4-glycidyloxyphenyl)propane inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [AGT protein results in increased expression of SERPINE1 mRNA]]; 2-chloro-5-nitrobenzanilide inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [AGT protein results in increased expression of and results in increased secretion of SERPINE1 protein]]; 2-chloro-5-nitrobenzanilide inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [AGT protein results in increased expression of SERPINE1 mRNA]] |
CTD |
PMID:18278065 |
|
NCBI chr12:19,601,272...19,611,657
Ensembl chr12:19,601,272...19,611,657
|
|
G |
Smad2 |
SMAD family member 2 |
multiple interactions |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [TGFB1 protein results in increased phosphorylation of SMAD2 protein]; SMAD2 protein modified form affects the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [TGFB1 protein results in increased expression of CCN2]] |
CTD |
PMID:19429239 |
|
NCBI chr18:69,849,884...69,918,926
Ensembl chr18:69,850,377...69,912,323
|
|
G |
Socs1 |
suppressor of cytokine signaling 1 |
increases expression |
EXP |
15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of SOCS1 mRNA |
CTD |
PMID:12584205 |
|
NCBI chr10:4,882,651...4,884,342
Ensembl chr10:4,882,560...4,884,383
|
|
G |
Socs3 |
suppressor of cytokine signaling 3 |
increases expression |
EXP |
15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of SOCS3 mRNA |
CTD |
PMID:12584205 |
|
NCBI chr10:103,193,909...103,197,322
Ensembl chr10:103,193,537...103,197,787
|
|
G |
Spp1 |
secreted phosphoprotein 1 |
decreases expression |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 results in decreased expression of SPP1 mRNA |
CTD |
PMID:12021203 |
|
NCBI chr14:5,308,885...5,315,120
Ensembl chr14:5,308,885...5,315,162
|
|
G |
Stat1 |
signal transducer and activator of transcription 1 |
multiple interactions |
ISO EXP |
15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IL6 protein results in increased phosphorylation of STAT1 protein] 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of STAT1 protein] 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IFNG protein results in increased activity of and results in increased localization of [STAT1 protein binds to STAT1 protein]]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IFNG protein results in increased phosphorylation of STAT1 protein]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [peroxyvanadate results in increased phosphorylation of STAT1 protein]; Acetylcysteine inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IFNG protein results in increased phosphorylation of STAT1 protein]]; CAT protein inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IFNG protein results in increased phosphorylation of STAT1 protein]]; Glutathione inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IFNG protein results in increased phosphorylation of STAT1 protein]]; Hydrogen Peroxide promotes the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IFNG protein results in increased phosphorylation of STAT1 protein]]; peroxyvanadate inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IFNG protein results in increased phosphorylation of STAT1 protein]] |
CTD |
PMID:12584205 PMID:12847270 |
|
NCBI chr 9:49,419,561...49,459,969
Ensembl chr 9:49,419,340...49,588,540
|
|
G |
Stat3 |
signal transducer and activator of transcription 3 |
multiple interactions |
ISO EXP |
15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [LIF protein results in increased expression of STAT3 protein]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [LIF protein results in increased phosphorylation of STAT3 protein]; 2,2-bis(4-glycidyloxyphenyl)propane inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [LIF protein results in increased expression of STAT3 protein]]; 2,2-bis(4-glycidyloxyphenyl)propane inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [LIF protein results in increased phosphorylation of STAT3 protein]]; T 0070907 inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [LIF protein results in increased expression of STAT3 protein]]; T 0070907 inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [LIF protein results in increased phosphorylation of STAT3 protein]] 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of STAT3 protein] 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IL6 protein results in increased phosphorylation of STAT3 protein] |
CTD |
PMID:12584205 PMID:12847270 PMID:19922793 |
|
NCBI chr10:85,811,206...85,863,057
Ensembl chr10:85,811,218...85,863,057
|
|
G |
Tbxa2r |
thromboxane A2 receptor |
multiple interactions decreases expression |
ISO |
PPARG protein affects the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in decreased expression of TBXA2R mRNA alternative form] |
CTD |
PMID:16499875 |
|
NCBI chr 7:8,383,347...8,390,753
Ensembl chr 7:8,383,378...8,388,176
|
|
G |
Tg |
thyroglobulin |
multiple interactions increases expression |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 promotes the reaction [TSHB protein results in increased expression of TG protein] 15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of TG protein |
CTD |
PMID:11078701 |
|
NCBI chr 7:98,418,293...98,603,210
Ensembl chr 7:98,418,293...98,603,210
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
multiple interactions decreases expression decreases response to substance |
ISO EXP |
15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [TGFB1 protein results in increased expression of and results in increased secretion of CCN2 protein]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [TGFB1 protein results in increased expression of CCN2 mRNA]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [TGFB1 protein results in increased phosphorylation of SMAD2 protein]; SMAD2 protein modified form affects the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [TGFB1 protein results in increased expression of CCN2]] 15-deoxy-delta(12,14)-prostaglandin J2 results in decreased expression of TGFB1 mRNA 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [AGT protein results in increased expression of TGFB1 protein] 15-deoxy-delta(12,14)-prostaglandin J2 promotes the reaction [alitretinoin results in decreased expression of TGFB1 mRNA]; 2,2-bis(4-glycidyloxyphenyl)propane inhibits the reaction [[alitretinoin co-treated with 15-deoxy-delta(12,14)-prostaglandin J2] results in decreased expression of TGFB1 mRNA]; 2-chloro-5-nitrobenzanilide inhibits the reaction [[alitretinoin co-treated with 15-deoxy-delta(12,14)-prostaglandin J2] results in decreased expression of TGFB1 mRNA]; RPS6KB1 protein inhibits the reaction [[15-deoxy-delta(12,14)-prostaglandin J2 co-treated with alitretinoin] results in decreased expression of TGFB1 mRNA] 15-deoxy-delta(12,14)-prostaglandin J2 results in decreased susceptibility to TGFB1 protein |
CTD |
PMID:16611854 PMID:18278065 PMID:19429239 |
|
NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847
|
|
G |
Th |
tyrosine hydroxylase |
increases expression |
EXP |
15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of TH protein |
CTD |
PMID:15212945 |
|
NCBI chr 1:198,071,500...198,078,832
Ensembl chr 1:198,071,503...198,109,767
|
|
G |
Tlr2 |
toll-like receptor 2 |
multiple interactions decreases expression |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [Lipopolysaccharides results in increased expression of TLR2 mRNA] 15-deoxy-delta(12,14)-prostaglandin J2 results in decreased expression of TLR2 mRNA |
CTD |
PMID:20174873 |
|
NCBI chr 2:169,200,620...169,206,819
Ensembl chr 2:169,197,419...169,206,630
|
|
G |
Tnf |
tumor necrosis factor |
decreases expression multiple interactions |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 results in decreased expression of TNF protein 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA] |
CTD |
PMID:12604364 PMID:19888466 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Tshb |
thyroid stimulating hormone subunit beta |
multiple interactions |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 promotes the reaction [TSHB protein results in increased expression of TG protein] |
CTD |
PMID:11078701 |
|
NCBI chr 2:190,224,676...190,229,559
Ensembl chr 2:190,224,676...190,229,559
|
|
G |
Tslp |
thymic stromal lymphopoietin |
multiple interactions |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP mRNA]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP protein] |
CTD |
PMID:23688403 |
|
NCBI chr18:24,447,409...24,454,244
Ensembl chr18:24,449,844...24,453,548
|
|
G |
Vim |
vimentin |
decreases expression |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 results in decreased expression of VIM |
CTD |
PMID:15254749 |
|
NCBI chr17:76,668,701...76,677,186
Ensembl chr17:76,668,647...76,677,187
|
|
G |
Wnt10b |
Wnt family member 10B |
decreases expression |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 results in decreased expression of WNT10B mRNA |
CTD |
PMID:12021203 |
|
NCBI chr 7:129,922,088...129,927,892
Ensembl chr 7:129,922,088...129,927,892
|
|
G |
Xiap |
X-linked inhibitor of apoptosis |
decreases expression |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 results in decreased expression of XIAP protein |
CTD |
PMID:15498850 PMID:16299251 |
|
NCBI chr X:120,890,537...120,938,413
Ensembl chr X:120,897,907...120,934,700
|
|
|
G |
Hmox1 |
heme oxygenase 1 |
increases expression |
ISO |
15-keto-5,8,11,13-eicosatetraenoic acid results in increased expression of HMOX1 protein |
CTD |
PMID:25450232 |
|
NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079
|
|
G |
Ikbkb |
inhibitor of nuclear factor kappa B kinase subunit beta |
multiple interactions decreases activity |
ISO |
[15-keto-5,8,11,13-eicosatetraenoic acid results in decreased activity of IKBKB protein] which results in decreased phosphorylation of NFKBIA protein |
CTD |
PMID:25450232 |
|
NCBI chr16:69,319,487...69,373,251
Ensembl chr16:69,319,554...69,373,250
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
ISO |
15-keto-5,8,11,13-eicosatetraenoic acid inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B mRNA] |
CTD |
PMID:25450232 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
ISO |
15-keto-5,8,11,13-eicosatetraenoic acid inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 mRNA] |
CTD |
PMID:25450232 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Nfkbia |
NFKB inhibitor alpha |
multiple interactions |
ISO |
[15-keto-5,8,11,13-eicosatetraenoic acid results in decreased activity of IKBKB protein] which results in decreased phosphorylation of NFKBIA protein |
CTD |
PMID:25450232 |
|
NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941
|
|
G |
Nqo1 |
NAD(P)H quinone dehydrogenase 1 |
increases expression |
ISO |
15-keto-5,8,11,13-eicosatetraenoic acid results in increased expression of NQO1 protein |
CTD |
PMID:25450232 |
|
NCBI chr19:35,295,633...35,310,528
Ensembl chr19:35,295,573...35,310,557
|
|
G |
Tnf |
tumor necrosis factor |
decreases expression multiple interactions |
ISO |
15-keto-5,8,11,13-eicosatetraenoic acid results in decreased expression of TNF mRNA 15-keto-5,8,11,13-eicosatetraenoic acid inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA] |
CTD |
PMID:25450232 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
|
G |
Ptgr1 |
prostaglandin reductase 1 |
increases metabolic processing multiple interactions |
ISO |
PTGR1 protein results in increased metabolism of 15-ketoprostaglandin F2alpha [PTGR1 protein results in increased metabolism of 15-ketoprostaglandin F2alpha] which results in increased abundance of 15-keto-13,14-dihydroprostaglandin F2alpha |
CTD |
PMID:25619643 |
|
NCBI chr 5:73,784,000...73,802,624
Ensembl chr 5:73,784,009...73,802,666
|
|
|
G |
Cyp2e1 |
cytochrome P450, family 2, subfamily e, polypeptide 1 |
affects metabolic processing |
EXP |
CYP2E1 protein affects the metabolism of 19-hydroxy-5,8,11,14-eicosatetraenoic acid |
CTD |
PMID:15205388 |
|
NCBI chr 1:195,840,330...195,850,728
Ensembl chr 1:195,840,058...195,864,023
|
|
G |
Cyp4f18 |
cytochrome P450, family 4, subfamily f, polypeptide 18 |
increases chemical synthesis |
ISO |
CYP4F3 protein alternative form results in increased chemical synthesis of 19-hydroxy-5,8,11,14-eicosatetraenoic acid |
CTD |
PMID:30259074 |
|
NCBI chr16:17,763,543...17,804,944
Ensembl chr16:17,707,317...17,804,940
|
|
|
G |
Cyp2e1 |
cytochrome P450, family 2, subfamily e, polypeptide 1 |
affects metabolic processing |
EXP |
CYP2E1 protein affects the metabolism of 19-hydroxy-5,8,11,14-eicosatetraenoic acid |
CTD |
PMID:15205388 |
|
NCBI chr 1:195,840,330...195,850,728
Ensembl chr 1:195,840,058...195,864,023
|
|
G |
Cyp4f18 |
cytochrome P450, family 4, subfamily f, polypeptide 18 |
increases chemical synthesis |
ISO |
CYP4F3 protein alternative form results in increased chemical synthesis of 19-hydroxy-5,8,11,14-eicosatetraenoic acid |
CTD |
PMID:30259074 |
|
NCBI chr16:17,763,543...17,804,944
Ensembl chr16:17,707,317...17,804,940
|
|
|
G |
Abhd12 |
abhydrolase domain containing 12, lysophospholipase |
increases hydrolysis |
ISO |
ABHD12 protein results in increased hydrolysis of glyceryl 2-arachidonate |
CTD |
PMID:18096503 |
|
NCBI chr 3:139,659,315...139,719,529
Ensembl chr 3:139,659,317...139,719,564
|
|
G |
Abhd6 |
abhydrolase domain containing 6, acylglycerol lipase |
increases hydrolysis |
ISO |
ABHD6 protein results in increased hydrolysis of glyceryl 2-arachidonate |
CTD |
PMID:18096503 |
|
NCBI chr15:16,859,740...16,907,094
Ensembl chr15:16,859,738...16,906,985
|
|
G |
Acta2 |
actin alpha 2, smooth muscle |
increases expression multiple interactions |
EXP |
glyceryl 2-arachidonate results in increased expression of ACTA2 mRNA Acetaldehyde promotes the reaction [glyceryl 2-arachidonate results in increased expression of ACTA2 mRNA] |
CTD |
PMID:21863215 |
|
NCBI chr 1:231,746,527...231,759,307
Ensembl chr 1:231,746,548...231,759,554
|
|
G |
Apoe |
apolipoprotein E |
multiple interactions |
ISO |
[[APOE protein affects the susceptibility to [Cholesterol, Dietary co-treated with Dietary Fats]] which affects the susceptibility to JZL 184] which affects the abundance of glyceryl 2-arachidonate |
CTD |
PMID:29813086 |
|
NCBI chr 1:79,353,924...79,357,852
Ensembl chr 1:79,353,916...79,357,932
|
|
G |
Arrb1 |
arrestin, beta 1 |
multiple interactions |
ISO |
glyceryl 2-arachidonate affects the reaction [CNR1 protein affects the localization of ARRB1 protein]; glyceryl 2-arachidonate promotes the reaction [CNR2 protein affects the localization of ARRB1 protein]; GRK2 protein promotes the reaction [glyceryl 2-arachidonate affects the reaction [CNR1 protein affects the localization of ARRB1 protein]] |
CTD |
PMID:31024316 |
|
NCBI chr 1:153,837,964...153,912,111
Ensembl chr 1:153,838,078...153,904,061
|
|
G |
Arrb2 |
arrestin, beta 2 |
multiple interactions |
ISO |
[GRK2 protein co-treated with glyceryl 2-arachidonate] affects the reaction [CNR1 protein affects the localization of ARRB2 protein]; [GRK2 protein co-treated with glyceryl 2-arachidonate] promotes the reaction [CNR2 protein affects the localization of ARRB2 protein]; glyceryl 2-arachidonate promotes the reaction [CNR1 protein affects the localization of ARRB2 protein]; glyceryl 2-arachidonate promotes the reaction [CNR2 protein affects the localization of ARRB2 protein] |
CTD |
PMID:31024316 |
|
NCBI chr10:55,146,887...55,154,854
Ensembl chr10:55,146,818...55,154,850
|
|
G |
Atf4 |
activating transcription factor 4 |
increases expression multiple interactions |
ISO |
glyceryl 2-arachidonate results in increased expression of ATF4 mRNA iodopravadoline inhibits the reaction [glyceryl 2-arachidonate results in increased expression of ATF4 mRNA] |
CTD |
PMID:32357311 |
|
NCBI chr 7:111,804,135...111,806,457
Ensembl chr 7:111,804,183...111,806,446
|
|
G |
Btg2 |
BTG anti-proliferation factor 2 |
increases expression |
ISO |
glyceryl 2-arachidonate results in increased expression of BTG2 mRNA |
CTD |
PMID:28095641 |
|
NCBI chr13:45,531,881...45,535,642
Ensembl chr13:45,531,925...45,535,628
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
increases expression |
ISO |
glyceryl 2-arachidonate results in increased expression of CCL2 protein |
CTD |
PMID:15115777 |
|
NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226
|
|
G |
Ccr1 |
C-C motif chemokine receptor 1 |
increases expression |
ISO |
glyceryl 2-arachidonate results in increased expression of CCR1 mRNA |
CTD |
PMID:29813086 |
|
NCBI chr 8:123,556,286...123,561,841
|
|
G |
Cd36 |
CD36 molecule |
increases expression |
ISO |
glyceryl 2-arachidonate results in increased expression of CD36 mRNA |
CTD |
PMID:29813086 |
|
NCBI chr 4:17,317,343...17,410,084
Ensembl chr 4:17,354,466...17,513,903
|
|
G |
Ces1d |
carboxylesterase 1D |
increases hydrolysis multiple interactions |
ISO |
CES1 protein results in increased hydrolysis of glyceryl 2-arachidonate [CES1 protein results in increased hydrolysis of glyceryl 2-arachidonate] which results in increased chemical synthesis of Arachidonic Acid |
CTD |
PMID:21049984 |
|
NCBI chr19:13,873,490...13,912,035
Ensembl chr19:13,796,623...13,912,035
|
|
G |
Ces2h |
carboxylesterase 2H |
increases hydrolysis multiple interactions |
ISO |
CES2 protein results in increased hydrolysis of glyceryl 2-arachidonate [CES2 protein results in increased hydrolysis of glyceryl 2-arachidonate] which results in increased chemical synthesis of Arachidonic Acid |
CTD |
PMID:21049984 |
|
NCBI chr19:32,974,242...32,988,842
Ensembl chr19:32,974,242...32,988,830
|
|
G |
Cnr1 |
cannabinoid receptor 1 |
multiple interactions increases expression |
ISO EXP |
CNR1 gene mutant form inhibits the reaction [glyceryl 2-arachidonate results in increased expression of CYP27A1 mRNA]; CNR1 gene mutant form inhibits the reaction [glyceryl 2-arachidonate results in increased expression of CYP7A1 mRNA]; CNR1 gene mutant form inhibits the reaction [glyceryl 2-arachidonate results in increased expression of CYP7B1 mRNA]; CNR1 gene mutant form inhibits the reaction [glyceryl 2-arachidonate results in increased expression of CYP8B1 mRNA]; CNR1 gene mutant form inhibits the reaction [glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAPK1 protein]; CNR1 gene mutant form inhibits the reaction [glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAPK3 protein]; CNR1 protein affects the reaction [glyceryl 2-arachidonate inhibits the reaction [Sulfur Dioxide results in increased expression of PTGS2 protein]] glyceryl 2-arachidonate results in increased expression of CNR1 mRNA [GRK2 protein co-treated with glyceryl 2-arachidonate] affects the reaction [CNR1 protein affects the localization of ARRB2 protein]; CNR1 gene mutant form inhibits the reaction [glyceryl 2-arachidonate results in increased expression of CYP27A1 mRNA]; CNR1 gene mutant form inhibits the reaction [glyceryl 2-arachidonate results in increased expression of CYP7A1 mRNA]; CNR1 gene mutant form inhibits the reaction [glyceryl 2-arachidonate results in increased expression of CYP8B1 mRNA]; glyceryl 2-arachidonate affects the reaction [CNR1 protein affects the localization of ARRB1 protein]; glyceryl 2-arachidonate promotes the reaction [CNR1 protein affects the localization of ARRB2 protein]; GRK2 protein promotes the reaction [glyceryl 2-arachidonate affects the reaction [CNR1 protein affects the localization of ARRB1 protein]] Acetaldehyde promotes the reaction [glyceryl 2-arachidonate results in increased expression of CNR1 mRNA]; Nitroglycerin affects the reaction [glyceryl 2-arachidonate affects the activity of CNR1 protein] |
CTD |
PMID:12657697 PMID:15899896 PMID:16775503 PMID:21863215 PMID:23894352 PMID:26209559 PMID:28095641 PMID:31024316 More...
|
|
NCBI chr 5:48,408,543...48,436,099
Ensembl chr 5:48,408,574...48,435,099
|
|
G |
Cnr2 |
cannabinoid receptor 2 |
multiple interactions affects response to substance |
ISO |
[GRK2 protein co-treated with glyceryl 2-arachidonate] promotes the reaction [CNR2 protein affects the localization of ARRB2 protein]; [SR 144528 binds to and results in increased activity of CNR2 protein] inhibits the reaction [glyceryl 2-arachidonate results in increased expression of CXCL8 protein]; CNR2 protein affects the reaction [glyceryl 2-arachidonate results in increased expression of CXCL8 protein]; CNR2 protein affects the reaction [glyceryl 2-arachidonate results in increased transport of Calcium]; glyceryl 2-arachidonate binds to and results in increased activity of CNR2 protein; glyceryl 2-arachidonate promotes the reaction [CNR2 protein affects the localization of ARRB1 protein]; glyceryl 2-arachidonate promotes the reaction [CNR2 protein affects the localization of ARRB2 protein]; Pertussis Toxin inhibits the reaction [CNR2 protein affects the reaction [glyceryl 2-arachidonate results in increased transport of Calcium]]; SR 144528 inhibits the reaction [CNR2 protein affects the reaction [glyceryl 2-arachidonate results in increased transport of Calcium]] CNR2 gene SNP affects the susceptibility to glyceryl 2-arachidonate |
CTD |
PMID:10617657 PMID:15115777 PMID:20124950 PMID:27194477 PMID:30102254 PMID:31024316 More...
|
|
NCBI chr 5:148,125,222...148,151,548
Ensembl chr 5:148,125,604...148,151,548
|
|
G |
Creb3l3 |
cAMP responsive element binding protein 3-like 3 |
multiple interactions increases expression |
ISO |
glyceryl 2-arachidonate promotes the reaction [CREB3L3 protein binds to CYP27A1 promoter]; glyceryl 2-arachidonate promotes the reaction [CREB3L3 protein binds to CYP7A1 promoter]; INS protein inhibits the reaction [glyceryl 2-arachidonate promotes the reaction [CREB3L3 protein binds to CYP27A1 promoter]]; INS protein inhibits the reaction [glyceryl 2-arachidonate promotes the reaction [CREB3L3 protein binds to CYP7A1 promoter]]; INS protein inhibits the reaction [glyceryl 2-arachidonate results in increased expression of CREB3L3 mRNA] |
CTD |
PMID:23894352 |
|
NCBI chr 7:8,622,614...8,631,053
Ensembl chr 7:8,622,614...8,631,048
|
|
G |
Crh |
corticotropin releasing hormone |
increases abundance |
ISO |
CRH protein results in increased abundance of glyceryl 2-arachidonate |
CTD |
PMID:26821211 |
|
NCBI chr 2:102,143,055...102,144,919
Ensembl chr 2:102,143,055...102,144,919
|
|
G |
Cyp27a1 |
cytochrome P450, family 27, subfamily a, polypeptide 1 |
multiple interactions increases expression |
ISO |
CNR1 gene mutant form inhibits the reaction [glyceryl 2-arachidonate results in increased expression of CYP27A1 mRNA]; glyceryl 2-arachidonate promotes the reaction [CREB3L3 protein binds to CYP27A1 promoter]; INS protein inhibits the reaction [glyceryl 2-arachidonate promotes the reaction [CREB3L3 protein binds to CYP27A1 promoter]]; INS protein inhibits the reaction [glyceryl 2-arachidonate results in increased expression of CYP27A1 mRNA] |
CTD |
PMID:23894352 PMID:28095641 |
|
NCBI chr 9:76,264,655...76,294,551
Ensembl chr 9:76,264,860...76,294,551
|
|
G |
Cyp7a1 |
cytochrome P450 family 7 subfamily A member 1 |
multiple interactions increases expression |
ISO |
CNR1 gene mutant form inhibits the reaction [glyceryl 2-arachidonate results in increased expression of CYP7A1 mRNA]; glyceryl 2-arachidonate promotes the reaction [CREB3L3 protein binds to CYP7A1 promoter]; INS protein inhibits the reaction [glyceryl 2-arachidonate promotes the reaction [CREB3L3 protein binds to CYP7A1 promoter]]; INS protein inhibits the reaction [glyceryl 2-arachidonate results in increased expression of CYP7A1 mRNA] |
CTD |
PMID:23894352 PMID:28095641 |
|
NCBI chr 5:19,376,979...19,386,676
Ensembl chr 5:19,376,974...19,386,688
|
|
G |
Cyp7b1 |
cytochrome P450 family 7 subfamily B member 1 |
increases expression multiple interactions |
ISO |
glyceryl 2-arachidonate results in increased expression of CYP7B1 mRNA CNR1 gene mutant form inhibits the reaction [glyceryl 2-arachidonate results in increased expression of CYP7B1 mRNA] |
CTD |
PMID:23894352 |
|
NCBI chr 2:100,502,791...100,669,713
Ensembl chr 2:100,502,791...100,669,698
|
|
G |
Cyp8b1 |
cytochrome P450 family 8 subfamily B member 1 |
increases expression multiple interactions |
ISO |
glyceryl 2-arachidonate results in increased expression of CYP8B1 mRNA CNR1 gene mutant form inhibits the reaction [glyceryl 2-arachidonate results in increased expression of CYP8B1 mRNA] |
CTD |
PMID:23894352 PMID:28095641 |
|
NCBI chr 8:121,578,123...121,580,093
Ensembl chr 8:121,557,062...121,580,166
|
|
G |
Dagla |
diacylglycerol lipase, alpha |
multiple interactions |
ISO |
1-((fluoro(methyl)phosphoryl)oxy)-3-isopropoxypropan-2-yl oleate inhibits the reaction [DAGLA protein modified form results in increased chemical synthesis of glyceryl 2-arachidonate] |
CTD |
PMID:27071101 |
|
NCBI chr 1:206,890,635...206,947,332
Ensembl chr 1:206,890,638...206,947,232
|
|
G |
Ddit3 |
DNA-damage inducible transcript 3 |
increases expression multiple interactions |
ISO |
glyceryl 2-arachidonate results in increased expression of DDIT3 mRNA; glyceryl 2-arachidonate results in increased expression of DDIT3 protein iodopravadoline inhibits the reaction [glyceryl 2-arachidonate results in increased expression of DDIT3 mRNA]; iodopravadoline inhibits the reaction [glyceryl 2-arachidonate results in increased expression of DDIT3 protein] |
CTD |
PMID:29441458 PMID:32357311 |
|
NCBI chr 7:63,115,645...63,121,203
Ensembl chr 7:63,116,380...63,121,201
|
|
G |
Eif2s1 |
eukaryotic translation initiation factor 2 subunit alpha |
multiple interactions increases phosphorylation |
ISO |
GSK2656157 inhibits the reaction [glyceryl 2-arachidonate results in increased phosphorylation of EIF2S1 protein]; iodopravadoline inhibits the reaction [glyceryl 2-arachidonate results in increased phosphorylation of EIF2S1 protein] |
CTD |
PMID:32357311 |
|
NCBI chr 6:97,672,829...97,697,499
Ensembl chr 6:97,672,766...97,706,225
|
|
G |
Esrrg |
estrogen-related receptor gamma |
increases abundance |
ISO |
ESRRG protein results in increased abundance of glyceryl 2-arachidonate |
CTD |
PMID:31912162 |
|
NCBI chr13:99,167,656...99,788,016
Ensembl chr13:99,564,669...99,783,397
|
|
G |
Fabp1 |
fatty acid binding protein 1 |
affects abundance multiple interactions |
ISO |
FABP1 protein affects the abundance of glyceryl 2-arachidonate FABP1 protein affects the reaction [Dronabinol results in increased abundance of glyceryl 2-arachidonate]; FABP1 protein affects the reaction [glyceryl 2-arachidonate results in increased abundance of anandamide] |
CTD |
PMID:29414765 |
|
NCBI chr 4:103,191,015...103,194,791
Ensembl chr 4:103,191,006...103,194,788
|
|
G |
Fmr1 |
fragile X messenger ribonucleoprotein 1 |
multiple interactions |
ISO |
[FMR1 gene mutant form results in increased activity of MGLL] which results in increased degradation of glyceryl 2-arachidonate |
CTD |
PMID:20393458 |
|
NCBI chr X:147,240,239...147,278,057
Ensembl chr X:147,240,301...147,278,050
|
|
G |
Fyn |
FYN proto-oncogene, Src family tyrosine kinase |
multiple interactions |
EXP |
FYN gene mutant form inhibits the reaction [glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAPK1 protein]; FYN gene mutant form inhibits the reaction [glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAPK3 protein] |
CTD |
PMID:12657697 |
|
NCBI chr20:42,767,733...42,960,903
Ensembl chr20:42,766,369...42,959,911
|
|
G |
Grk2 |
G protein-coupled receptor kinase 2 |
multiple interactions |
ISO |
[GRK2 protein co-treated with glyceryl 2-arachidonate] affects the reaction [CNR1 protein affects the localization of ARRB2 protein]; [GRK2 protein co-treated with glyceryl 2-arachidonate] promotes the reaction [CNR2 protein affects the localization of ARRB2 protein]; GRK2 protein promotes the reaction [glyceryl 2-arachidonate affects the reaction [CNR1 protein affects the localization of ARRB1 protein]] |
CTD |
PMID:31024316 |
|
NCBI chr 1:201,581,480...201,601,580
Ensembl chr 1:201,581,480...201,601,582
|
|
G |
Hcrt |
hypocretin neuropeptide precursor |
increases chemical synthesis multiple interactions |
ISO |
HCRT protein modified form results in increased chemical synthesis of glyceryl 2-arachidonate 1-(2-methylbenzoxazol-6-yl)-3-(1,5)naphthyridin-4-yl urea inhibits the reaction [HCRT protein modified form results in increased chemical synthesis of glyceryl 2-arachidonate] |
CTD |
PMID:27071101 |
|
NCBI chr10:85,689,992...85,691,206
Ensembl chr10:85,689,465...85,691,210
|
|
G |
Hspa5 |
heat shock protein family A (Hsp70) member 5 |
increases expression |
ISO |
glyceryl 2-arachidonate results in increased expression of HSPA5 mRNA |
CTD |
PMID:32357311 |
|
NCBI chr 3:18,055,507...18,059,969
Ensembl chr 3:18,055,405...18,059,891
|
|
G |
Icam1 |
intercellular adhesion molecule 1 |
increases expression |
ISO |
glyceryl 2-arachidonate results in increased expression of ICAM1 mRNA |
CTD |
PMID:29813086 |
|
NCBI chr 8:19,553,063...19,565,438
Ensembl chr 8:19,553,645...19,565,438
|
|
G |
Il1b |
interleukin 1 beta |
decreases expression multiple interactions |
ISO |
glyceryl 2-arachidonate results in decreased expression of IL1B mRNA glyceryl 2-arachidonate inhibits the reaction [Serotonin promotes the reaction [Dextran Sulfate results in increased expression of IL1B protein]] |
CTD |
PMID:16364651 PMID:30611738 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il2 |
interleukin 2 |
multiple interactions |
ISO |
glyceryl 2-arachidonate metabolite inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Calcium Ionophores] results in increased secretion of IL2 protein]; T 0070907 inhibits the reaction [glyceryl 2-arachidonate metabolite inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Calcium Ionophores] results in increased secretion of IL2 protein]] |
CTD |
PMID:21511917 |
|
NCBI chr 2:120,004,862...120,009,566
Ensembl chr 2:120,004,862...120,009,566
|
|
G |
Il6 |
interleukin 6 |
decreases expression multiple interactions |
ISO |
glyceryl 2-arachidonate results in decreased expression of IL6 mRNA glyceryl 2-arachidonate inhibits the reaction [Serotonin promotes the reaction [Dextran Sulfate results in increased expression of IL6 protein]] |
CTD |
PMID:16364651 PMID:30611738 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Ins2 |
insulin 2 |
multiple interactions |
ISO |
INS protein inhibits the reaction [glyceryl 2-arachidonate promotes the reaction [CREB3L3 protein binds to CYP27A1 promoter]]; INS protein inhibits the reaction [glyceryl 2-arachidonate promotes the reaction [CREB3L3 protein binds to CYP7A1 promoter]]; INS protein inhibits the reaction [glyceryl 2-arachidonate results in increased expression of CREB3L3 mRNA]; INS protein inhibits the reaction [glyceryl 2-arachidonate results in increased expression of CYP27A1 mRNA]; INS protein inhibits the reaction [glyceryl 2-arachidonate results in increased expression of CYP7A1 mRNA] |
CTD |
PMID:23894352 |
|
NCBI chr 1:197,843,277...197,992,522
Ensembl chr 1:197,843,281...197,864,775
|
|
G |
Lep |
leptin |
multiple interactions |
ISO |
[Dietary Fats co-treated with LEP protein] results in increased chemical synthesis of glyceryl 2-arachidonate |
CTD |
PMID:27071101 |
|
NCBI chr 4:57,661,127...57,675,262
Ensembl chr 4:57,661,131...57,675,262
|
|
G |
Map2k1 |
mitogen activated protein kinase kinase 1 |
multiple interactions |
EXP |
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAP2K1 protein]; glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAP2K1 protein; U 0126 inhibits the reaction [glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAP2K1 protein] |
CTD |
PMID:12657697 |
|
NCBI chr 8:64,683,449...64,754,900
Ensembl chr 8:64,683,449...64,755,147
|
|
G |
Map2k2 |
mitogen activated protein kinase kinase 2 |
multiple interactions |
EXP |
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAP2K2 protein]; glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAP2K2 protein; U 0126 inhibits the reaction [glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAP2K2 protein] |
CTD |
PMID:12657697 |
|
NCBI chr 7:8,590,729...8,610,279
Ensembl chr 7:8,580,905...8,610,243
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions decreases phosphorylation |
ISO EXP |
CNR1 gene mutant form inhibits the reaction [glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAPK1 protein]; glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAPK1 protein glyceryl 2-arachidonate results in decreased phosphorylation of MAPK1 protein 8-Bromo Cyclic Adenosine Monophosphate inhibits the reaction [glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAPK1 protein]; FYN gene mutant form inhibits the reaction [glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAPK1 protein]; glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAPK1 protein; Rimonabant inhibits the reaction [glyceryl 2-arachidonate results in decreased phosphorylation of MAPK1 protein]; Rimonabant inhibits the reaction [glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAPK1 protein] |
CTD |
PMID:12657697 PMID:31917333 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions decreases phosphorylation |
ISO EXP |
CNR1 gene mutant form inhibits the reaction [glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAPK3 protein]; glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAPK3 protein glyceryl 2-arachidonate results in decreased phosphorylation of MAPK3 protein 8-Bromo Cyclic Adenosine Monophosphate inhibits the reaction [glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAPK3 protein]; FYN gene mutant form inhibits the reaction [glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAPK3 protein]; glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAPK3 protein; Rimonabant inhibits the reaction [glyceryl 2-arachidonate results in decreased phosphorylation of MAPK3 protein]; Rimonabant inhibits the reaction [glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAPK3 protein] |
CTD |
PMID:12657697 PMID:31917333 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Mgll |
monoglyceride lipase |
multiple interactions affects abundance increases degradation increases abundance increases hydrolysis |
EXP ISO |
[Chlorpyrifos results in decreased activity of MGLL protein] which results in increased abundance of glyceryl 2-arachidonate; JZL 184 inhibits the reaction [MGLL protein results in increased hydrolysis of glyceryl 2-arachidonate] MGLL protein affects the abundance of glyceryl 2-arachidonate MGLL protein results in increased degradation of glyceryl 2-arachidonate [FMR1 gene mutant form results in increased activity of MGLL] which results in increased degradation of glyceryl 2-arachidonate; [JZL 184 results in decreased activity of MGLL protein] which results in increased abundance of glyceryl 2-arachidonate; [MJN110 results in decreased activity of MGLL protein] which results in decreased hydrolysis of and results in increased abundance of glyceryl 2-arachidonate MGLL gene mutant form results in increased abundance of glyceryl 2-arachidonate |
CTD |
PMID:18096503 PMID:20393458 PMID:21507991 PMID:23761300 PMID:25030704 PMID:26209559 PMID:26642910 PMID:26791602 PMID:30301768 More...
|
|
NCBI chr 4:121,192,187...121,294,187
Ensembl chr 4:121,192,195...121,294,179
|
|
G |
Mpo |
myeloperoxidase |
multiple interactions |
ISO |
glyceryl 2-arachidonate inhibits the reaction [Serotonin promotes the reaction [Dextran Sulfate results in increased activity of MPO protein]] |
CTD |
PMID:30611738 |
|
NCBI chr10:72,594,458...72,608,862
Ensembl chr10:72,594,661...72,604,819
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
multiple interactions increases cleavage |
ISO |
GSK2656157 inhibits the reaction [glyceryl 2-arachidonate results in increased cleavage of PARP1 protein] |
CTD |
PMID:29441458 PMID:32357311 |
|
NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
|
|
G |
Ppara |
peroxisome proliferator activated receptor alpha |
affects localization multiple interactions |
EXP |
glyceryl 2-arachidonate affects the localization of PPARA protein [palmidrol co-treated with glyceryl 2-arachidonate] affects the localization of PPARA protein; [palmidrol co-treated with glyceryl 2-arachidonate] affects the reaction [lipopolysaccharide, E. coli O26-B6 affects the localization of PPARA protein]; glyceryl 2-arachidonate affects the reaction [lipopolysaccharide, E. coli O26-B6 affects the localization of PPARA protein] |
CTD |
PMID:31787870 |
|
NCBI chr 7:116,832,405...116,900,878
Ensembl chr 7:116,832,756...116,895,346
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
affects binding multiple interactions increases expression |
ISO |
glyceryl 2-arachidonate metabolite binds to PPARG protein glyceryl 2-arachidonate inhibits the reaction [Sulfur Dioxide results in decreased expression of PPARG protein]; PPARG protein affects the reaction [glyceryl 2-arachidonate inhibits the reaction [Sulfur Dioxide results in increased expression of PTGS2 protein]]; PPARG protein affects the reaction [glyceryl 2-arachidonate inhibits the reaction [Sulfur Dioxide results in increased phosphorylation of RELA protein]] T 0070907 inhibits the reaction [glyceryl 2-arachidonate metabolite results in increased expression of PPARG mRNA] |
CTD |
PMID:21511917 PMID:26209559 |
|
NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468
|
|
G |
Ptgs1 |
prostaglandin-endoperoxide synthase 1 |
multiple interactions |
EXP |
[Indomethacin results in decreased expression of PTGS1] which results in increased activity of glyceryl 2-arachidonate |
CTD |
PMID:17245358 |
|
NCBI chr 3:19,584,015...19,605,589
Ensembl chr 3:19,584,015...19,605,586
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
increases metabolic processing multiple interactions |
ISO |
PTGS2 protein results in increased metabolism of glyceryl 2-arachidonate 2-chloro-5-nitrobenzanilide inhibits the reaction [glyceryl 2-arachidonate inhibits the reaction [Sulfur Dioxide results in increased expression of PTGS2 protein]]; CNR1 protein affects the reaction [glyceryl 2-arachidonate inhibits the reaction [Sulfur Dioxide results in increased expression of PTGS2 protein]]; glyceryl 2-arachidonate inhibits the reaction [Sulfur Dioxide results in increased expression of PTGS2 protein]; PPARG protein affects the reaction [glyceryl 2-arachidonate inhibits the reaction [Sulfur Dioxide results in increased expression of PTGS2 protein]]; rimonabant inhibits the reaction [glyceryl 2-arachidonate inhibits the reaction [Sulfur Dioxide results in increased expression of PTGS2 protein]] glyceryl 2-arachidonate inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Calcium Ionophores] results in increased expression of PTGS2 mRNA]; Ibuprofen inhibits the reaction [PTGS2 protein results in increased metabolism of glyceryl 2-arachidonate] |
CTD |
PMID:18297109 PMID:21511917 PMID:26209559 |
|
NCBI chr13:62,164,080...62,169,770
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
ISO |
2-chloro-5-nitrobenzanilide inhibits the reaction [glyceryl 2-arachidonate inhibits the reaction [Sulfur Dioxide results in increased phosphorylation of RELA protein]]; glyceryl 2-arachidonate inhibits the reaction [Sulfur Dioxide results in increased phosphorylation of RELA protein]; PPARG protein affects the reaction [glyceryl 2-arachidonate inhibits the reaction [Sulfur Dioxide results in increased phosphorylation of RELA protein]] |
CTD |
PMID:26209559 |
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Tnf |
tumor necrosis factor |
decreases expression multiple interactions |
ISO EXP |
glyceryl 2-arachidonate results in decreased expression of TNF mRNA glyceryl 2-arachidonate inhibits the reaction [[Serotonin co-treated with Dextran Sulfate] results in increased expression of TNF protein]; glyceryl 2-arachidonate inhibits the reaction [amyloid beta-protein (25-35) results in increased expression of TNF protein] glyceryl 2-arachidonate inhibits the reaction [lipopolysaccharide, E. coli O26-B6 results in increased expression of TNF protein] |
CTD |
PMID:12509806 PMID:16364651 PMID:30611738 PMID:30769029 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Trpv1 |
transient receptor potential cation channel, subfamily V, member 1 |
multiple interactions affects response to substance |
EXP ISO |
glyceryl 2-arachidonate binds to and results in increased activity of TRPV1 protein TRPV1 protein affects the susceptibility to glyceryl 2-arachidonate |
CTD |
PMID:18550765 PMID:21949157 |
|
NCBI chr10:57,851,428...57,876,513
Ensembl chr10:57,851,428...57,876,513
|
|
G |
Yy1 |
YY1 transcription factor |
increases expression |
ISO |
glyceryl 2-arachidonate results in increased expression of YY1 mRNA |
CTD |
PMID:28095641 |
|
NCBI chr 6:127,706,739...127,731,907
Ensembl chr 6:127,707,596...127,732,747
|
|
|
G |
Apoa1 |
apolipoprotein A1 |
decreases expression |
EXP |
2-bromopalmitate results in decreased expression of APOA1 mRNA |
CTD |
PMID:7556148 |
|
NCBI chr 8:46,527,251...46,529,035
Ensembl chr 8:46,527,144...46,529,035
|
|
G |
Cebpb |
CCAAT/enhancer binding protein beta |
multiple interactions |
ISO |
2-bromopalmitate promotes the reaction [Tretinoin results in increased expression of CEBPB mRNA] |
CTD |
PMID:30076181 |
|
NCBI chr 3:156,398,035...156,399,466
Ensembl chr 3:156,397,052...156,399,473
|
|
G |
Fas |
Fas cell surface death receptor |
decreases expression |
ISO |
2-bromopalmitate results in decreased expression of FAS mRNA |
CTD |
PMID:16712844 |
|
NCBI chr 1:231,798,963...231,832,591
Ensembl chr 1:231,798,960...231,832,591
|
|
G |
Gapdh |
glyceraldehyde-3-phosphate dehydrogenase |
increases activity |
EXP |
2-bromopalmitate results in increased activity of GAPDH protein |
CTD |
PMID:10650946 |
|
NCBI chr 4:157,962,312...157,967,158
Ensembl chr 4:157,962,343...157,966,235
|
|
G |
Ifit3 |
interferon-induced protein with tetratricopeptide repeats 3 |
multiple interactions |
ISO |
2-bromopalmitate promotes the reaction [Tretinoin results in increased expression of IFIT3 mRNA] |
CTD |
PMID:30076181 |
|
NCBI chr 1:232,114,166...232,119,311
Ensembl chr 1:232,114,166...232,119,307
|
|
G |
Irf1 |
interferon regulatory factor 1 |
multiple interactions |
ISO |
2-bromopalmitate promotes the reaction [Tretinoin results in increased expression of IRF1 mRNA] |
CTD |
PMID:30076181 |
|
NCBI chr10:37,917,155...37,924,166
Ensembl chr10:37,916,670...37,924,166
|
|
G |
Lat2 |
linker for activation of T cells family, member 2 |
decreases expression |
ISO |
2-bromopalmitate results in decreased expression of LAT2 protein |
CTD |
PMID:23001822 |
|
NCBI chr12:22,104,163...22,118,294
Ensembl chr12:22,104,219...22,118,288
|
|
G |
Ldlr |
low density lipoprotein receptor |
increases expression |
ISO |
2-bromopalmitate results in increased expression of LDLR mRNA |
CTD |
PMID:23150725 |
|
NCBI chr 8:20,270,020...20,292,981
Ensembl chr 8:20,270,041...20,294,580
|
|
G |
Lrat |
lecithin retinol acyltransferase |
increases expression |
EXP |
2-bromopalmitate results in increased expression of LRAT mRNA |
CTD |
PMID:12576510 |
|
NCBI chr 2:168,264,093...168,273,155
Ensembl chr 2:168,266,877...168,273,619
|
|
G |
Ly6e |
lymphocyte antigen 6 family member E |
multiple interactions |
ISO |
2-bromopalmitate promotes the reaction [Tretinoin results in increased expression of LY6E mRNA] |
CTD |
PMID:30076181 |
|
NCBI chr 7:106,935,530...106,939,689
Ensembl chr 7:106,935,761...106,939,689
|
|
G |
Mpo |
myeloperoxidase |
multiple interactions |
ISO |
2-bromopalmitate promotes the reaction [Tretinoin results in decreased expression of MPO mRNA] |
CTD |
PMID:30076181 |
|
NCBI chr10:72,594,458...72,608,862
Ensembl chr10:72,594,661...72,604,819
|
|
G |
Ppard |
peroxisome proliferator-activated receptor delta |
increases activity multiple interactions |
ISO |
2-bromopalmitate results in increased activity of PPARD protein 2-bromopalmitate results in increased activity of [RXRA protein binds to PPARD protein] |
CTD |
PMID:15997096 PMID:21543282 PMID:23150725 |
|
NCBI chr20:6,298,785...6,363,970
Ensembl chr20:6,298,785...6,363,968
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
increases expression |
EXP |
2-bromopalmitate results in increased expression of PPARG protein |
CTD |
PMID:10650946 |
|
NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468
|
|
G |
Rara |
retinoic acid receptor, alpha |
multiple interactions |
ISO |
2-bromopalmitate binds to and results in increased expression of RARA protein; 2-bromopalmitate inhibits the reaction [Am 580 results in decreased expression of RARA protein]; 2-bromopalmitate inhibits the reaction [Tretinoin results in decreased expression of RARA protein]; [2-bromopalmitate results in increased susceptibility to Tretinoin] which results in increased expression of RARA protein |
CTD |
PMID:30076181 |
|
NCBI chr10:83,883,490...83,928,932
Ensembl chr10:83,893,384...83,928,142
|
|
G |
Rarb |
retinoic acid receptor, beta |
multiple interactions |
ISO |
2-bromopalmitate promotes the reaction [Tretinoin results in increased expression of RARB mRNA] |
CTD |
PMID:30076181 |
|
NCBI chr15:8,700,533...9,051,288
Ensembl chr15:8,406,492...9,051,288
|
|
G |
Rbp1 |
retinol binding protein 1 |
increases expression |
EXP |
2-bromopalmitate results in increased expression of RBP1 mRNA |
CTD |
PMID:12576510 |
|
NCBI chr 8:99,025,218...99,046,740
Ensembl chr 8:99,025,206...99,046,743
|
|
G |
Rxra |
retinoid X receptor alpha |
multiple interactions |
ISO |
2-bromopalmitate results in increased activity of [RXRA protein binds to PPARD protein] |
CTD |
PMID:15997096 |
|
NCBI chr 3:10,989,832...11,076,366
Ensembl chr 3:10,989,832...11,073,712
|
|
G |
Spi1 |
Spi-1 proto-oncogene |
multiple interactions |
ISO |
2-bromopalmitate promotes the reaction [Tretinoin results in increased expression of SPI1 mRNA] |
CTD |
PMID:30076181 |
|
NCBI chr 3:77,059,744...77,093,730
Ensembl chr 3:77,073,012...77,092,393
|
|
G |
Tgm2 |
transglutaminase 2 |
multiple interactions |
ISO |
2-bromopalmitate promotes the reaction [Tretinoin results in increased expression of TGM2 mRNA] |
CTD |
PMID:30076181 |
|
NCBI chr 3:146,772,684...146,801,924
Ensembl chr 3:146,772,687...146,801,981
|
|
G |
Ucp2 |
uncoupling protein 2 |
increases expression |
EXP |
2-bromopalmitate results in increased expression of UCP2 mRNA |
CTD |
PMID:11341955 |
|
NCBI chr 1:154,839,242...154,845,612
Ensembl chr 1:154,839,209...154,845,611
|
|
|
G |
Rxra |
retinoid X receptor alpha |
affects binding |
ISO |
2-hydroxyphytanic acid binds to RXRA protein |
CTD |
PMID:23843199 |
|
NCBI chr 3:10,989,832...11,076,366
Ensembl chr 3:10,989,832...11,073,712
|
|
G |
Rxrb |
retinoid X receptor beta |
affects binding |
ISO |
2-hydroxyphytanic acid binds to RXRB protein |
CTD |
PMID:23843199 |
|
NCBI chr20:4,816,813...4,823,267
Ensembl chr20:4,816,815...4,828,773
|
|
G |
Rxrg |
retinoid X receptor gamma |
affects binding |
ISO |
2-hydroxyphytanic acid binds to RXRG protein |
CTD |
PMID:23843199 |
|
NCBI chr13:79,743,430...79,785,173
Ensembl chr13:79,743,563...79,785,167
|
|
|
G |
Fabp1 |
fatty acid binding protein 1 |
affects abundance |
ISO |
FABP1 protein affects the abundance of 2-oleoylglycerol |
CTD |
PMID:29414765 |
|
NCBI chr 4:103,191,015...103,194,791
Ensembl chr 4:103,191,006...103,194,788
|
|
G |
Mgll |
monoglyceride lipase |
increases degradation multiple interactions |
EXP |
MGLL protein results in increased degradation of 2-oleoylglycerol Nitroglycerin promotes the reaction [MGLL protein results in increased degradation of 2-oleoylglycerol] |
CTD |
PMID:19515121 |
|
NCBI chr 4:121,192,187...121,294,187
Ensembl chr 4:121,192,195...121,294,179
|
|
|
G |
Clock |
clock circadian regulator |
affects abundance |
ISO |
CLOCK protein affects the abundance of 20-hydroxy-5,8,11,14-eicosatetraenoic acid |
CTD |
PMID:22440902 |
|
NCBI chr14:31,908,542...31,992,673
Ensembl chr14:31,908,566...31,990,400
|
|
G |
Cyp4a1 |
cytochrome P450, family 4, subfamily a, polypeptide 1 |
multiple interactions increases chemical synthesis |
EXP |
20-hydroxy-5,8,11,14-eicosatetraenoic acid affects the reaction [CYP4A1 protein affects the susceptibility to Phenylephrine]; 20-hydroxy-5,8,11,14-eicosatetraenoic acid inhibits the reaction [DDMS inhibits the reaction [CYP4A1 protein results in increased susceptibility to Phenylephrine]] CYP4A1 protein results in increased chemical synthesis of 20-hydroxy-5,8,11,14-eicosatetraenoic acid |
CTD |
PMID:11124159 PMID:12388396 |
|
NCBI chr 5:129,123,323...129,137,464
Ensembl chr 5:129,123,336...129,137,464
|
|
G |
Cyp4a2 |
cytochrome P450, family 4, subfamily a, polypeptide 2 |
increases expression |
EXP |
20-hydroxy-5,8,11,14-eicosatetraenoic acid results in increased expression of CYP4A2 mRNA |
CTD |
PMID:22442195 |
|
NCBI chr 5:128,922,355...128,934,188
Ensembl chr 5:128,923,615...128,934,165
|
|
G |
Cyp4f18 |
cytochrome P450, family 4, subfamily f, polypeptide 18 |
increases chemical synthesis |
ISO |
CYP4F3 protein alternative form results in increased chemical synthesis of 20-hydroxy-5,8,11,14-eicosatetraenoic acid |
CTD |
PMID:30259074 |
|
NCBI chr16:17,763,543...17,804,944
Ensembl chr16:17,707,317...17,804,940
|
|
G |
Nfatc4 |
nuclear factor of activated T-cells 4 |
multiple interactions increases localization |
ISO EXP |
Cyclosporine inhibits the reaction [20-hydroxy-5,8,11,14-eicosatetraenoic acid results in increased localization of NFATC4 protein]; Tacrolimus inhibits the reaction [20-hydroxy-5,8,11,14-eicosatetraenoic acid results in increased localization of NFATC4 protein] |
CTD |
PMID:16055480 |
|
NCBI chr15:29,286,998...29,314,610
Ensembl chr15:29,305,535...29,314,610
|
|
G |
Pomc |
proopiomelanocortin |
multiple interactions increases abundance |
EXP |
HET0016 inhibits the reaction [POMC protein affects the abundance of 20-hydroxy-5,8,11,14-eicosatetraenoic acid] POMC protein results in increased abundance of 20-hydroxy-5,8,11,14-eicosatetraenoic acid |
CTD |
PMID:18067589 PMID:19458537 |
|
NCBI chr 6:26,939,844...26,945,666
Ensembl chr 6:26,939,837...26,945,664
|
|
G |
Ugt1a1 |
UDP glucuronosyltransferase family 1 member A1 |
increases glucuronidation |
ISO |
UGT1A1 protein results in increased glucuronidation of 20-hydroxy-5,8,11,14-eicosatetraenoic acid |
CTD |
PMID:15231852 |
|
NCBI chr 9:88,801,344...88,808,465
Ensembl chr 9:88,713,184...88,808,465
|
|
G |
Ugt1a5 |
UDP glucuronosyltransferase family 1 member A5 |
increases glucuronidation |
ISO |
UGT1A4 protein results in increased glucuronidation of 20-hydroxy-5,8,11,14-eicosatetraenoic acid |
CTD |
PMID:15231852 |
|
NCBI chr 9:88,762,250...88,808,465
Ensembl chr 9:88,713,184...88,808,465
|
|
G |
Ugt2b7 |
UDP glucuronosyltransferase family 2 member B7 |
increases glucuronidation |
ISO |
UGT2B7 protein results in increased glucuronidation of 20-hydroxy-5,8,11,14-eicosatetraenoic acid |
CTD |
PMID:15231852 |
|
NCBI chr14:20,896,682...20,919,604
Ensembl chr14:20,896,682...20,919,604
|
|
|
G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
multiple interactions increases chemical synthesis |
ISO |
Ketoconazole inhibits the reaction [CYP3A4 protein results in increased chemical synthesis of 5,6-epoxy-8,11,14-eicosatrienoic acid] |
CTD |
PMID:12675279 |
|
NCBI chr12:9,207,986...9,230,038
Ensembl chr12:9,015,383...9,285,008
|
|
G |
Ephx2 |
epoxide hydrolase 2 |
increases abundance |
ISO |
EPHX2 gene mutant form results in increased abundance of 5,6-epoxy-8,11,14-eicosatrienoic acid |
CTD |
PMID:19896470 |
|
NCBI chr15:40,289,901...40,327,632
Ensembl chr15:40,289,902...40,327,615
|
|
|
G |
Csf2 |
colony stimulating factor 2 |
increases secretion |
ISO |
5-oxo-6,8,11,14-eicosatetraenoic acid results in increased secretion of CSF2 protein |
CTD |
PMID:15136573 |
|
NCBI chr10:38,386,945...38,388,926
Ensembl chr10:38,386,945...38,389,199
|
|
|
G |
Agt |
angiotensinogen |
increases abundance multiple interactions |
EXP |
AGT protein alternative form results in increased abundance of 6-Ketoprostaglandin F1 alpha Dexamethasone inhibits the reaction [AGT protein alternative form results in increased abundance of 6-Ketoprostaglandin F1 alpha] |
CTD |
PMID:4030047 |
|
NCBI chr19:52,529,139...52,549,618
Ensembl chr19:52,529,185...52,540,977
|
|
G |
Alox15 |
arachidonate 15-lipoxygenase |
multiple interactions |
ISO |
[ALOX15 protein affects the metabolism of Arachidonic Acid] which results in increased abundance of 6-Ketoprostaglandin F1 alpha |
CTD |
PMID:21193584 |
|
NCBI chr10:55,060,169...55,068,885
Ensembl chr10:55,060,412...55,068,874
|
|
G |
Apoe |
apolipoprotein E |
increases abundance multiple interactions |
ISO |
APOE results in increased abundance of 6-Ketoprostaglandin F1 alpha nimesulide inhibits the reaction [APOE results in increased abundance of 6-Ketoprostaglandin F1 alpha] |
CTD |
PMID:14966570 |
|
NCBI chr 1:79,353,924...79,357,852
Ensembl chr 1:79,353,916...79,357,932
|
|
G |
Avp |
arginine vasopressin |
increases abundance multiple interactions |
EXP |
AVP protein results in increased abundance of 6-Ketoprostaglandin F1 alpha Dexamethasone inhibits the reaction [AVP protein results in increased abundance of 6-Ketoprostaglandin F1 alpha] |
CTD |
PMID:4030047 |
|
NCBI chr 3:117,793,447...117,805,091
Ensembl chr 3:117,793,457...117,795,425
|
|
G |
Bdkrb2 |
bradykinin receptor B2 |
affects abundance multiple interactions |
ISO EXP |
BDKRB2 affects the abundance of 6-Ketoprostaglandin F1 alpha [kallidin, des-Arg(10)- binds to and results in increased activity of BDKRB2 protein] which results in increased secretion of 6-Ketoprostaglandin F1 alpha; [KNG1 protein modified form binds to and results in increased activity of BDKRB2 protein] which results in increased secretion of 6-Ketoprostaglandin F1 alpha PD 123319 affects the reaction [BDKRB2 affects the abundance of 6-Ketoprostaglandin F1 alpha] |
CTD |
PMID:16514058 PMID:29775649 |
|
NCBI chr 6:124,472,317...124,502,497
Ensembl chr 6:124,472,566...124,502,497
|
|
G |
Calca |
calcitonin-related polypeptide alpha |
decreases abundance increases abundance |
ISO EXP |
CALCA protein alternative form results in decreased abundance of 6-Ketoprostaglandin F1 alpha CALCA protein results in increased abundance of 6-Ketoprostaglandin F1 alpha |
CTD |
PMID:12024109 |
|
NCBI chr 1:168,878,212...168,883,176
Ensembl chr 1:168,878,214...168,883,105
|
|
G |
Klkb1 |
kallikrein B1 |
multiple interactions increases abundance |
ISO |
7-Ala-angiotensin (1-7) inhibits the reaction [KLKB1 gene mutant form results in increased abundance of 6-Ketoprostaglandin F1 alpha]; nimesulide inhibits the reaction [KLKB1 gene mutant form results in increased abundance of 6-Ketoprostaglandin F1 alpha] |
CTD |
PMID:25339356 |
|
NCBI chr16:46,958,634...46,982,054
Ensembl chr16:46,958,707...46,982,053
|
|
G |
Kng2 |
kininogen 2 |
increases abundance multiple interactions |
EXP |
KNG1 protein alternative form results in increased abundance of 6-Ketoprostaglandin F1 alpha [KNG1 protein modified form binds to and results in increased activity of BDKRB2 protein] which results in increased secretion of 6-Ketoprostaglandin F1 alpha; Dexamethasone inhibits the reaction [KNG1 protein alternative form results in increased abundance of 6-Ketoprostaglandin F1 alpha] |
CTD |
PMID:4030047 PMID:29775649 |
|
NCBI chr11:77,913,876...77,936,247
Ensembl chr11:77,909,612...78,002,971
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions |
ISO |
NOS2 protein promotes the reaction [[Morphine results in increased expression of PTGS2 protein] which results in increased abundance of 6-Ketoprostaglandin F1 alpha] |
CTD |
PMID:16325209 |
|
NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
|
|
G |
Ptgis |
prostaglandin I2 synthase |
multiple interactions increases chemical synthesis |
EXP |
[Carnitine results in increased expression of PTGIS mRNA] which results in increased chemical synthesis of 6-Ketoprostaglandin F1 alpha PTGIS protein results in increased chemical synthesis of 6-Ketoprostaglandin F1 alpha |
CTD |
PMID:19491382 |
|
NCBI chr 3:155,928,564...155,964,228
Ensembl chr 3:155,916,412...155,965,451
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions |
ISO |
[Morphine results in increased expression of PTGS2 protein] which results in increased abundance of 6-Ketoprostaglandin F1 alpha; NOS2 protein promotes the reaction [[Morphine results in increased expression of PTGS2 protein] which results in increased abundance of 6-Ketoprostaglandin F1 alpha]; PTGS2 gene mutant form inhibits the reaction [[Nanotubes, Carbon co-treated with OVAL protein] results in increased abundance of 6-Ketoprostaglandin F1 alpha]; S-methylisothiopseudouronium inhibits the reaction [[Morphine results in increased expression of PTGS2 protein] which results in increased abundance of 6-Ketoprostaglandin F1 alpha] |
CTD |
PMID:16325209 PMID:23642096 |
|
NCBI chr13:62,164,080...62,169,770
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Tnf |
tumor necrosis factor |
increases abundance |
ISO |
TNF protein results in increased abundance of 6-Ketoprostaglandin F1 alpha |
CTD |
PMID:1993070 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
|
G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
multiple interactions increases chemical synthesis |
ISO |
Ketoconazole inhibits the reaction [CYP3A4 protein results in increased chemical synthesis of 8,9-epoxyeicosatrienoic acid] |
CTD |
PMID:12675279 |
|
NCBI chr12:9,207,986...9,230,038
Ensembl chr12:9,015,383...9,285,008
|
|
G |
Ephx1 |
epoxide hydrolase 1 |
affects hydrolysis |
ISO |
EPHX1 protein affects the hydrolysis of 8,9-epoxyeicosatrienoic acid |
CTD |
PMID:28975360 |
|
NCBI chr13:92,714,315...92,744,124
Ensembl chr13:92,714,315...92,790,235
|
|
G |
Ephx2 |
epoxide hydrolase 2 |
increases abundance |
ISO |
EPHX2 gene mutant form results in increased abundance of 8,9-epoxyeicosatrienoic acid |
CTD |
PMID:19896470 |
|
NCBI chr15:40,289,901...40,327,632
Ensembl chr15:40,289,902...40,327,615
|
|
|
G |
Ptger4 |
prostaglandin E receptor 4 |
affects response to substance |
ISO |
PTGER4 protein affects the susceptibility to 8-isoprostaglandin E2 |
CTD |
PMID:22565502 |
|
NCBI chr 2:54,330,563...54,347,451
Ensembl chr 2:54,335,424...54,346,670
|
|
|
G |
Apoe |
apolipoprotein E |
multiple interactions |
ISO |
[APOE gene mutant form affects the susceptibility to Folic Acid] which results in decreased abundance of 8-epi-prostaglandin F2alpha |
CTD |
PMID:17118406 |
|
NCBI chr 1:79,353,924...79,357,852
Ensembl chr 1:79,353,916...79,357,932
|
|
G |
App |
amyloid beta precursor protein |
multiple interactions increases abundance |
ISO |
[Lead co-treated with APP protein modified form] results in increased abundance of 8-epi-prostaglandin F2alpha APP protein modified form results in increased abundance of 8-epi-prostaglandin F2alpha |
CTD |
PMID:22610977 |
|
NCBI chr11:24,019,774...24,236,584
Ensembl chr11:24,019,778...24,236,561
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions increases abundance increases chemical synthesis |
ISO EXP |
1-((4-methylsulfonyl)phenyl)-3-trifluoromethyl-5-(4-fluorophenyl)pyrazole inhibits the reaction [IL1B results in increased chemical synthesis of 8-epi-prostaglandin F2alpha]; 6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid inhibits the reaction [IL1B results in increased chemical synthesis of 8-epi-prostaglandin F2alpha]; Ascorbic Acid inhibits the reaction [IL1B results in increased chemical synthesis of 8-epi-prostaglandin F2alpha]; Ascorbic Acid promotes the reaction [Aspirin inhibits the reaction [IL1B results in increased chemical synthesis of 8-epi-prostaglandin F2alpha]]; Aspirin inhibits the reaction [IL1B results in increased chemical synthesis of 8-epi-prostaglandin F2alpha]; Dehydroascorbic Acid inhibits the reaction [IL1B results in increased chemical synthesis of 8-epi-prostaglandin F2alpha]; Indomethacin inhibits the reaction [IL1B results in increased chemical synthesis of 8-epi-prostaglandin F2alpha]; resveratrol inhibits the reaction [IL1B protein results in increased abundance of 8-epi-prostaglandin F2alpha] pyrrolidine dithiocarbamic acid inhibits the reaction [IL1B protein results in increased abundance of 8-epi-prostaglandin F2alpha]; Rotenone inhibits the reaction [IL1B protein results in increased abundance of 8-epi-prostaglandin F2alpha] |
CTD |
PMID:11530235 PMID:16529823 PMID:19751497 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Pafah2 |
platelet-activating factor acetylhydrolase 2 |
affects metabolic processing multiple interactions |
ISO |
PAFAH2 protein affects the metabolism of 8-epi-prostaglandin F2alpha PAFAH2 protein affects the reaction [Carbon Tetrachloride results in increased abundance of 8-epi-prostaglandin F2alpha] |
CTD |
PMID:18024956 |
|
NCBI chr 5:146,607,050...146,636,203
Ensembl chr 5:146,613,498...146,634,943
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions |
ISO |
[L 745337 results in decreased activity of PTGS2 protein] which results in decreased chemical synthesis of 8-epi-prostaglandin F2alpha; [lipopolysaccharide, E. coli O26-B6 results in increased expression of PTGS2 protein] which results in increased chemical synthesis of 8-epi-prostaglandin F2alpha; [Tetradecanoylphorbol Acetate results in increased expression of PTGS2 protein] which results in increased chemical synthesis of 8-epi-prostaglandin F2alpha |
CTD |
PMID:8621535 |
|
NCBI chr13:62,164,080...62,169,770
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Tbxa2r |
thromboxane A2 receptor |
multiple interactions affects response to substance |
ISO |
8-epi-prostaglandin F2alpha binds to and results in increased activity of TBXA2R protein TBXA2R protein affects the susceptibility to 8-epi-prostaglandin F2alpha |
CTD |
PMID:18158556 PMID:22565502 |
|
NCBI chr 7:8,383,347...8,390,753
Ensembl chr 7:8,383,378...8,388,176
|
|
|
G |
Ephx3 |
epoxide hydrolase 3 |
multiple interactions |
ISO |
[EPHX3 gene mutant form results in decreased hydrolysis of Epoxy Compounds] results in decreased abundance of [9,10,13-trihydroxy-11-octadecenoic acid binds to Ceramides]; [EPHX3 gene mutant form results in decreased hydrolysis of Epoxy Compounds] which results in decreased chemical synthesis of 9,10,13-trihydroxy-11-octadecenoic acid |
CTD |
PMID:33334892 |
|
NCBI chr 7:11,206,812...11,212,122
Ensembl chr 7:11,206,812...11,212,122
|
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
decreases expression |
ISO |
eleostearic acid results in decreased expression of BCL2 protein |
CTD |
PMID:15961301 |
|
NCBI chr13:22,689,783...22,853,920
|
|
G |
Cat |
catalase |
multiple interactions decreases activity |
EXP |
eleostearic acid inhibits the reaction [methylmercuric chloride results in decreased activity of CAT protein]; eleostearic acid inhibits the reaction [sodium arsenite results in decreased activity of CAT protein] eleostearic acid results in decreased activity of CAT protein |
CTD |
PMID:20851731 PMID:21382362 PMID:22269903 PMID:23422533 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Gadd45a |
growth arrest and DNA-damage-inducible, alpha |
increases expression |
ISO |
eleostearic acid results in increased expression of GADD45A protein |
CTD |
PMID:15961301 |
|
NCBI chr 4:96,154,789...96,157,091
Ensembl chr 4:96,154,789...96,157,115
|
|
G |
Gpt |
glutamic--pyruvic transaminase |
multiple interactions |
EXP |
eleostearic acid inhibits the reaction [methylmercuric chloride results in increased activity of GPT protein] |
CTD |
PMID:22269903 |
|
NCBI chr 7:108,416,646...108,419,495
Ensembl chr 7:108,416,642...108,419,494
|
|
G |
Gsr |
glutathione-disulfide reductase |
decreases activity |
EXP |
eleostearic acid results in decreased activity of GSR protein |
CTD |
PMID:23422533 |
|
NCBI chr16:58,482,209...58,525,256
Ensembl chr16:58,482,505...58,525,661
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
increases expression |
ISO |
eleostearic acid results in increased expression of PPARG mRNA; eleostearic acid results in increased expression of PPARG protein |
CTD |
PMID:15961301 |
|
NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468
|
|
G |
Tp53 |
tumor protein p53 |
increases expression |
ISO |
eleostearic acid results in increased expression of TP53 protein |
CTD |
PMID:15961301 |
|
NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524
|
|
|
G |
Adipor1 |
adiponectin receptor 1 |
multiple interactions |
EXP |
[trans-10,cis-12-conjugated linoleic acid co-treated with cis-9, trans-11-conjugated linoleic acid] results in increased expression of ADIPOR1 mRNA |
CTD |
PMID:17408517 |
|
NCBI chr13:45,859,461...45,879,248
Ensembl chr13:45,859,533...45,879,241
|
|
G |
Adipor2 |
adiponectin receptor 2 |
multiple interactions |
EXP |
[trans-10,cis-12-conjugated linoleic acid co-treated with cis-9, trans-11-conjugated linoleic acid] results in increased expression of ADIPOR2 mRNA |
CTD |
PMID:17408517 |
|
NCBI chr 4:152,524,604...152,588,848
Ensembl chr 4:152,524,623...152,559,355
|
|
G |
Cd68 |
Cd68 molecule |
affects expression |
ISO |
cis-9, trans-11-conjugated linoleic acid affects the expression of CD68 mRNA |
CTD |
PMID:17327424 |
|
NCBI chr10:54,381,814...54,383,693
Ensembl chr10:54,381,815...54,383,697
|
|
G |
Cycs |
cytochrome c, somatic |
multiple interactions |
EXP |
[trans-10,cis-12-conjugated linoleic acid co-treated with cis-9, trans-11-conjugated linoleic acid] results in increased activity of CYCS protein |
CTD |
PMID:17408517 |
|
NCBI chr 4:79,651,894...79,653,994
Ensembl chr 4:79,651,378...79,654,054
|
|
G |
Fmo3 |
flavin containing dimethylaniline monoxygenase 3 |
decreases expression |
ISO |
cis-9, trans-11-conjugated linoleic acid results in decreased expression of FMO3 mRNA |
CTD |
PMID:17217560 |
|
NCBI chr13:75,309,367...75,334,915
Ensembl chr13:75,309,374...75,328,028
|
|
G |
Gsr |
glutathione-disulfide reductase |
multiple interactions |
EXP |
[trans-10,cis-12-conjugated linoleic acid co-treated with cis-9, trans-11-conjugated linoleic acid] results in increased activity of GSR protein |
CTD |
PMID:17408517 |
|
NCBI chr16:58,482,209...58,525,256
Ensembl chr16:58,482,505...58,525,661
|
|
G |
Insr |
insulin receptor |
affects expression |
ISO |
cis-9, trans-11-conjugated linoleic acid affects the expression of INSR protein |
CTD |
PMID:17327424 |
|
NCBI chr12:1,193,193...1,330,976
Ensembl chr12:1,197,100...1,330,883
|
|
G |
Irs1 |
insulin receptor substrate 1 |
multiple interactions |
EXP ISO |
[trans-10,cis-12-conjugated linoleic acid co-treated with cis-9, trans-11-conjugated linoleic acid] results in decreased phosphorylation of IRS1 protein cis-9, trans-11-conjugated linoleic acid inhibits the reaction [TNF protein results in decreased expression of IRS1 mRNA] |
CTD |
PMID:17327424 PMID:17408517 |
|
NCBI chr 9:83,552,964...83,605,797
Ensembl chr 9:83,548,944...83,606,122
|
|
G |
Map2k1 |
mitogen activated protein kinase kinase 1 |
multiple interactions |
EXP |
[cis-9, trans-11-conjugated linoleic acid co-treated with trans-10,cis-12-conjugated linoleic acid] results in increased phosphorylation of and results in increased activity of MAP2K1 protein; cis-9, trans-11-conjugated linoleic acid results in increased phosphorylation of and results in increased activity of MAP2K1 protein |
CTD |
PMID:17869086 |
|
NCBI chr 8:64,683,449...64,754,900
Ensembl chr 8:64,683,449...64,755,147
|
|
G |
Map2k3 |
mitogen activated protein kinase kinase 3 |
multiple interactions |
EXP |
[cis-9, trans-11-conjugated linoleic acid co-treated with trans-10,cis-12-conjugated linoleic acid] results in increased phosphorylation of and results in increased activity of MAP2K3 protein; cis-9, trans-11-conjugated linoleic acid results in increased phosphorylation of and results in increased activity of MAP2K3 protein |
CTD |
PMID:17869086 |
|
NCBI chr10:45,608,145...45,629,492
Ensembl chr10:45,607,163...45,629,492
|
|
G |
Me1 |
malic enzyme 1 |
increases expression |
ISO |
cis-9, trans-11-conjugated linoleic acid results in increased expression of ME1 mRNA |
CTD |
PMID:17217560 |
|
NCBI chr 8:87,549,043...87,660,251
Ensembl chr 8:87,549,043...87,660,304
|
|
G |
Nfkb1 |
nuclear factor kappa B subunit 1 |
affects activity |
ISO |
cis-9, trans-11-conjugated linoleic acid affects the activity of NFKB1 protein |
CTD |
PMID:17327424 |
|
NCBI chr 2:224,016,214...224,132,135
Ensembl chr 2:224,016,214...224,110,404
|
|
G |
Nfkb2 |
nuclear factor kappa B subunit 2 |
affects activity |
ISO |
cis-9, trans-11-conjugated linoleic acid affects the activity of NFKB2 protein |
CTD |
PMID:17327424 |
|
NCBI chr 1:245,164,586...245,173,225
Ensembl chr 1:245,165,950...245,173,213
|
|
G |
Nr1h3 |
nuclear receptor subfamily 1, group H, member 3 |
affects expression |
ISO |
cis-9, trans-11-conjugated linoleic acid affects the expression of NR1H3 mRNA |
CTD |
PMID:17327424 |
|
NCBI chr 3:77,158,808...77,168,907
Ensembl chr 3:77,158,808...77,168,722
|
|
G |
Por |
cytochrome p450 oxidoreductase |
decreases expression |
ISO |
cis-9, trans-11-conjugated linoleic acid results in decreased expression of POR mRNA |
CTD |
PMID:17217560 |
|
NCBI chr12:20,951,058...20,999,198
Ensembl chr12:20,951,058...20,999,245
|
|
G |
Ppara |
peroxisome proliferator activated receptor alpha |
multiple interactions |
EXP |
[trans-10,cis-12-conjugated linoleic acid co-treated with cis-9, trans-11-conjugated linoleic acid] results in increased expression of PPARA mRNA; [trans-10,cis-12-conjugated linoleic acid co-treated with cis-9, trans-11-conjugated linoleic acid] results in increased expression of PPARA protein |
CTD |
PMID:17408517 |
|
NCBI chr 7:116,832,405...116,900,878
Ensembl chr 7:116,832,756...116,895,346
|
|
G |
Rel |
REL proto-oncogene, NF-kB subunit |
affects activity |
ISO |
cis-9, trans-11-conjugated linoleic acid affects the activity of REL protein |
CTD |
PMID:17327424 |
|
NCBI chr14:97,690,105...97,721,194
Ensembl chr14:97,695,161...97,720,892
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
ISO |
cis-9, trans-11-conjugated linoleic acid affects the expression of and affects the activity of RELA protein |
CTD |
PMID:17327424 |
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Relb |
RELB proto-oncogene, NF-kB subunit |
affects activity |
ISO |
cis-9, trans-11-conjugated linoleic acid affects the activity of RELB protein |
CTD |
PMID:17327424 |
|
NCBI chr 1:79,257,738...79,285,490
Ensembl chr 1:79,257,725...79,285,507
|
|
G |
Scd |
stearoyl-CoA desaturase |
increases expression |
ISO |
cis-9, trans-11-conjugated linoleic acid results in increased expression of SCD1 mRNA |
CTD |
PMID:17217560 |
|
NCBI chr 1:243,269,745...243,282,878
Ensembl chr 1:243,269,747...243,282,562
|
|
G |
Slc2a4 |
solute carrier family 2 member 4 |
increases expression multiple interactions |
ISO |
cis-9, trans-11-conjugated linoleic acid results in increased expression of SLC2A4 protein cis-9, trans-11-conjugated linoleic acid inhibits the reaction [TNF protein results in decreased expression of SLC2A4 mRNA] |
CTD |
PMID:17327424 |
|
NCBI chr10:54,666,015...54,671,581
Ensembl chr10:54,666,015...54,671,565
|
|
G |
Sod2 |
superoxide dismutase 2 |
multiple interactions |
EXP |
[trans-10,cis-12-conjugated linoleic acid co-treated with cis-9, trans-11-conjugated linoleic acid] results in increased activity of SOD2 protein |
CTD |
PMID:17408517 |
|
NCBI chr 1:47,638,318...47,645,163
Ensembl chr 1:47,636,528...47,645,189
|
|
G |
Srebf1 |
sterol regulatory element binding transcription factor 1 |
affects expression |
ISO |
cis-9, trans-11-conjugated linoleic acid affects the expression of SREBF1 mRNA |
CTD |
PMID:17327424 |
|
NCBI chr10:45,007,637...45,029,650
Ensembl chr10:45,007,637...45,029,650
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions affects expression |
ISO |
cis-9, trans-11-conjugated linoleic acid inhibits the reaction [TNF protein results in decreased expression of IRS1 mRNA]; cis-9, trans-11-conjugated linoleic acid inhibits the reaction [TNF protein results in decreased expression of SLC2A4 mRNA] cis-9, trans-11-conjugated linoleic acid affects the expression of TNF mRNA |
CTD |
PMID:17327424 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
|
G |
Adtrp |
androgen-dependent TFPI-regulating protein |
affects chemical synthesis |
ISO |
ADTRP protein affects the chemical synthesis of 9-hydroxystearic acid |
CTD |
PMID:32152231 |
|
NCBI chr17:22,930,012...22,993,834
Ensembl chr17:22,930,740...22,993,826
|
|
G |
Aig1 |
androgen-induced 1 |
affects chemical synthesis |
ISO |
AIG1 protein affects the chemical synthesis of 9-hydroxystearic acid |
CTD |
PMID:32152231 |
|
NCBI chr 1:8,046,430...8,269,276
Ensembl chr 1:8,046,430...8,269,084
|
|
|
G |
Cd36 |
CD36 molecule |
increases expression |
ISO |
9,11-linoleic acid results in increased expression of CD36 mRNA |
CTD |
PMID:18155510 |
|
NCBI chr 4:17,317,343...17,410,084
Ensembl chr 4:17,354,466...17,513,903
|
|
G |
Foxo1 |
forkhead box O1 |
affects localization |
ISO |
9,11-linoleic acid affects the localization of FOXO1 protein |
CTD |
PMID:15992797 |
|
NCBI chr 2:136,312,168...136,390,603
Ensembl chr 2:136,312,168...136,387,790
|
|
G |
Ppara |
peroxisome proliferator activated receptor alpha |
affects binding |
ISO |
9,11-linoleic acid binds to PPARA protein |
CTD |
PMID:23843199 |
|
NCBI chr 7:116,832,405...116,900,878
Ensembl chr 7:116,832,756...116,895,346
|
|
G |
Ppard |
peroxisome proliferator-activated receptor delta |
affects binding |
ISO |
9,11-linoleic acid binds to PPARB protein |
CTD |
PMID:23843199 |
|
NCBI chr20:6,298,785...6,363,970
Ensembl chr20:6,298,785...6,363,968
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
affects binding increases activity |
ISO |
9,11-linoleic acid binds to PPARG protein 9,11-linoleic acid results in increased activity of PPARG protein |
CTD |
PMID:18155510 PMID:23843199 |
|
NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468
|
|
G |
Tp53 |
tumor protein p53 |
multiple interactions |
ISO |
9,11-linoleic acid results in increased phosphorylation of and affects the localization of TP53 protein |
CTD |
PMID:15992797 |
|
NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524
|
|
|
G |
Agt |
angiotensinogen |
multiple interactions |
EXP |
arachidonyltrifluoromethane inhibits the reaction [AGT protein results in increased abundance of Epoprostenol] |
CTD |
PMID:14613874 |
|
NCBI chr19:52,529,139...52,549,618
Ensembl chr19:52,529,185...52,540,977
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
multiple interactions |
ISO |
arachidonyltrifluoromethane inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 mRNA] |
CTD |
PMID:18938131 |
|
NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125
|
|
G |
Enpp2 |
ectonucleotide pyrophosphatase/phosphodiesterase 2 |
multiple interactions |
ISO |
arachidonyltrifluoromethane inhibits the reaction [[ENPP2 protein co-treated with Capsaicin] results in increased abundance of lysophosphatidic acid] |
CTD |
PMID:19014389 |
|
NCBI chr 7:86,202,345...86,325,050
Ensembl chr 7:86,202,350...86,324,827
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
ISO |
arachidonyltrifluoromethane inhibits the reaction [NAD inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased secretion of IL1B protein]] |
CTD |
PMID:29642561 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Ins2 |
insulin 2 |
increases secretion multiple interactions |
ISO |
arachidonyltrifluoromethane results in increased secretion of INS protein arachidonyltrifluoromethane inhibits the reaction [Glucose results in increased secretion of INS protein] |
CTD |
PMID:17192482 |
|
NCBI chr 1:197,843,277...197,992,522
Ensembl chr 1:197,843,281...197,864,775
|
|
G |
Lep |
leptin |
multiple interactions |
ISO |
arachidonyltrifluoromethane inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of LEP mRNA] |
CTD |
PMID:19063610 |
|
NCBI chr 4:57,661,127...57,675,262
Ensembl chr 4:57,661,131...57,675,262
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions |
ISO |
arachidonyltrifluoromethane inhibits the reaction [NRG1 protein alternative form results in increased phosphorylation of and results in increased activity of MAPK1 protein] |
CTD |
PMID:15231676 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions |
ISO |
arachidonyltrifluoromethane inhibits the reaction [NRG1 protein alternative form results in increased phosphorylation of and results in increased activity of MAPK3 protein] |
CTD |
PMID:15231676 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Nrg1 |
neuregulin 1 |
multiple interactions |
ISO |
arachidonyltrifluoromethane inhibits the reaction [NRG1 protein alternative form results in increased phosphorylation of and results in increased activity of MAPK1 protein]; arachidonyltrifluoromethane inhibits the reaction [NRG1 protein alternative form results in increased phosphorylation of and results in increased activity of MAPK3 protein] |
CTD |
PMID:15231676 |
|
NCBI chr16:59,250,658...60,303,024
Ensembl chr16:59,250,854...60,296,884
|
|
G |
Pla2g4a |
phospholipase A2 group IVA |
multiple interactions |
ISO |
arachidonyltrifluoromethane inhibits the reaction [Tetrachlorodibenzodioxin results in increased activity of PLA2G4A protein] arachidonyltrifluoromethane inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of PLA2G4A mRNA] |
CTD |
PMID:18938131 PMID:19063610 PMID:19162293 |
|
NCBI chr13:61,877,818...62,022,261
Ensembl chr13:61,877,813...62,022,266
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
multiple interactions |
ISO |
arachidonyltrifluoromethane inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of PPARG mRNA] |
CTD |
PMID:19063610 |
|
NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions |
ISO |
arachidonyltrifluoromethane inhibits the reaction [Tetrachlorodibenzodioxin results in increased activity of PTGS2 protein]; arachidonyltrifluoromethane inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of PTGS2 mRNA]; arachidonyltrifluoromethane promotes the reaction [Nifedipine inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of PTGS2 mRNA]] |
CTD |
PMID:18938131 PMID:19063610 PMID:19162293 |
|
NCBI chr13:62,164,080...62,169,770
Ensembl chr13:62,163,932...62,172,188
|
|
G |
S100a11 |
S100 calcium binding protein A11 |
multiple interactions |
ISO |
arachidonyltrifluoromethane inhibits the reaction [S100A11 mutant form results in increased susceptibility to Cisplatin]; arachidonyltrifluoromethane inhibits the reaction [S100A11 mutant form results in increased susceptibility to Oxaliplatin] |
CTD |
PMID:25940438 |
|
NCBI chr 2:179,191,504...179,197,098
Ensembl chr 2:179,191,715...179,197,044
|
|
G |
Socs3 |
suppressor of cytokine signaling 3 |
multiple interactions |
ISO |
arachidonyltrifluoromethane inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of SOCS3 mRNA] |
CTD |
PMID:19063610 |
|
NCBI chr10:103,193,909...103,197,322
Ensembl chr10:103,193,537...103,197,787
|
|
G |
Sod2 |
superoxide dismutase 2 |
multiple interactions |
ISO |
arachidonyltrifluoromethane inhibits the reaction [TNF protein results in increased expression of SOD2] |
CTD |
PMID:11264281 |
|
NCBI chr 1:47,638,318...47,645,163
Ensembl chr 1:47,636,528...47,645,189
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
ISO |
arachidonyltrifluoromethane inhibits the reaction [TNF protein results in increased expression of SOD2] |
CTD |
PMID:11264281 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Vegfa |
vascular endothelial growth factor A |
multiple interactions |
ISO |
arachidonyltrifluoromethane inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of VEGFA mRNA] arachidonyltrifluoromethane promotes the reaction [Nifedipine inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of VEGFA mRNA]] |
CTD |
PMID:19063610 PMID:19162293 |
|
NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641
|
|
|
G |
Ereg |
epiregulin |
multiple interactions |
ISO |
[AL 8810 results in decreased activity of PTGFR protein] inhibits the reaction [[trans-10,cis-12-conjugated linoleic acid results in increased abundance of Dinoprost] which results in increased expression of EREG] |
CTD |
PMID:22583689 |
|
NCBI chr14:17,027,287...17,041,062
Ensembl chr14:17,027,287...17,041,062
|
|
G |
Fabp4 |
fatty acid binding protein 4 |
increases expression |
ISO |
AL 8810 results in increased expression of FABP4 mRNA |
CTD |
PMID:21236357 |
|
NCBI chr 2:91,580,858...91,585,578
Ensembl chr 2:91,580,885...91,585,578
|
|
G |
Gclm |
glutamate cysteine ligase, modifier subunit |
multiple interactions |
ISO |
AL 8810 inhibits the reaction [fluprostenol promotes the reaction [Oxidopamine results in increased expression of GCLM mRNA]] |
CTD |
PMID:33486071 |
|
NCBI chr 2:210,347,482...210,367,537
Ensembl chr 2:210,347,482...210,367,535
|
|
G |
Hmox1 |
heme oxygenase 1 |
multiple interactions |
ISO |
AL 8810 inhibits the reaction [fluprostenol promotes the reaction [Oxidopamine results in increased expression of HMOX1 mRNA]] |
CTD |
PMID:33486071 |
|
NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions |
ISO |
AL 8810 inhibits the reaction [Oxidopamine results in increased phosphorylation of MAPK1 protein] |
CTD |
PMID:33486071 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions |
ISO |
AL 8810 inhibits the reaction [Oxidopamine results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:33486071 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Nfe2l2 |
NFE2 like bZIP transcription factor 2 |
multiple interactions |
ISO |
AL 8810 inhibits the reaction [Oxidopamine affects the localization of NFE2L2 protein] |
CTD |
PMID:33486071 |
|
NCBI chr 3:60,594,239...60,621,785
Ensembl chr 3:60,594,242...60,621,737
|
|
G |
Nqo1 |
NAD(P)H quinone dehydrogenase 1 |
multiple interactions |
ISO |
AL 8810 inhibits the reaction [fluprostenol promotes the reaction [Oxidopamine results in increased expression of NQO1 mRNA]] |
CTD |
PMID:33486071 |
|
NCBI chr19:35,295,633...35,310,528
Ensembl chr19:35,295,573...35,310,557
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
increases expression |
ISO |
AL 8810 results in increased expression of PPARG mRNA |
CTD |
PMID:21236357 |
|
NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468
|
|
G |
Ptgfr |
prostaglandin F receptor |
multiple interactions |
ISO |
[AL 8810 results in decreased activity of PTGFR protein] inhibits the reaction [[trans-10,cis-12-conjugated linoleic acid results in increased abundance of Dinoprost] which results in increased expression of EREG] |
CTD |
PMID:22583689 |
|
NCBI chr 2:240,731,185...240,766,674
Ensembl chr 2:240,733,375...240,765,650
|
|
|
G |
Rxra |
retinoid X receptor alpha |
multiple interactions |
ISO |
adrenic acid binds to and results in increased activity of RXRA protein |
CTD |
PMID:16258897 |
|
NCBI chr 3:10,989,832...11,076,366
Ensembl chr 3:10,989,832...11,073,712
|
|
G |
Tp53 |
tumor protein p53 |
multiple interactions |
ISO |
[TP53 protein mutant form results in increased susceptibility to Niclosamide] which results in increased abundance of adrenic acid |
CTD |
PMID:30258081 |
|
NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524
|
|
|
G |
Cat |
catalase |
increases activity |
EXP |
retinol palmitate results in increased activity of CAT protein |
CTD |
PMID:20679000 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Ep300 |
E1A binding protein p300 |
multiple interactions |
EXP |
retinol palmitate promotes the reaction [EP300 protein binds to MMP9 protein] |
CTD |
PMID:17164434 |
|
NCBI chr 7:113,108,476...113,178,529
Ensembl chr 7:113,106,247...113,136,088 Ensembl chr 7:113,106,247...113,136,088
|
|
G |
Il10 |
interleukin 10 |
multiple interactions |
ISO |
retinol palmitate inhibits the reaction [Lipopolysaccharides results in increased secretion of IL10 protein] |
CTD |
PMID:17377406 |
|
NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313
|
|
G |
Il1rn |
interleukin 1 receptor antagonist |
multiple interactions |
ISO |
retinol palmitate inhibits the reaction [Lipopolysaccharides results in increased secretion of IL1RN protein] |
CTD |
PMID:17377406 |
|
NCBI chr 3:7,111,567...7,127,451
Ensembl chr 3:7,111,550...7,127,445
|
|
G |
Lipe |
lipase E, hormone sensitive type |
increases hydrolysis multiple interactions |
ISO |
LIPE protein results in increased hydrolysis of retinol palmitate PLIN3 protein inhibits the reaction [LIPE protein results in increased hydrolysis of retinol palmitate] |
CTD |
PMID:16741517 |
|
NCBI chr 1:80,965,612...80,984,313
Ensembl chr 1:80,965,627...80,984,310
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
multiple interactions increases expression |
EXP |
retinol palmitate promotes the reaction [EP300 protein binds to MMP9 protein]; retinol palmitate promotes the reaction [RARA protein binds to MMP9 protein] retinol palmitate results in increased expression of MMP9 mRNA |
CTD |
PMID:17164434 |
|
NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120
|
|
G |
Plin3 |
perilipin 3 |
multiple interactions |
ISO |
PLIN3 protein inhibits the reaction [LIPE protein results in increased hydrolysis of retinol palmitate]; PLIN3 protein inhibits the reaction [PNPLA4 protein results in increased hydrolysis of retinol palmitate] |
CTD |
PMID:16741517 |
|
NCBI chr 9:1,111,178...1,123,117
Ensembl chr 9:1,102,366...1,123,147
|
|
G |
Pnpla4 |
patatin like phospholipase domain containing 4 |
increases hydrolysis multiple interactions |
ISO |
PNPLA4 protein results in increased hydrolysis of retinol palmitate PLIN3 protein inhibits the reaction [PNPLA4 protein results in increased hydrolysis of retinol palmitate] |
CTD |
PMID:16741517 |
|
NCBI chr X:42,313,554...42,318,451
Ensembl chr X:42,305,373...42,318,552
|
|
G |
Rara |
retinoic acid receptor, alpha |
multiple interactions |
EXP |
retinol palmitate promotes the reaction [RARA protein binds to MMP9 protein] |
CTD |
PMID:17164434 |
|
NCBI chr10:83,883,490...83,928,932
Ensembl chr10:83,893,384...83,928,142
|
|
G |
Scarb1 |
scavenger receptor class B, member 1 |
increases expression |
EXP |
retinol palmitate results in increased expression of SCARB1 mRNA |
CTD |
PMID:17299104 |
|
NCBI chr12:31,296,143...31,362,649
Ensembl chr12:31,296,156...31,362,647
|
|
|
G |
Alox15 |
arachidonate 15-lipoxygenase |
multiple interactions |
ISO |
[caffeic acid results in decreased activity of ALOX15 protein] which results in decreased chemical synthesis of 13-hydroxy-9,11-octadecadienoic acid; [caffeic acid results in decreased activity of ALOX15 protein] which results in increased abundance of 13-hydroxy-9,11-octadecadienoic acid; [Masoprocol results in decreased activity of ALOX15 protein] which results in increased abundance of 13-hydroxy-9,11-octadecadienoic acid; [N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide results in increased expression of ALOX15 protein] which results in increased chemical synthesis of 13-hydroxy-9,11-octadecadienoic acid; [Sulindac results in increased expression of ALOX15 protein] which results in increased chemical synthesis of 13-hydroxy-9,11-octadecadienoic acid; [Vorinostat results in increased expression of ALOX15 protein] which results in increased abundance of 13-hydroxy-9,11-octadecadienoic acid |
CTD |
PMID:11406566 PMID:15574791 |
|
NCBI chr10:55,060,169...55,068,885
Ensembl chr10:55,060,412...55,068,874
|
|
G |
Cat |
catalase |
increases expression |
ISO |
13-hydroxy-9,11-octadecadienoic acid results in increased expression of CAT protein |
CTD |
PMID:10946007 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
|
G |
Abcb11 |
ATP binding cassette subfamily B member 11 |
multiple interactions |
ISO |
alpha-Linolenic Acid promotes the reaction [GW 4064 results in increased expression of ABCB11 mRNA] |
CTD |
PMID:15307955 |
|
NCBI chr 3:54,016,854...54,112,797
Ensembl chr 3:54,017,127...54,112,730
|
|
G |
Acaca |
acetyl-CoA carboxylase alpha |
decreases expression |
EXP |
alpha-Linolenic Acid results in decreased expression of ACACA mRNA |
CTD |
PMID:14563831 |
|
NCBI chr10:69,014,261...69,276,453
Ensembl chr10:69,014,170...69,276,457
|
|
G |
Acly |
ATP citrate lyase |
decreases expression |
EXP |
alpha-Linolenic Acid results in decreased expression of ACLY mRNA |
CTD |
PMID:14563831 |
|
NCBI chr10:85,412,045...85,464,253
Ensembl chr10:85,412,049...85,463,320
|
|
G |
Bche |
butyrylcholinesterase |
increases expression increases secretion |
ISO |
alpha-Linolenic Acid results in increased expression of BCHE mRNA alpha-Linolenic Acid results in increased secretion of BCHE protein |
CTD |
PMID:27106529 |
|
NCBI chr 2:158,308,674...158,401,148
Ensembl chr 2:158,307,584...158,401,148
|
|
G |
Cat |
catalase |
multiple interactions |
EXP |
alpha-Linolenic Acid inhibits the reaction [methylmercuric chloride results in decreased activity of CAT protein] |
CTD |
PMID:22269903 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
multiple interactions |
EXP |
alpha-Linolenic Acid inhibits the reaction [[Cholesterol, Dietary co-treated with NG-Nitroarginine Methyl Ester] results in increased expression of CCL2 protein]; alpha-Linolenic Acid inhibits the reaction [Particulate Matter promotes the reaction [[Cholesterol, Dietary co-treated with NG-Nitroarginine Methyl Ester] results in increased expression of CCL2 mRNA]]; alpha-Linolenic Acid inhibits the reaction [Particulate Matter promotes the reaction [[Cholesterol, Dietary co-treated with NG-Nitroarginine Methyl Ester] results in increased expression of CCL2 protein]]; Particulate Matter inhibits the reaction [alpha-Linolenic Acid inhibits the reaction [[Cholesterol, Dietary co-treated with NG-Nitroarginine Methyl Ester] results in increased expression of CCL2 protein]] |
CTD |
PMID:29423081 |
|
NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226
|
|
G |
Cebpb |
CCAAT/enhancer binding protein beta |
decreases expression |
EXP |
alpha-Linolenic Acid results in decreased expression of CEBPB mRNA |
CTD |
PMID:14563831 |
|
NCBI chr 3:156,398,035...156,399,466
Ensembl chr 3:156,397,052...156,399,473
|
|
G |
Cpt1a |
carnitine palmitoyltransferase 1A |
increases expression |
ISO |
alpha-Linolenic Acid results in increased expression of CPT1A mRNA |
CTD |
PMID:15307955 |
|
NCBI chr 1:200,564,634...200,627,059
Ensembl chr 1:200,565,613...200,627,055
|
|
G |
Cybb |
cytochrome b-245 beta chain |
multiple interactions |
EXP |
alpha-Linolenic Acid inhibits the reaction [[Cholesterol co-treated with Particulate Matter] results in increased expression of CYBB protein] |
CTD |
PMID:30672636 |
|
NCBI chr X:13,360,583...13,392,517
Ensembl chr X:13,359,430...13,392,586
|
|
G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
decreases activity |
ISO |
alpha-Linolenic Acid results in decreased activity of CYP1A2 protein |
CTD |
PMID:16978661 |
|
NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312
|
|
G |
Cyp24a1 |
cytochrome P450, family 24, subfamily a, polypeptide 1 |
multiple interactions |
ISO |
alpha-Linolenic Acid inhibits the reaction [Calcitriol results in increased expression of CYP24A1 mRNA] |
CTD |
PMID:19667161 |
|
NCBI chr 3:159,275,947...159,290,383
Ensembl chr 3:159,275,947...159,290,383
|
|
G |
Cyp2c6v1 |
cytochrome P450, family 2, subfamily C, polypeptide 6, variant 1 |
multiple interactions decreases activity |
ISO |
CYP2C19 protein results in increased metabolism of [alpha-Linolenic Acid co-treated with NADP] alpha-Linolenic Acid results in decreased activity of CYP2C19 protein |
CTD |
PMID:16978661 |
|
NCBI chr 1:237,938,521...237,976,238
Ensembl chr 1:237,693,094...238,057,596
|
|
G |
Cyp2e1 |
cytochrome P450, family 2, subfamily e, polypeptide 1 |
decreases activity |
ISO |
alpha-Linolenic Acid results in decreased activity of CYP2E1 protein |
CTD |
PMID:16978661 |
|
NCBI chr 1:195,840,330...195,850,728
Ensembl chr 1:195,840,058...195,864,023
|
|
G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
decreases activity |
ISO |
alpha-Linolenic Acid results in decreased activity of CYP3A4 protein |
CTD |
PMID:16978661 |
|
NCBI chr12:9,207,986...9,230,038
Ensembl chr12:9,015,383...9,285,008
|
|
G |
Dio1 |
iodothyronine deiodinase 1 |
decreases activity |
ISO |
alpha-Linolenic Acid results in decreased activity of DIO1 protein |
CTD |
PMID:30561685 |
|
NCBI chr 5:122,074,285...122,090,983
Ensembl chr 5:122,074,279...122,090,970
|
|
G |
Dio2 |
iodothyronine deiodinase 2 |
decreases activity |
ISO |
alpha-Linolenic Acid results in decreased activity of DIO2 protein |
CTD |
PMID:30561685 |
|
NCBI chr 6:109,665,523...109,679,809
Ensembl chr 6:109,665,523...109,679,809
|
|
G |
Dio3 |
iodothyronine deiodinase 3 |
decreases activity |
ISO |
alpha-Linolenic Acid results in decreased activity of DIO3 protein |
CTD |
PMID:30561685 |
|
NCBI chr 6:129,285,747...129,287,608
Ensembl chr 6:129,285,749...129,286,660
|
|
G |
Fads1 |
fatty acid desaturase 1 |
multiple interactions |
ISO |
[[alpha-Linolenic Acid co-treated with Estradiol] results in increased expression of FADS1 mRNA] which affects the abundance of Fatty Acids, Unsaturated; [[alpha-Linolenic Acid co-treated with Testosterone] results in decreased expression of FADS1 mRNA] which affects the abundance of Fatty Acids, Unsaturated; [alpha-Linolenic Acid co-treated with Estradiol] results in increased expression of FADS1 mRNA; [alpha-Linolenic Acid co-treated with Testosterone] results in decreased expression of FADS1 mRNA; fulvestrant inhibits the reaction [[alpha-Linolenic Acid co-treated with Estradiol] results in increased expression of FADS1 mRNA] |
CTD |
PMID:19576517 |
|
NCBI chr 1:206,827,724...206,842,734
Ensembl chr 1:206,827,765...206,842,734
|
|
G |
Fasn |
fatty acid synthase |
decreases expression |
EXP |
alpha-Linolenic Acid results in decreased expression of FASN mRNA |
CTD |
PMID:14563831 |
|
NCBI chr10:106,072,093...106,090,259
Ensembl chr10:106,072,091...106,090,261
|
|
G |
Gclc |
glutamate-cysteine ligase, catalytic subunit |
increases activity increases expression |
ISO |
alpha-Linolenic Acid results in increased activity of GCLC protein alpha-Linolenic Acid results in increased expression of GCLC mRNA |
CTD |
PMID:17092368 |
|
NCBI chr 8:78,629,899...78,668,547
Ensembl chr 8:78,630,127...78,668,544
|
|
G |
Gpt |
glutamic--pyruvic transaminase |
multiple interactions |
EXP |
alpha-Linolenic Acid inhibits the reaction [methylmercuric chloride results in increased activity of GPT protein] |
CTD |
PMID:22269903 |
|
NCBI chr 7:108,416,646...108,419,495
Ensembl chr 7:108,416,642...108,419,494
|
|
G |
Gsta1 |
glutathione S-transferase alpha 1 |
increases expression multiple interactions |
ISO |
alpha-Linolenic Acid results in increased expression of GSTA1 mRNA NFE2L2 protein promotes the reaction [alpha-Linolenic Acid results in increased expression of GSTA1 mRNA] |
CTD |
PMID:28555106 |
|
NCBI chr 9:23,703,476...23,720,121
Ensembl chr 9:23,703,477...23,720,121
|
|
G |
Hmox1 |
heme oxygenase 1 |
increases expression multiple interactions |
ISO EXP |
alpha-Linolenic Acid results in increased expression of HMOX1 mRNA alpha-Linolenic Acid inhibits the reaction [Particulate Matter promotes the reaction [Cholesterol results in increased expression of HMOX1 mRNA]] |
CTD |
PMID:17092368 PMID:30672636 |
|
NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079
|
|
G |
Ifng |
interferon gamma |
multiple interactions |
EXP |
alpha-Linolenic Acid inhibits the reaction [[Cholesterol co-treated with Particulate Matter] results in increased expression of IFNG protein]; alpha-Linolenic Acid inhibits the reaction [[Cholesterol, Dietary co-treated with NG-Nitroarginine Methyl Ester] results in increased expression of IFNG mRNA]; alpha-Linolenic Acid inhibits the reaction [[Cholesterol, Dietary co-treated with NG-Nitroarginine Methyl Ester] results in increased expression of IFNG protein]; alpha-Linolenic Acid inhibits the reaction [Particulate Matter promotes the reaction [[Cholesterol, Dietary co-treated with NG-Nitroarginine Methyl Ester] results in increased expression of IFNG mRNA]]; alpha-Linolenic Acid inhibits the reaction [Particulate Matter promotes the reaction [[Cholesterol, Dietary co-treated with NG-Nitroarginine Methyl Ester] results in increased expression of IFNG protein]] |
CTD |
PMID:29423081 PMID:30672636 |
|
NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
ISO EXP |
[Eicosapentaenoic Acid co-treated with Docosahexaenoic Acids co-treated with alpha-Linolenic Acid] results in increased expression of IL1B protein alpha-Linolenic Acid inhibits the reaction [[Cholesterol co-treated with Particulate Matter] results in increased expression of IL1B protein] |
CTD |
PMID:16305726 PMID:30672636 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il4 |
interleukin 4 |
multiple interactions |
ISO |
[Eicosapentaenoic Acid co-treated with Docosahexaenoic Acids co-treated with alpha-Linolenic Acid] results in decreased expression of IL4 protein |
CTD |
PMID:16305726 |
|
NCBI chr10:37,771,203...37,776,750
Ensembl chr10:37,771,203...37,776,750
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
EXP |
alpha-Linolenic Acid inhibits the reaction [[Cholesterol, Dietary co-treated with NG-Nitroarginine Methyl Ester] results in increased expression of IL6 mRNA]; alpha-Linolenic Acid inhibits the reaction [[Cholesterol, Dietary co-treated with NG-Nitroarginine Methyl Ester] results in increased expression of IL6 protein]; alpha-Linolenic Acid inhibits the reaction [Cholesterol promotes the reaction [Particulate Matter results in increased expression of IL6 protein]]; alpha-Linolenic Acid inhibits the reaction [Particulate Matter promotes the reaction [[Cholesterol, Dietary co-treated with NG-Nitroarginine Methyl Ester] results in increased expression of IL6 mRNA]]; alpha-Linolenic Acid inhibits the reaction [Particulate Matter promotes the reaction [[Cholesterol, Dietary co-treated with NG-Nitroarginine Methyl Ester] results in increased expression of IL6 protein]]; Particulate Matter inhibits the reaction [alpha-Linolenic Acid inhibits the reaction [[Cholesterol, Dietary co-treated with NG-Nitroarginine Methyl Ester] results in increased expression of IL6 mRNA]] |
CTD |
PMID:29423081 PMID:30672636 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Kng2 |
kininogen 2 |
multiple interactions |
ISO |
alpha-Linolenic Acid inhibits the reaction [GW 4064 results in increased expression of KNG1 mRNA] |
CTD |
PMID:15307955 |
|
NCBI chr11:77,913,876...77,936,247
Ensembl chr11:77,909,612...78,002,971
|
|
G |
Nfe2l2 |
NFE2 like bZIP transcription factor 2 |
multiple interactions |
ISO EXP |
NFE2L2 protein promotes the reaction [alpha-Linolenic Acid results in increased expression of CYP2A6 mRNA]; NFE2L2 protein promotes the reaction [alpha-Linolenic Acid results in increased expression of CYP2A6 protein]; NFE2L2 protein promotes the reaction [alpha-Linolenic Acid results in increased expression of GSTA1 mRNA] alpha-Linolenic Acid inhibits the reaction [Cholesterol promotes the reaction [Particulate Matter results in increased expression of NFE2L2 mRNA]]; alpha-Linolenic Acid inhibits the reaction [Cholesterol results in increased expression of NFE2L2 mRNA]; alpha-Linolenic Acid inhibits the reaction [Particulate Matter promotes the reaction [Cholesterol results in increased expression of NFE2L2 mRNA]] |
CTD |
PMID:28555106 PMID:30672636 |
|
NCBI chr 3:60,594,239...60,621,785
Ensembl chr 3:60,594,242...60,621,737
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions |
EXP |
alpha-Linolenic Acid inhibits the reaction [[Cholesterol, Dietary co-treated with NG-Nitroarginine Methyl Ester] results in increased expression of NOS2 mRNA]; alpha-Linolenic Acid inhibits the reaction [[Cholesterol, Dietary co-treated with NG-Nitroarginine Methyl Ester] results in increased expression of NOS2 protein]; alpha-Linolenic Acid inhibits the reaction [Particulate Matter promotes the reaction [[Cholesterol, Dietary co-treated with NG-Nitroarginine Methyl Ester] results in increased expression of NOS2 mRNA]]; alpha-Linolenic Acid inhibits the reaction [Particulate Matter promotes the reaction [[Cholesterol, Dietary co-treated with NG-Nitroarginine Methyl Ester] results in increased expression of NOS2 protein]]; Particulate Matter inhibits the reaction [alpha-Linolenic Acid inhibits the reaction [[Cholesterol, Dietary co-treated with NG-Nitroarginine Methyl Ester] results in increased expression of NOS2 mRNA]]; Particulate Matter inhibits the reaction [alpha-Linolenic Acid inhibits the reaction [[Cholesterol, Dietary co-treated with NG-Nitroarginine Methyl Ester] results in increased expression of NOS2 protein]] |
CTD |
PMID:29423081 |
|
NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
|
|
G |
Nqo1 |
NAD(P)H quinone dehydrogenase 1 |
multiple interactions |
EXP |
alpha-Linolenic Acid inhibits the reaction [Particulate Matter promotes the reaction [Cholesterol results in increased expression of NQO1 mRNA]] |
CTD |
PMID:30672636 |
|
NCBI chr19:35,295,633...35,310,528
Ensembl chr19:35,295,573...35,310,557
|
|
G |
Nr1h2 |
nuclear receptor subfamily 1, group H, member 2 |
multiple interactions |
ISO |
alpha-Linolenic Acid binds to and results in increased activity of NR1H2 protein |
CTD |
PMID:16731579 |
|
NCBI chr 1:95,041,967...95,047,377
Ensembl chr 1:95,041,967...95,047,377
|
|
G |
Nr1h4 |
nuclear receptor subfamily 1, group H, member 4 |
multiple interactions affects binding |
ISO |
alpha-Linolenic Acid inhibits the reaction [Chenodeoxycholic Acid results in increased activity of NR1H4 protein] alpha-Linolenic Acid binds to NR1H4 protein |
CTD |
PMID:15307955 |
|
NCBI chr 7:23,846,122...23,942,085
Ensembl chr 7:23,846,122...23,942,047
|
|
G |
Pck1 |
phosphoenolpyruvate carboxykinase 1 |
multiple interactions |
ISO |
[Glucose deficiency co-treated with alpha-Linolenic Acid] results in increased expression of PCK1 mRNA |
CTD |
PMID:8536680 |
|
NCBI chr 3:161,930,256...161,936,205
Ensembl chr 3:161,930,256...161,936,191
|
|
G |
Plin2 |
perilipin 2 |
increases expression |
EXP ISO |
alpha-Linolenic Acid results in increased expression of PLIN2 mRNA; alpha-Linolenic Acid results in increased expression of PLIN2 protein |
CTD |
PMID:16489205 |
|
NCBI chr 5:101,156,643...101,211,738
Ensembl chr 5:101,154,411...101,242,319
|
|
G |
Ppara |
peroxisome proliferator activated receptor alpha |
multiple interactions affects abundance increases expression |
EXP ISO |
alpha-Linolenic Acid binds to and results in increased activity of PPARA protein PPARA protein affects the abundance of alpha-Linolenic Acid alpha-Linolenic Acid results in increased expression of PPARA mRNA alpha-Linolenic Acid binds to and results in increased activity of PPARA protein; Calcitriol promotes the reaction [alpha-Linolenic Acid results in increased expression of PPARA mRNA] alpha-Linolenic Acid binds to and results in increased activity of PPARA protein; Diethylhexyl Phthalate inhibits the reaction [PPARA protein affects the abundance of alpha-Linolenic Acid] |
CTD |
PMID:10403814 PMID:16731579 PMID:18154422 PMID:19667161 PMID:23619606 |
|
NCBI chr 7:116,832,405...116,900,878
Ensembl chr 7:116,832,756...116,895,346
|
|
G |
Ppard |
peroxisome proliferator-activated receptor delta |
increases expression multiple interactions |
| |